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Abstract 
 
 Peptidic natural products are produced by diverse organisms ranging from 
bacteria to humans. These secondary metabolites can be assembled by the ribosome or 
by nonribosomal peptide synthetase (NRPS) enzymatic assembly lines. The 
architectural complexity and biological activity of such compounds make them interesting 
targets for study. Frequently, nonribosomal peptides contain nonproteinogenic amino 
acid building blocks, and the biosynthetic routes to both ribosomal and nonribosomal 
peptides often utilize tailoring enzymes. These specialized enzymes catalyze 
mechanistically challenging reactions and provide peptidic natural products with 
structural motifs not normally found in proteins. Structural studies of these tailoring 
enzymes will further our understanding of biosynthetic pathways, and engineered 
tailoring enzymes could find use as promiscuous catalysts for the chemoenzymatic 
synthesis of natural product analogs. 
 The L-tyrosine 2,3-aminomutase SgTAM catalyzes the formation of β-tyrosine 
from L-tyrosine, and is used in the biosynthetic pathway to the enediyne antitumor 
antibiotic C-1027. This enzyme contains the rare electrophilic prosthetic group 4-
methylideneimidazole-5-one (MIO) and is homologous to the histidine ammonia lyase 
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family of enzymes. While lyases form α,β-unsaturated carboxylates as products, SgTAM 
catalyzes additional chemical steps that result in an overall 2,3-amino shift. The precise 
mechanistic role of MIO in the ammonia lyase and aminomutase families of enzymes 
was actively debated for over 50 years. Here, we report the first x-ray crystal structure of 
an MIO-dependent aminomutase and detail the synthesis and characterization of 
mechanistic probes for this enzyme. Furthermore, we report several structures of 
SgTAM bound to substrate analogs. These co-crystal structures reveal how SgTAM 
achieves substrate recognition and suggest a specific role for MIO in catalysis. The 
results of our studies allow for the rational engineering of MIO-based aminomutases and 
ammonia lyases with altered physical properties and substrate specificities.  
 Additionally, we are currently studying several enzymes involved in the 
biosynthesis of the tricyclic depsipeptide microviridin J. This ribosomal peptide natural 
product contains two lactones and one lactam, which are introduced by two enzymes 
belonging to the ATP-grasp ligase superfamily of proteins. Here, we detail the 
overexpression of these enzymes, MdnJ-B and MdnJ-C, in E. coli and report the 
optimization of conditions which lead to the crystallization of both enzymes. The 
structural characterization of MdnJ-B and MdnJ-C will lead to a greater understanding of 
macrocycle formation in ribosomal peptide biosynthesis, and engineered variants of 
these enzymes may find use as macrocylcization catalysts.  
 v
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Chapter 1 
 
 
 
Biosynthesis of Peptidic Natural Products 
 
 
 
 
 
 
Adapted from Montavon, T.J.; Bruner, S.D. Comprehensive Natural Products II 2009, in 
press.
1.1 Introduction 
 Peptidic natural products (PNPs) are ubiquitous in nature. These secondary 
metabolites, produced by diverse organisms ranging from bacteria to humans, display 
remarkable structural diversity and biological activities. They are often used by 
producing organisms as toxins towards other species,1 as surfactants,2 or as 
siderophores,3 but may also serve other functions.   
 There are two general classes of peptidic natural products: ribosomal peptides 
(RPs) and nonribosomal peptides (NRPs). Ribosomal peptides are biosynthesized as 
large, precursor peptides termed prepeptides.4 Prepeptides typically consist of an N-
terminal leader sequence important for enzyme recognition and cellular trafficking and a 
C-terminal sequence that is ultimately converted to the natural product. After enzymatic 
functionalization of the prepeptide has occurred, the N-terminal leader sequence is 
cleaved by a peptidase yielding the active natural product. The structural diversity of this 
class of compounds is limited by the use of the 20 canonical amino acids as building 
blocks.  
 Peptides synthesized by the ribosome vary greatly in length. The shortest known 
ribosomal peptide is the microcin C7 precursor,5 which is 7 amino acids long, while the 
largest known protein, titin, contains 34,350 amino acids.6 Representative examples of 
this class of natural products include the antibiotic food preservative nisin A,7 the 
antibiotic microcin C7,8 and the cytotoxic compound patellamide A (Figure 1A).9 
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  Conversely, nonribosomal peptides are biosynthesized by large multimodular 
enzymatic assembly lines termed nonribosomal peptide synthetases (NRPSs).10 In NRP 
biosynthesis, mRNA is not used as a template. Instead, NRPSs use a thiol-template 
mechanism, similar to that employed in the biosynthesis of fatty acids and 
polyketides,11,12 to assemble full length peptides. The thiol containing 
phosphopantetheine prosthetic group provides NRPSs with a flexible arm, approximately 
20 Å in length, which is used for substrate trafficking between individual enzymatic 
domains.13 The prosthetic group, which is derived from coenzyme A (CoA), is added to 
small carrier domains of NRPSs by a phosphopantetheinyl  transferase (PPTase).14 In 
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NRP biosynthesis, the enzymatic machinery acts as a template controlling the number 
and order of amino acids in the natural product. 
 The structural diversity of this class of natural products is greater than that of 
ribosomal peptides as NRPSs can utilize nonproteinogenic amino acids as building 
blocks. Indeed, over 200 nonproteinogenic amino acids appear in various NRP natural 
products.15 However, strict size limitations for NRPs arise from the fact that the 
biosynthetic machinery required for their synthesis is very large (~100 kDa of protein 
machinery per incorporated amino acid). Most NRPs contain between 2 and 10 
monomers. Representative examples of NRPs include the penicillins,16 the iron binding 
siderophore enterobactin,17 and the glycopeptide antibiotic vancomycin (Figure 1B).18  
 One hallmark of PNPs is the incorporation of unusual functionality not normally 
found in proteins. Modifications to amino acid building blocks and the peptide backbones 
in both classes of PNPs are introduced by specialized tailoring enzymes.19 These 
enzymes frequently catalyze unusual and chemically challenging transformations. The 
functionalizations introduced by such enzymes are often critical to the biological activity 
of PNPs. Biochemical and structural studies of tailoring enzymes will greatly aid in the 
development of novel chemoenzymatic methods for the production of natural product 
analogs with altered biological activities. Additionally, tailoring enzymes could find use as 
catalysts for the production of unusual amino acids or for the chemoselective formation 
of functional groups in synthetic peptide libraries.  
 
1.2 Biosynthesis of Nonribosomal Peptides 
 In NRP producing organisms genes responsible for the synthesis of non-natural 
amino acid precursors, peptide biosynthesis, immunity, regulation, and export are often 
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clustered together. The assembly of NRPs occurs in four main stages. First, the 
producing organism must acquire the proteinogenic and nonproteinogenic amino acid 
building blocks needed for NRP biosynthesis. Next, the amino acids are linked together 
via peptide bond formation. Chain termination then yields the full-length peptide, which 
can be further modified by tailoring enzymes to yield the biologically active natural 
product. 
 In NRPSs, each module is responsible for the incorporation of one amino acid 
into the PNP (Figure 2). Minimally, a module contains three distinct domains, which are 
often covalently linked to one another. Adenylation domains (A domains) are responsible 
for the selection and activation of a single amino acid monomer. After activation, the 
amino acid is covalently tethered to the assembly line on a peptidyl carrier protein (PCP 
domain) as a thioester. Condensation domains (C domains) then catalyze peptide bond 
formation between the amine of the downstream acceptor and the thioester carbon of 
the upstream amino acyl or peptidyl thioester donor. Thus, like proteins, NRPs are 
biosynthesized in an N- to C-terminal manner. After the full length peptide has been 
assembled, it is normally released from the assembly line by a thioesterase (TE) 
domain, which can catalyze hydrolysis yielding a C-terminal carboxylate or 
intramolecular cyclization resulting in the formation of a cyclic lactam, lactone, or 
thiolactone.20  Most NRPSs display a domain organization of A-PCP-(C-A-PCP)n-TE. 
The initiation module of NRPSs normally lacks a C domain, while the following modules 
may include any required additional domains. The assembly of polyketide (PK) natural 
products occurs via a similar thiotemplating mechanism,11,12 and many hybrid NRP-PK 
exist in nature.  
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Figure 2. Summary of the steps in an NRPS assembly line. The example of the construction of a dipeptide is illustrated. R and R'
represent amino acid sidechains.  
 The pathway to the antibiotic vancomycin, produced by Amycolatopsis orientalis, 
serves as a general example of NRP biosynthesis (Figure 3).18 The genes responsible 
for vancomycin biosynthesis, regulation, export, and self-resistance are clustered in a 
contiguous region of the genome. The biosynthesis of vancomycin begins with the 
assembly of nonproteinogenic amino acid precursors such as phenylglycine. Once the 
precursors have been made, they are covalently linked to the vancomycin synthetase as 
thioesters and are then joined together via peptide bond formation. The resulting 
heptapeptide undergoes post-synthetic tailoring steps, which introduce biaryl and biaryl-
ether crosslinks between the amino acid side chains. After hydrolysis of the modified 
peptide by the TE domain, the aglycon is decorated with sugar moieties to yield 
vancomycin.21 
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1.3 Biosynthesis of Ribosomal Peptides 
 Genes for the biosynthesis of RPs are also normally clustered in the genome of 
the producing organism.22 Ribosomal peptide natural products are usually derived from 
larger prepeptides. Once the gene encoding for the biosynthesis of this precursor has 
been translated by the ribosome, dedicated tailoring enzymes introduce modifications to 
the peptide.23 After these tailoring reactions have been completed, the functionalized 
peptide is normally cleaved by a peptidase yielding the natural product.24 The number 
and complexity of tailoring reactions utilized in the biosynthesis of ribosomal peptides 
rivals that found in NRP biosynthesis.25 However, ribosomal peptides generally have 
less structural diversity when compared to their nonribosomal counterparts. This 
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discrepancy results from the fact that the ribosome cannot use nonproteinogenic amino 
acids as building blocks. Indeed, no known RP biosynthetic pathways utilize non natural 
amino acids as precursors. Such activity would require the evolution of novel tRNAs and 
tRNA synthetase pairs specific for each nonproteinogenic amino acid.  
 The biosynthesis of the antibiotic nisin A serves as a general example of how 
ribosomal peptides are assembled (Figure 4).23 This natural product is 34 amino acids in 
length and contains a number of structural modifications including one lanthionine, 
several methyllanthionines, and three dehydro amino acids (Figure 4A). The genes 
responsible for the synthesis of nisin, immunity, and regulation are clustered on a 
conjugative transposon in the producing organism Lactococcus lactis.26 
 The gene nisA encodes for the nisin prepeptide, which contains 57 amino acids. 
The 23 amino acid N-terminal leader sequence, which is ultimately cleaved to generate 
the active natural product, has been shown to be important for recognition by the nisin 
tailoring enzymes and transport proteins.7 Once the mRNA encoding for nisin 
biosynthesis has been translated, the prepeptide is processed by two enzymes that 
catalyze lanthionine, methyl lanthionine, and dehydroamino acid formation. The resulting 
peptide is then transported across the cytoplasmic membrane and is cleaved by a 
peptidase to yield the nisin A. Like many ribosomally synthesized natural products, nisin 
displays no biological activity until its signaling sequence has been cleaved. 
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1.4 Comparison of Ribosomal and Nonribosomal Peptide Biosynthesis 
 The biosynthesis of both ribosomal and nonribosomal peptides occurs in a 
template-directed fashion.27,28  In ribosomal synthesis, the mRNA encoding for the 
prepeptide specifies the primary structure of the natural product. Conversely, in NRP 
biosynthesis the enzymatic machinery acts as the template and the number and order of 
domains in the synthetase specifies the primary sequence of the NRP natural product. In 
NRPSs, peptide assembly is preceded by the charging of PCP domains, which are 
approximately 100 amino acids in length, with a thiol-terminated phosphopantetheine 
arm (Ppant). Ppant is derived from CoA and is attached to a conserved Ser residue of 
the PCP domain by a phosphopantetheinyl transferase (PPTase) (Figure 5A).14 This 
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prosthetic group serves as the site of attachment for amino acid monomers to the 
assembly line. Although PCPs do not display catalytic activity, they serve a central role 
in the trafficking of substrates through the assembly line and interact with multiple 
protein binding partners.29  
  The activation of amino acids in both ribosomal and nonribosomal peptide 
synthesis occurs in similar manners. In ribosomal peptide synthesis, amino acids are 
recognized and activated by aminoacyl tRNA synthetases (Figure 5B).30 These enzymes 
utilize Mg2+ and ATP as cofactors and activate amino acids via a two-step mechanism. 
In the first step, the synthetase catalyzes mixed anhydride formation between the α-
phosphate of ATP and the carboxylate of an amino acid resulting in formation of an 
aminoacyl adenylate and pyrophosphate. In the second step, the activated amino acid is 
transferred to either the 2′- or 3′-hydroxyl group of the terminal adenine residue of the 
cognate tRNA. If the amino acid is linked to the 2′-hydroxyl of adenine, it undergoes 
rearrangement to the 3′-position. After formation, the aminoacyl tRNA is transferred to 
the ribosome as a ternary complex with the GTPase elongation factor Tu (EF-Tu).31 
 Similarly, activation of amino acids in NRPSs is catalyzed by adenylation 
domains. These domains, which are composed of approximately 550 amino acids, also 
use Mg2+ and ATP to form aminoacyl adenylates (Figure 5C).32 After activation has 
occurred, A domains catalyze the transfer of the amino acid to the thiol-terminated Ppant 
arm of the downstream PCP domain.  
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 Peptide bond formation in the ribosome and on NRPSs occurs via distinct 
mechanisms (Figure 6). During ribosomal synthesis, amide formation occurs between 
the α−amino group of the charged tRNA in the aminoacyl (A) site of the ribosome and 
the carbonyl carbon of the aminoacyl-tRNA in the peptidyl site (P). The site of this 
reaction is termed the peptidyl transfer center (PTC). Biochemical and structural studies 
have shown that the 2' hydroxyl group of an adenosine nucleotide residue of the 
peptidyl-tRNA acts as a proton shuttle and plays a prominent role in peptide bond 
formation.33,34 This residue likely acts as a base that deprotonates the amino-group of 
the aminoacyl-tRNA nucleophile in the A site of the ribosome. After peptide bond 
formation occurs, the 3' end of the deacylated tRNA in the P site and the peptidyl-tRNA 
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in the A site move to the exit (E) site and P site, respectively.35 This process is repeated 
until the full length peptide has been assembled.  
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 In NRPSs, C domains are responsible for catalyzing peptide bond formation 
between the amine of the downstream aminoacyl-S-PCP thioester and the upstream 
peptidyl thioester resulting in transfer of the growing peptide down the assembly line. C 
domains are composed of approximately 450 amino acids and share sequence 
homology with acyltransferases.36 Members of each of these classes of enzymes have a 
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conserved HHXXXDG motif.37 Biochemical experiments have shown that this motif is 
important for catalysis and the second histidine of this sequence is thought to act as an 
enzymatic base.38 
 The termination of protein synthesis in the ribosome is brought about by the 
binding of a stop codon in mRNA to the A site of the ribosome. When this molecular 
event occurs, several proteins known as release factors mediate hydrolysis of the full 
length peptide from the P site tRNA.39 The detailed molecular mechanism of chain 
release is not well understood.  Hydrolysis of the peptide to generate a C-terminal 
carboxylate is followed by disassembly of the ribosome complex.  
 
 In NRPS biosynthesis, chain termination is usually brought about by the action of 
a terminal TE domain. After the full length peptide has been formed, it is transferred to a 
conserved Ser residue in the TE domain yielding a peptidyl-O-TE intermediate. TE 
domains may catalyze hydrolysis or macrocyclization of the full length peptide (Figure 
7).20 Alternate strategies for chain termination in NRPSs exist. For instance, chain 
release via reduction, oxidation, and peptide condensation occurs in the biosynthesis of 
the NRPs anthramycin,40 melithiazol,41 and vibriobactin,42 respectively. The wide range 
of termination strategies in NRP biosynthesis contributes to the great structural diversity 
of this class of natural products. 
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 1.5 Engineering Peptide Biosynthetic Machinery 
 The combination of genetic, biochemical, and structural studies of enzymes 
involved in the biosynthesis of PNPs has led to the creation of new methods for 
engineering biosynthetic pathways. Ultimately, engineering these pathways may lead to 
the development of novel natural product analogs with altered bioactivity and potential 
therapeutic use. A detailed structural understanding of PNP biosynthetic pathways is 
beginning to emerge. The TE domain from surfactin biosynthesis has been structurally 
characterized43 and the structures of two adenylation domains involved in the 
biosynthesis of NRPs have been solved.44,45 Additionally, the structure of a PCP domain 
from the biosynthetic pathway to tyrocidine has been extensively studied using NMR 
spectroscopy29 and the  freestanding condensation domain in vibriobactin biosynthesis 
has been studied using X-ray crystallography.36 The structures of several multidomain 
NRPS constructs have also been solved. These include a PCP-C didomain from the 
tyrocidine synthetase,46 a PCP-TE didomain from the enterobactin synthetase,47 and a 
full length C-A-PCP-TE termination module from the gramicidin synthetase.48 Together, 
these studies have provided detailed information about domain-domain interactions and 
the overall structure of synthetase modules. This information will be critical for future 
efforts involving the engineering of NRPS machinery.  
 Designing new NRPSs which produce desired peptide analogs is challenging for 
a number of reasons. First, the biosynthetic machinery is very large and accurate 
peptide formation relies on a number of protein-protein interactions between domains. 
Unfortunately, linker regions between domains share little homology with one another 
making it difficult to engineer modules which communicate with one another.3 
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Additionally, the substrate specificity displayed by individual A, C, and TE domains make 
‘domain swapping’ difficult.49   
 Several approaches to engineering NRPS assembly lines have been reported. 
Marahiel and colleagues have shown that the PCP-TE bidomain of the termination 
module of gramicidin S synthetase can be used to oligomerize and cyclize a number of 
peptidyl thioesters.50 Additionally, Stachelhaus et. al. have carried out ‘domain swapping’ 
experiments in which the terminal A-PCP bidomain in the surfactin synthetase was 
replaced with A-PCP bidomains with altered substrate specificity. The engineered 
synthetases were able to produce novel peptides, but they suffered from limited activity 
due to the specificity of the upstream C domain.51 Moreover, Doekel and Marahiel have 
reported that by carefully designing linker regions between two independent modules, 
functional hybrid NRPSs can be constructed.52 Additional efforts involving the creation of 
engineered NRP pathways have focused on rationally altering the specificity of A 
domains in synthetases53 and controlling protein-protein interactions between modules 
that are not covalently attached to one another.54 Chimeric NRPSs generated by the 
above methods often suffer from low activity and produce unwanted shunt metabolites. 
Recently, Fishbach and coworkers have shown that the activity of chimeric NRPS 
assemblies can be improved via directed evolution.55 This technique shows great 
promise for future efforts aimed at engineering NRPSs. 
 Efforts focusing on the generation of novel RP natural product analogs using 
biosynthetic engineering have had greater success. Frequently, tailoring enzymes that 
act upon RP natural product precursors recognize only the N-terminal signaling 
sequence of the peptide and the side-chain functional groups that they modify.25 Thus, it 
is possible to introduce point mutations in the gene encoding for the prepeptide and use 
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in vivo methods for the production of novel RP analogs. This strategy has been 
employed for the generation of numerous nisin analogs.22,56 In some cases, mutations to 
the prepeptide do not result in the production of the predicted analog, and the rules 
governing recognition of the prepeptide by tailoring enzymes are not completely 
understood.23 Thus, the production of novel peptide analogs using such methods can be 
difficult. 
 
1.6 Tailoring Enzymes in PNP Biosynthetic Pathways 
 PNPs often display conformational rigidity, membrane-permeability, and 
resistance to proteolysis.25 These characteristics, along with the biological activity of the 
natural product, are dependent on the presence of structural motifs not normally found in 
proteins. Modifications to the peptide backbone of a natural product can be catalyzed by 
a number of different tailoring enzymes. Studies concerning the structure of tailoring 
enzymes and the unusual reactions they catalyze will greatly contribute to our 
understanding of natural product biosynthesis. Information gained from such studies can 
be used to engineer tailoring enzymes for the production of novel building blocks and 
natural product analogs.  
 NRP and RP natural products contain many of the same modifications. These 
modifications are often introduced by non-homologous tailoring enzymes that catalyze 
similar transformations. Such enzymes presumably arose through convergent 
evolution.25  The most common tailoring enzymes found in NRP and RP biosynthetic 
pathways will be discussed in detail below. 
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1.7 Heterocycle Formation in Peptidic Natural Products 
 Many ribosomal and nonribosomal natural products contain 5-membered 
heterocyclic rings. These moieties are formed via cyclodehydration reactions between 
sidechain thiols of Cys residues or hydroxyl groups of Ser or Thr residues with an 
adjacent carbonyl carbon in the peptide, resulting in formation of thiazoline, oxazoline, 
and methyloxazoline moieties, respectively.57 In the biosynthesis of both RP and NRPs, 
the resulting heterocycles can be oxidized to produce thiazoles, oxazoles, or 
methyloxazoles. The presence of heterocyclic moieties dramatically alters the peptide 
backbone and makes the resulting product resistant to hydrolysis and proteolytic 
cleavage.19  
 In NRPS biosynthesis, heterocyclic ring formation is catalyzed by cyclization (Cy) 
domains (Figure 8A). These domains are evolutionarily specialized C domains that 
catalyze amide bond formation as well as cyclodehydrations. Cy domains contain a 
conserved DXXXXD sequence in place of the HHXXXXDG found in C domains.37 The 
second aspartate of this motif in the Cy domain is important for both amide bond 
formation and heterocyclization.58 Recent studies of the Cy domain from the bacitracin 
synthetase have shown that Cy domains first catalyze peptide bond formation between 
the donor and acceptor substrates, which is followed by the cyclization and dehydration 
reactions.59 
 In ribosomal peptide biosynthesis, heterocyclic ring formation is usually catalyzed 
by a zinc-binding tailoring enzyme (Figure 8B). The formation of heterocyclic rings in the 
RP microcin B17, which contains four oxazoles and four thiazoles, has been well 
studied.60 Formation of all four heterocycles is catalyzed by the enzyme complex 
McbBCD, which contains a zinc-dependent protein, a docking domain with 
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ATPase/GTPase activity, and an oxidase. It is thought that the zinc-dependent protein, 
McbB, is responsible for heterocyclization although this assumption is difficult to prove 
since removal of any of the three proteins from the complex results in loss of 
heterocyclization activity.61 After formation of the heterocyclic rings in the prepeptide has 
occurred, the flavin (FMN)-dependent enzyme McbC catalyzes oxidation of the 
thiazoline and oxazoline rings to thiazoles and oxazoles, respectively.62 A similar 
biosynthetic logic is used in the formation of the RP patellamide A, although the enzyme 
complex responsible for heterocycle formation of this compound lacks an 
ATPase/GTPase domain.9   
 
 The enzymes responsible for heterocycle formation in NRP and RPs share no 
homology with one another; however, NRPSs contain oxidase domains (Ox) which are 
related to those used in RP biosynthetic pathways. In NRPSs, these domains also 
require FMN as a cofactor and are used in the formation of oxazoles and thiazoles 
(Figure 9A).63 These domains are usually inserted into an adenylation domain, although 
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they may also act in trans.64  In NRP biosynthesis, oxazolines and thiazolines can also 
be reduced to the corresponding thiazolidines and oxazolidines (Figure 9B). Such a 
reaction is carried out by an in trans acting NAD(P)H-dependent reductase domain (R) in 
pycochelin biosynthesis.65 Reductive tailoring of this nature is not known in RP 
biosynthesis.  
 
 
1.8 D-Amino Acid formation in Peptidic Natural Products 
 D-amino acids are frequently incorporated in NRPs. These modified building 
blocks increase the protease resistance of natural products.66 In NRPs, D-amino acids 
can be assembled in three different manners. In cyclosporin67 and leinamycin68 
biosynthesis, D-amino acids are formed from L-amino acid precursors by PLP-dependent 
racemases. After epimerization has occurred, the amino acids are adenylated and 
loaded onto NRPS assembly lines. In most instances, D-amino acids are formed on 
NRPS assembly lines by epimerization (E) domains within a C-A-PCP-E module. 
Epimerization domains are ~470 amino acids in length and contain a similar HHXXXDG 
motif found in C domains.36 Rapid-quench kinetic experiments have shown that E 
domains catalyze the formation of an equilibrating mixture of D- and L-PCP bound 
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intermediates.69 The donor site of the corresponding downstream C domain displays 
enantioselectivity and reacts only with the D-enantiomer of the upstream aminoacyl or 
peptidyl-S-PCP intermediate.70  
 
 NRPS assembly lines may also contain hybrid E/C domains. These specialized 
condensation domain directly follow a C-A-PCP module that activates an L-amino acid. 
After formation of the aminoacyl-S-PCP acceptor on the module containing the E/C 
domain has occurred, this domain catalyzes the epimerization of the α-carbon on the 
upstream donor followed by amide bond formation.71 These domains are termed DCL 
catalysts and have a conserved HH[I/L]XXXXGD motif at their N-terminus in addition to 
the conserved His sequence found in normal C domains.72,37 
 D-amino acids are relatively rare in ribosomal peptide natural products. Two 
bacteriocins, gasserin A73 and reutericin 6,74 contain D-Ala residues. The formation of D-
Ala in these natural products has not been biochemically characterized. Additionally, the 
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RP trunkamide A contains a D-Phe residue adjacent to a thiazoline ring. However, the 
formation of this D-amino acid is likely not enzyme catalyzed (Figure 10B).75 Several 
RPs, such as lacticin 3147 contain D-Ala residues derived from Ser through a two-step 
process involving dehydration followed by diastereoselective reduction of the resultant 
dehydroalanine (Figure 10C).76 
 
1.9 Dehydro Amino Acids and Lanthionines in Peptidic Natural Products 
 Eneamino acids and lanthionine functional groups are found in many RP natural 
products including nisin A26 and sublancin.77 The α,β-unsaturated amino acids in these 
compounds arise from dehydration of Ser or Thr residues yielding 2,3-didehydroalanine 
and (Z)-2,3-didehydrobutyrine, respectively (Figure 4B). These reactions are catalyzed 
by ATP and Mg2+ dependent dehydratase enzymes generally termed LanB proteins 
(Figure 11A).78 The resulting α,β-unsaturated amide is highly reactive, and these 
modified sidechains are known to react both intra- and intermolecularly with various 
nucleophiles.79 Often, these functional groups react with the thiol sidechain of Cys 
residues within the same peptide yielding either lanthionine or methyllanthionine rings 
(Figure 4A). The cyclization reaction occurs in a stereoselective fashion and is catalyzed 
by zinc-dependent cyclases termed LanC enzymes.78 The lanthionine functional group 
provides structural rigidity and increases the protease resistance of RPs.80   
 The formation of these functional groups in the lantibiotic lacticin 481 has been 
well studied. The enzyme LctM, catalyzes dehydration of Ser and Thr residues as well 
as cyclization to form lanthionine rings during the biosynthesis of this natural product. 
Biochemical experiments have shown that this two-domain enzyme uses ATP to 
phosphorylate the hydroxyl side chains of Ser and Thr sidechains prior to dehydration 
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(Figure 11A).81 After formation of the eneamino acids is complete, the second domain of 
this enzyme catalyzes lanthionine formation.82 The structure of the cyclase NisC from 
nisin biosynthesis revealed that these cyclase enzymes use a coordinated zinc ion to 
catalyze intramolecular heterocyclization (Figure 11B).83  
 
 Although several NRPs including syringomycin84 and the microcystins85  contain 
dehydro amino acids, no known compounds of this class contain lanthionine 
functionality. The mechanism of Ser and Thr dehydration in the biosynthesis of NRPs is 
not yet known. 
 
1.10 Formylated Amino Acids in Peptidic Natural Products 
 Some NRPs, such as linear gramicidin86 and anabaenopeptilid,86 have N-
formylated amino acids at their N-terminus. The NRPSs encoding for the biosynthesis of 
these compounds contain a formylation (F) domain in an initiation module with a domain 
organization of F-A-PCP. The formyl group of these natural products is derived from the 
cofactor N10-formyltetrahydrofolate (Figure 12A).87 
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  Several RPs, such as lacticin Q88 and aureocin A53,89 contain N-
formylmethionine residues. Among the RPs, these compounds are unusual as they lack 
an N-terminal leader sequence. As in protein synthesis, the formyl group is added to the 
N-terminal methionine residue by a formyltransferase while it is attached to the initiating 
fMet-tRNA.90 In most RPs, the presence of an N-terminal fMet residue is not long lived 
and the formyl group is removed by a peptide deformylase after translation.91 
Alternatively, the N-terminal methionine can be removed by methionine aminopeptidase 
(Figure 12B).92  
 
1.11 Methylation of Peptidic Natural Products 
 N-methyl amides are present in many NRPs including complestatin,93 
chondramide,94 and cyclosporine.95 These methyl groups are introduced by S-
adenosylmethionine (SAM) dependent N-methyl transferase domains (N-MTs). These 
domains are incorporated within A domains in an NRPS module with a C-A-MT-PCP 
domain organization (Figure 13A).96 Oxygen MT  domains (O-MTs) that methylate 
tyrosine side chains are used in the biosynthetic pathways to the NRPs 
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anabaenopeptilide97 and cryptophycin (Figure 13B).98 Two additional types of MT 
domains are found in NRP biosynthetic pathways. Carbon MT domains (C-MTs) are 
utilized in the biosynthesis of yersiniabactin99 and daptomycin.100 In the yersiniabactin 
synthetase, this C-MT domain is within a Cy-MT-PCP-TE module and catalyzes 
methylation at the α-carbon of an intermediate thiazoline ring (Figure 13B).99 The C-MT 
domain utilized in the biosynthesis of daptomycin is not located on the assembly line, 
and it methylates the soluble substrate α-ketoglutarate.100 Additionally, the melithiazol 
synthetase utilizes a MT domain in trans to form a C-terminal methyl ester in this natural 
product.41 
 
 No known RPs contain N-methyl amides. However, the RP cypemycin contains 
an N-methylated Ala residue at its N-terminus101 while microcyclamide from M. 
aeruginosa contains a His residue with an N-methylated sidechain (Figure 13C).102 
Methylation of these two natural products have not been biochemically characterized. 
 
1.12 α-Hydroxy Acid Moieties in Peptidic Natural Products 
 The valinomycin103 and cereulide104 NRPSs contain ketoreductase domains (KR), 
which are used for the synthesis of α-hydroxy acid building blocks. These enzymes 
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utilize NAD(P)H as a cofactor, and are found within modules with an A-KR-PCP domain 
organization (Figure 14A). The A domains of these modules selectively activate α-keto 
acids and catalyze the formation of an α-ketoacyl-S-PCP intermediate, which is 
subsequently reduced to a PCP-bound, α-hydroxythioester by the KR domain. The 
substrate specificity of these enzymes differs from KR domains in PKSs, which 
selectively reduce β-ketoacyl substrates. 
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Figure 14. (A) Formation of -hydroxy acids by ketoreductase (KR) domain in NRPS biosynthesis. (B) Probable route to -hydroxy
acids in RP biosynthesis.  
 α-Hydroxy acids are found infrequently in ribosomal peptides. Several RPs, 
including epilancin K7,105 contain N-terminal 2-hydroxypropionyl units. This moiety is 
likely derived from L-Ser in a multistep process involving dehydration, spontaneous 
conversion of the resultant dehydroalanine to a 2-oxopropionyl unit, and reduction of the 
resultant α-ketoamide to an α-hydroxyamide (Figure 14B).25 The reductases involved in 
these transformations have not been biochemically characterized.  
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1.13 Disulfide Bond Formation in Peptidic Natural Products 
 Frequently, ribosomal peptides including entorcin A and other type II bacteriocins 
contain disulfide functional groups.106 In most instances, disulfide formation occurs in a 
spontaneous fashion due to the proximity of two Cys sidechains.107 Alternatively, 
disulfide formation can also be catalyzed by enzymes termed protein disulfide 
isomerases (PDIs, Figure 15A). As an example, in vivo experiments have shown that the 
deletion of the PDI enzymes BdbB and BdbC in B. subtilis results in the formation of 
sublacin 168 analogs that lack disulfide bridges.108 
 
 Disulfides are much less common in NRPs. The nonribosomal peptide FK228 
contains a disulfide linkage between L-Cys and D-Cys residues. The formation of this 
disulfide bridge is likely catalyzed by an FAD-dependent pyridine nucleotide-disulfide 
oxidoreductase;109 however, this enzyme has not been biochemically characterized. 
Additionally, gliotoxin and other structurally related NRPS diketopiperazines contain 
unusual disulfide linkages between sulfur atoms added to the peptide backbone (Figure 
15B).110 The biosynthetic origin of these sulfur atoms and the resultant disulfide bridge is 
unclear at present. 
 
1.14 Glycosylation of Peptidic Natural Products 
 Highly modified sugar moieties are frequently incorporated in PK and NRP cores. 
The addition of sugars to the aglycon cores of these natural products is crucial to their 
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biological activity.111 The glycosyltransferases utilized in the biosynthesis of vancomycin 
have been structurally and biochemically characterized (Figure 16).21 The glucosyl 
transferase GftE catalyzes the addition of a glucosyl moiety to the phenolate of the 4-
OH-PheGly4 residue of the vancomycin aglycon. The resulting intermediate is further 
modified by the vancosaminyl transferase GtfD, which adds a vancosaminyl sugar to the 
C2'-oxygen of the glucose sugar. The structures of the vancosaminyl transferase GtfD112 
and the UDP-glucosyltransferase GtfB113 from the biosynthetic pathways of vancomycin 
and chloroeremomycin, respectively, have been structurally characterized. Additionally, 
the enzymes GtfE and GtfD from the vancomycin pathway have been utilized in the 
production of novel teicoplanin analogs containing altered sugar moieties.114 These 
studies showed that tailoring enzymes could be useful for the production of novel natural 
product analogs.  
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 To date, microcin E492m is the only example of a glycosylated bacteriocin of 
ribosomal origin. This natural product, produced by Klebsiella pneumoniae, consists of 
the ribosomal peptide MceA linked to the linearized form of the E. coli siderophore 
enterobactin through a glucose moiety.115 Recent studies concerning the biosynthesis of 
this highly unusual ‘trojan horse’ antibiotic have shown that the C-glycosyltransferase, 
MceC, catalyzes C-C bond formation between UDP-glucose and the aromatic ring of a 
dihydroxybenzoyl moiety of enterobactin (Figure 17). 116 The enzyme MceD then 
hydrolyzes one of the trilactone linkages of enterobactin, and the resulting compound is 
attached to the ribosomal peptide MceA by the enzyme complex MceIJ. This enzyme 
complex first activates the carboxy terminus of MceA via adenylation yielding a peptidyl-
adenylate that undergoes nucleophilic attack by the C4'-hydroxyl of the glucose moiety. 
The resulting intermediate is converted to the active, natural product via a spontaneous, 
base catalyzed rearrangement. 
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1.15 Macrocyclization in Ribosomal Peptides  
 As discussed above, macrocycle formation in NRP biosynthetic pathways is 
frequently catalyzed by TE domains that can form lactones, lactams, or thiolactones as 
products.20 Macrocyclization of ribosomal peptides occurs via several distinct 
mechanisms, and both N- to C-terminal and side-chain cyclizations are observed in RPs. 
The formation of macrocylic ring structures in ribosomal peptides has not been 
thoroughly studied and few mechanistic details are available concerning these 
transformations, which typically occur after proteolytic cleavage of the N-terminal leader 
sequence of the requisite prepeptide. Several studies focused on the cyclization of RPs 
are discussed in detail below.  
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  Recently, the gene clusters responsible for the biosynthesis of several N- to C- 
terminally cyclized cyanobactins have been sequenced.117 Each of these clusters 
encodes for two serine proteases similar to the proteases PatA and PatG found in the 
patellamide biosynthetic pathway.118,119 Schmidt and co-workers have shown that PatG 
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and its homologs catalyze both proteolysis of a C-terminal recognition sequence in 
cyanobactin prepeptides and subsequent cyclization of the resulting intermediate (Figure 
18A). A ‘transamidation’ mechanism was used to explain enzyme activity (Figure 
18B).118 
 The cyclization between an N-terminal Gly residue and the side-chain of a Glu 
residue of Microcin J25, a lasso peptide from E. coli, has also been studied.120 In vivo 
experiments revealed that the ATP/Mg2+ dependent enzyme McjC is responsible for 
macrocyclization (Figure 18C). This enzyme, which shows homology to the C-terminal 
domain of asparagine synthetase, likely activates the carboxylate of the requisite Glu 
residue as an aminoacyl adenylate as the first step in macrocyclization. In vitro 
experiments involving this enzyme have not been reported. 
 Microviridins are unusual ribosomal peptides which contain an unprecedented 
tricyclic depsipeptide cage-like core. Recently, Hertweck, Dittmann and co-workers 
reported the sequence analysis of the gene clusters responsible for the biosynthesis of 
microviridins B and J.121 Both gene clusters encode for two ATP-grasp like proteins. The 
heterologous expression of the gene cluster responsible for microviridin biosynthesis in 
E. coli revealed that the two ATP-grasp proteins were necessary for macrocycle 
formation (Figure 18D). Studies concerning the structure and function of the ATP-grasp 
ligases involved in microviridin J biosynthesis are currently underway in our lab. The 
results of these investigations will be discussed in depth in Chapter 4 of this work. 
 
1.16 Nonproteinogenic Amino Acids in NRPS biosynthesis 
 Over 350 nonproteinogenic amino acids exist in nature, and many of these are 
found in NRP natural products.15 Adenylation domains specific for each 
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nonproteinogenic amino acid are used to incorporate these monomers into the peptide 
cores of NRPs. Conversely, the incorporation of such building blocks in RPs, would 
require a unique codon/anticodon pair as well as a dedicated tRNA, and tRNA 
synthetase. For this reason, nonproteinogenic amino acids are not utilized as building 
blocks for RPs. 
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Figure 19, Summary of pathways to nonproteinogenic amino acids found in NRP natural products.  
 In NRP pathways, nonproteinogenic amino acids can be derived in three ways: i) 
from natural metabolic intermediates ii) via multistep pathways from simple biosynthetic 
precursors and iii) from modifications to proteinogenic amino acids. When such building 
blocks are derived from normal cellular metabolites, the genes encoding for their 
production are not typically clustered with NRPS genes. Examples of nonproteinogenic 
amino acids derived from cellular metabolites include L-aminoadipic acid, L-ornithine, D-
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alanine, and β-alanine.  L-Aminoadipic acid and L-ornithine are found in the penicillin 
antibiotics122 and various NRP siderophores,123 respectively (Figure 19A). L-aminoadipic 
acid is an intermediate in the metabolic pathway to lysine, while L-ornithine is a common 
intermediate in the biosynthesis of proline and arginine.124  
 β-Alanine and D-alanine are utilized in the biosynthesis of kirromycin125 and 
leinamycin,68 respectively (Figure 19A). In primary cellular metabolism, β-Alanine is 
derived from the decarboxylation of aspartate and is incorporated into Co-A.126 D-alanine 
is commonly found in bacterial cell walls, and this amino acid is produced from L-alanine 
by a PLP-dependent racemase.127 
 A limited number of nonproteinogenic amino acids incorporated in NRP natural 
products are not derived from available amino acids.  In these examples, the natural 
product biosynthetic gene clusters encode enzymes that prepare the nonproteinogenic 
amino acids from common cellular precursors via multistep pathways. Two examples of 
these types of building blocks are discussed below.  
 First, the vancomycin class of glycopeptides antibiotics utilize (S)-3,5-
dihydroxyphenylglycine (Dpg) as a building block (Figure 19B).18 Five gene products are 
responsible for the biosynthesis of this nonproteinogenic amino acid, which is derived 
from malonyl-CoA. The carbon skeleton of this moiety is constructed by three enzymes 
from a Type III PKS pathway generating a 3,5-dihydroxyphenylacetyl-CoA 
intermediate.128,129 Benzylic oxidation of this intermediate by the unusual, cofactor free 
and metal-independent dioxygenase DpgC yields 3,5-dihydroxyphenyl-2-oxoacetic acid 
which is converted to Dpg by an aminotransferase.130,131 Another recently described 
example of this category is the pathway to L-3-cyclohex-2'-enylalanine from 
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salinosporamide biosynthesis (Figure 19B).132 Recent labeling studies established that 
this amino acid is derived from shikimic acid via a multistep pathway.133  
 Nonproteinogenic amino acid building blocks can also be derived from the 20 
natural amino acids. One interesting example of this biosynthetic logic occurs en route to 
the NRP barbamide produced by L. majuscule (Figure 19C).134,135 This unusual natural 
product contains a δ-trichloro-L-leucine residue derived from L-leucine. In the pathway to 
this building block, L-leucine is first activated by the adenylation domain BarD and is then 
tethered to the PCP domain BarA as a thioester. This Leu-S-PCP intermediate serves as 
the substrate for two halogenases, BarB2 and BarB1, which catalyze the addition of 
three chlorine atoms to the δ-carbon of the Leu-S-PCP substrate. These two 
halogenases are homologs of α-ketoglutarate-dependent nonheme iron oxygenases,136 
and they both use Fe-centers to generate a reactive Cl-radical, which is transferred to 
‘unreactive’ δ-carbon of leucine.  
 Aromatic β-amino acids are found in several NRP derived natural products 
including paclitaxol,137 chondramide,138 and C-1027 (Figure 19C).139 These building 
blocks are derived from natural L-amino acids by the action of aminomutase enzymes, 
which utilize the unusual electrophilic prosthetic group 4-methylideneimidazole-5-one to 
catalyze a 2,3-amino shift.140 The mechanism of this transformation remained a topic of 
debate for over 50 years. The structure and function of the tyrosine aminomutase from 
C-1027 biosynthesis has been extensively studied in our laboratory and will be 
discussed in detail in Chapters 2 and 3 of this work. 
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Chapter 2 
 
 
 
Structure of the L-Tyrosine 2,3-Aminomutase, 
SgTAM 
 
 
 
 
 
 
Adapted from Christianson, C.V.; Montavon, T.J.; Van Lanen, S.G.; Shen, B.; Bruner, 
S.D. Biochemistry 2007, 46, 7205-7214.
2.1 Biosynthesis of the Enediyne Antitumor Antibiotic C-1027 
 In 1988, Otani and co-workers reported the isolation of the enediyne antitumor 
antibiotic C-1027 from the culture broth of the actinomycete Streptomyces globisporus.1 
The compound was isolated as a 1:1 complex with its apoprotein.2 Due to its labile 
nature, the structure of this enediyne was not solved until 1993 (Figure 1).3,4 C-1027 is 
the most potent enediyne yet isolated,5 and it displays activity against a wide number of 
cancer cells including leukemia L1210 and hepatoma H22 cells.6 C-1027 undergoes a 
spontaneous Masamune-Bergman cyclization7 in the absence of external activators, and 
has a half-life of 0.8 hours in methanol at room temperature.8  
 The potent biological activities and unique structures of enediynes prompted 
many researchers to study the biosynthetic origin of these compounds. Early labeling 
studies, which involved feeding producing organisms 13C-labelled acetate, established 
that the enediyne core of these compounds were likely constructed via a polyketide  
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pathway.9,10,11 In 2002, Thorson and Shen reported the sequencing of the biosynthetic 
gene clusters responsible for calicheamicin and C-1027, respectively.12,13 These studies 
revealed that enediynes were biosynthesized in a convergent manner. For instance, 
Shen’s studies established that the enediyne, deoxyamino sugar, benzoxazolinate, and 
β-tyrosine moieties of C-1027 were biosynthesized separately and subsequently coupled 
together by three enzymes to generate the natural product (Figure 1). 
 Further analysis of the C-1027 gene cluster suggested that the (S)-3-chloro-5-
hydroxy-β-tyrosine moiety of C-1027 was derived from L-tyrosine. Subsequent in vivo 
and in vitro experiments revealed the order of all steps involved in the biosynthesis of 
this moiety and its incorporation into the core of C-1027 (Figure 2).14 The conversion of 
L-tyrosine to (S)-β-tyrosine catalyzed by SgTAM is the first step in this pathway. The 
resulting β amino acid is then activated as an aminoacyl adenylate by the NRPS A 
domain SgcC1 and transferred to the peptidyl carrier protein SgcC2.15  This aminoacyl-
S-PCP intermediate serves as the substrate for the halogenase SgcC316 and the 
resulting intermediate is hydroxylated by SgcC.17 Finally, SgcC5 transfers the (S)-3-
chloro-β-tyrosine moiety to the enediyne core of C-1027 (Figure 2).  
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 The conversion of L-tyrosine to (S)-β-tyrosine in this pathway is particularly 
interesting. Enzymes which catalyze a 1,2-amino shift are termed aminomutases. At the 
time of Shen’s original study, only three types of aminomutase enzymes were known. 
The first class of aminomutases includes D-ornithine 5,4-aminomutase,18 leucine 2,3-
aminomutase,19 and D-lysine 5,6-aminomutase.20 These enzymes utilize both 
adenosylcobalamin and pyridoxal phosphate (PLP) for catalysis. Conversely, lysine 2,3-
aminomutese uses PLP and a four-iron-four-sulfur cluster to achieve amino migration.21 
These two classes of aminomutases utilize complex, radical-based chemistry to catalyze 
an amino shift. Glutamate 1-semialdehyde aminomutase differs from the above two 
types of aminomutases as it uses only PLP as a cofactor.22 Furthermore, the mechanism 
of the reaction catalyzed by this enzyme does not rely on radical generation.  
 No gene products from the biosynthetic pathway to C-1027 share homology with 
known types of aminomutases. However, the gene sgcC4 encodes for a protein 
displaying similarity to a class of enzymes known as histidine ammonia lyases (HALs).23 
These enzymes contain the unusual electrophilic prosthetic group 4-
methylideneimidazole-5-one (MIO) and catalyze the non-oxidative elimination of 
ammonia from the aromatic amino acids histidine, phenylalanine, and tyrosine (Figure 
3).  Shen and coworkers expressed the protein encoded for by sgcC4 in E. coli. They 
showed that this protein, a tyrosine aminomutase named SgTAM, contained MIO and 
catalyzed the formation of (S)-β-tyrosine from L-tyrosine.24 Thus, the reactivity of SgTAM 
differed from that of all other known MIO-containing enzymes and this enzyme 
represented a new class of aminomutases.   
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 2.2 History of MIO-containing Enzymes 
  In 1912 the molecular structure of urocanic acid was reported by Hunter, who 
suggested that it was derived from histidine as cinnamic acid was derived from 
phenylalanine.25 His observation led to a number of studies concerning the origin of this 
compound.26,27,28 Subsequent research showed that cell-free extracts from various 
organisms were able to convert histidine into glutamate. In 1926 Edlebacher showed 
that liver extracts catabolized histidine, and he termed such systems “histidases”.29  The 
conversion of histidine to glutamate was the subject of multiple research efforts, and 
several mechanistic proposals were put forth to describe this pathway.26,27,28
 In 1952, Tabor and Hayaishi found that cell-free extracts of Pseudomonas 
fluorescens could convert histidine to glutamic acid, formic acid, and two equivalents of 
ammonia.30 Further experiments showed that these extracts produced 15N ammonium 
when histidine containing a radiolabelled α-amine was used as a substrate, while 15N-
labelled glutamic acid was produced from histidine containing a radiolabelled γ-nitrogen. 
These experiments established that the first step in histidine catabolism was the 
production of urocanic acid.31 Three years later, the partial purification of the enzyme 
responsible for urocanic acid formation, termed “histidase” (later histidine ammonia 
lyase), was described by Tabor and Mehler.32  
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 The first mechanistic proposal concerning the elimination of ammonia from 
aromatic amino acids was put forth by Peterkofsky in 1962.33 He reported the 
biochemical characterization of histidine ammonia lyase from Pseudomans fluorescens 
and found that the optimal pH for enzyme activity was ~9.0. Peterkofsky noted that 
radiolabelled histidine was obtained when the enzyme was treated with both histidine 
and 2-14C-urocanic acid. However, no radiolabelled histidine was found when the 
enzyme was incubated with ammonia and 2-14C-urocanic acid. Additionally, when T2O 
was added to a reaction containing enzyme and histidine, tritium was found only at the 
β-position of histidine. These observations led Peterkofsky to propose that the reaction 
involved a covalent histidine amino-enzyme intermediate.  
 The nature of the enzymatic group responsible for reacting with the α-amine of 
histidine was unknown at the time. Subsequent experiments showed that histidine 
ammonia lyases (HALs) and phenylalanine ammonia lyases (PALs) most likely did not 
contain metal ions or a PLP cofactor34,35 but that these enzymes could be deactivated by 
treatment with nucleophilic reagents such as NaBH4 or CH3NO2.36 In 1969, separate 
experiments performed by Havir and Wickner on PAL and HAL, respectively led to the 
suggestion that both enzymes contained a dehydroalanine which acted as a catalytic 
electrophile (Figure 4).37,38 In these experiments, ammonia lyase enzymes were treated 
with tritium labeled NaB3H4. After hydrolysis of the inactivated enzymes, the tritium label 
was found at the β- position of alanine (Figure 4A). Pre-treatment of both ammonia 
lyases with their respective substrates prevented inactivation by NaBH4, providing strong 
evidence that the dehydroalanine was located in the active sites of lyases. 
  Later that year, Givot, Smith, and Abeles suggested that the dehydroalanine 
prosthetic group was bound to the enzyme as an imine. In this study, HAL from P. 
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fluorescens was first treated with 14C-labelled nitromethane. The resulting inactivated 
enzyme was then digested with trypsin, and the nitro group of labeled amino acids was 
reduced.39 This sequence yielded radiolabelled 2,4-diaminobutyrate, which was the 
expected product, and also gave 4-amino-2-hydroxy butyrate (Figure 4B). The latter 
product could only be obtained by hydrolysis of an imine linked to the protein backbone. 
These observations led Hanson and Havir to propose a mechanism for HAL and PAL 
activity involving 1,4-addition of the substrate’s amine to the β-carbon of the enzymatic 
electrophile as the first step. This amine addition mechanism was generally accepted for 
the next 30 years (Figure 5).40 
 
 These and other early biochemical experiments revealed important details about 
the mechanism of ammonia lyase activity.  First, the optimal pH range for lyase activity 
in each of the above studies was found to be between 8.5 and 9.0. Additionally, the 
stereochemistry of the elimination catalyzed by these lyases was found to occur in a 
trans fashion.39 Kinetic studies of PAL from potato tubers by Hanson and Havir showed 
that cinnamate was released before ammonia.41 Similarly, Abeles found that the rate 
limiting step in the reaction catalyzed by HAL from P. putida was the release of ammonia 
by the enzyme.39  
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 In their studies of PAL from potato tubers, Hanson and Havir noted that D-
phenylalanine acted as a competitive inhibitor with a Ki of 0.38 mM. However, 
pretreatment of the enzyme with D-phenylalanine followed by addition of NaBH4 did not 
protect the enzyme from inactivation. This result suggests that the inhibitor binds to the 
active site of the enzyme but does not covalently modify the electrophilic prosthetic 
group.41 Further studies using a number of inhibitors probed the structural requirements 
for lyase specificity. These studies revealed that HAL could only accept a limited number 
of substrates, while PAL was more promiscuous. 42,43 
 In 1985, Hermes and co-workers expanded upon the mechanism proposed by 
Hanson and Havir. By studying 15N isotope effects of 1,4-dihydrophenylalnine with PAL 
from Rhodotorula glutinus, Hermes showed that a carbanion intermediate was formed in 
the active site of the enzyme (Figure 5). Additionally, these experiments suggested that 
the first steps in the reaction were deprotonation of the substrate’s amine followed by 
addition to the electrophilic prosthetic group.44 Further experiments performed by 
Kasuya and coworkers revealed that the reaction catalyzed by HAL involved the 
reversible formation of a carbanion intermediate.45 These researchers utilized histidine 
with a 2H label at the C-5′ position of the substrate’s ring for kinetic studies. They found 
that the formation of unlabelled urocanic acid occurred at a constant rate over the time 
course of the experiments (Figure 5). The loss of the deuterium label from the substrate 
at a constant rate supports a reversible mechanism involving a carbanion.  
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 Together, these observations support the mechanism for lyase activity as shown 
in Figure 6 with PAL as the enzyme. The electrophilic prosthetic group is shown as MIO, 
although this group was thought to be a modified dehydroalanine residue until the crystal 
structure of HAL from Pseudomonas putida was solved by Rétey and coworkers in 
1999.46 In this mechanism, which is an extension of that proposed by Hanson and Havir, 
phenylalanine first binds to the active site of PAL and its α-amino group undergoes a 
1,4-addition to the exocyclic methylene carbon of MIO forming a covalent adduct. 
Removal of the substrate’s pro-(S) benzylic hydrogen by an enzymatic base yields a 
carbanion intermediate. Elimination of ammonia produces cinnamic acid and an amino-
MIO adduct, which upon expulsion of ammonia regenerates the prosthetic group. 
Aminomutase activity could be seen as an extension of this mechanism involving 1,4- 
addition of ammonia to the α,β-unsaturated cinnamate and subsequent protonation of 
the α carbon of the resulting enolate. This mechanism for MIO-based ammonia lyase 
activity was generally accepted until 1995. 
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 2.3 Friedel-Crafts Mechanism for MIO-based Lyase and Mutase Activity 
 One problem with the above mechanism is that it fails to explain how an 
enzymatic base can remove a relatively non-acidic β-hydrogen from substrates such as 
phenylanine and histidine. In their studies of the enzyme urocanase, which catalyzes the 
formation of β-(5′-imidazolonyl)propionic acid from (E)-urocanate and water, Rétey and 
coworkers discovered that a covalent adduct between nicotinamide adenine dinucleotide 
(NAD+) and  (E)-urocanate was formed as an intermediate in the reaction.47 To elucidate 
the structure of this adduct, Rétey and colleagues added 4-13C labeled nicotinate and 2-
13C labeled imidazolylpropianate to reaction mixtures containing the enzyme urocanase. 
Extensive NMR analysis of the resulting product showed that a covalent bond had been 
formed between the C4 atom of NAD+ and the C5′ atom of the substrate analog. This 
result led to the suggestion that urocanase catalyzes the addition of water to (E)-
urocanate via a mechanism involving an electrophilic-aromatic substitution reaction 
(Figure 7).48 Subsequently, the crystal structure of urocanse was solved; however, a 
covalent adduct between NAD+ and the substrate was not observed.49 
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  Before these studies of urocanase were published, enzymes capable of 
catalyzing electrophilic aromatic substitutions were not known. Rétey and others became 
enamored with the idea that other types of enzymes might be able to catalyze similar 
reactions. In 1995, Rétey proposed that the HAL family of enzymes also utilized a 
Friedel-Crafts type of mechanism.50,51 When Rétey’s proposal was published, it was still 
believed that HAL enzymes utilized dehydroalanine in their active sites. For clarity, this 
mechanism will be discussed with MIO as the prosthetic group.  
 In the Rétey mechanism, shown in Figure 8 for PAL, the substrate’s aromatic ring 
first undergoes an electrophilic aromatic substitution reaction with the exocyclic carbon 
of MIO. The resulting covalent MIO-adduct contains a resonance stabilized carbocation, 
which serves to acidify the β-hydrogens of the substrate. Removal of the pro(S)-
hydrogen by an enzymatic base is followed by regeneration of MIO and the formation of 
cinnamate. 
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  Support for such a mechanism was provided by experiments involving alternate 
substrates for HAL and PAL. Early work by Klee showed that in the reaction catalyzed 
by HAL, [β-2H2]histidine exhibited a deuterium kinetic isotope effect (KIE) of ~1.5-2.0; 
thus, proton abstraction in the HAL reaction is at least partially rate limiting. Conversely, 
when L-5-nitro[β-2H2]histidine was used as a substrate, no deuterium KIE was 
observed.52 Rétey and co-workers found that an S143A mutant of HAL, which lacked 
MIO, could convert L-5-nitro[β-2H2]histidine into the corresponding urocanic acid 
derivative although this mutant enzyme did not react readily with histidine. In fact, the 
mutant enzyme reacted with L-5-nitrohistidine with the same kinetic values as the wild-
type (WT) enzyme (Figure 9A).50 
 Similar experiments were performed with PAL. Hermes’ earlier work had 
established that no deuterium KIE was observed when [β-2H2]phenylalanine was used 
as a substrate. Rétey and coworkers were able to show that the Vmax of an S202A 
mutant of PAL, which lacks MIO, was 70 times greater for 4-nitrophenylalanine versus 
phenylalanine (Figure 9B).51 The results of these studies on HAL and PAL led Rétey to 
suggest that the nitro group of alternate substrates serves the same purpose as the 
prosthetic group of lyases, namely to acidify the β-hydrogens of the substrate. Rétey, 
posited that a Friedel-Crafts mechanism was operative as the carbocation formed in 
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such a reaction should greatly acidify the β-hydrogens of substrates. Additionally, Rétey 
and colleagues noted that D,L-meta tyrosine, which should be a good substrate for an 
electrophilic aromatic substitution, served as a substrate for PAL while L-tyrosine did 
not.51 
 
 The above results concerning alternate substrates for HAL and PAL do not 
necessarily prove that Rétey’s mechanism is operative. In fact, the aromatic rings of 
substrates containing nitro groups should be deactivated towards electrophilic aromatic 
substitution reactions. Also, the fact that histidine and phenylalanine served as reluctant 
substrates for lyases which did not contain the prosthetic group shows that the enzymes 
can acidify the substrate’s β-hydrogens without the use of an electrophile. These 
observations suggest that HAL and PAL bind specific conformations of their substrates, 
 57
and that in these conformations orbital alignment greatly promotes an elimination 
reaction.  
 Rétey’s suggestion that lyases catalyzed elimination via a Friedel-Crafts type of 
mechanism greatly renewed interest in these enzymes. To clarify the mechanism of the 
HAL family of enzymes, Paneth and coworkers used L-[2,6-3H]phenylalanine as an 
alternate substrate in reactions with PAL from Rhodotorula glutinis (Figure 9C). Initial 
calculations revealed that the secondary kinetic isotope effects for such a substrate 
should be less than unity if the ortho-carbon of [2,6-3H]phenylalanine changed 
hybridization from sp2 to sp3 during the reaction. Indeed, when the reaction was 
quenched before 5% conversion had been achieved, a kH/kT value of 0.85 was 
observed. However, as conversion increased this value rose to 1.15. Paneth suggested 
that during early time periods, the rate-determining step is electrophilic aromatic addition 
of phenylalanine to the prosthetic group of PAL and the rate-determining step changed 
as the reaction progresses.53 This interpretation seems at odds with the fact that PAL 
exhibits Michaelis-Menten kinetics. Additionally, Schramm and co-workers found that 
alternate substrates containing tritium atoms can exhibit secondary kinetic isotope 
effects due to differences in binding compared to unlabelled substrates.54 Moreover, 
Paneth and co-workers did not discuss the fact that a resonance structure of the 
carbanion intermediate in the Hanson and Havir mechanism would have an sp3 
hybridized ortho-carbon. This resonance structure could affect the results of their 
calculations. 
 Pioneering work by Klee had shown that HAL activity was irreversibly inhibited 
upon treatment of the enzyme with L-cysteine and L-homocysteine under aerobic and 
basic conditions.55,56 The thiol of cysteine is important for inhibition as cystine and S-
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methylcysteine do not inhibit HAL.  Researchers in the labs of Tanner and Rétey 
established the mechanism of inhibition by treating HAL with L-cysteine, digesting the 
enzyme, and analyzing the resulting chromophores by NMR. These experiments 
established that a covalent adduct was formed between the amino-group of L-cysteine 
and the exomethylene carbon of MIO.57,58 Subsequent reaction of the thiol group of this 
adduct with another L-cysteine molecule or β-mercaptoethanol (β-ME) yields the 
structures shown in Figure 10. Although L-cysteine does not contain an aromatic side-
chain, these experiments were used to support the Friedel-Crafts mechanism for MIO-
based lyase activity. To explain these results, Tanner and Rétey noted that the thiol 
group of L-cysteine is at approximately the same distance from the α-amino group as the 
C5′ atom in histidine. Thus, the thiol is perfectly positioned to react with MIO. After 
addition of the thiol to MIO, the adduct undergoes oxidation and subsequent 
rearrangement to generate an amino-MIO chromophore (Figure 10).  
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 Although these experiments were discussed as evidence that a Friedel-Crafts 
reaction occurs in MIO-containing enzymes, they by no means conclusively support one 
mechanism over the other. Another possible explanation as to why L-cysteine reacts with 
HAL is simply due to the high nucleophilicity of its thiol side-chain. Indeed, thiol 
containing molecules such as dithiothreitol have been shown to react with MIO 
containing enzymes,59 while other S-nucleophiles such as 2-benzylaminoethanethiol60 
and farnesylmercaptan61 react with dehydroalanine derivatives.  
 One final set of experiments shows that an MIO-catalyzed Friedel Crafts reaction 
is plausible. Rétey and coworkers synthesized the model compound (±)-γ-
[(dimethylamino)methyl]-3-methoxy-2,4,6-trimethyl-α-methylidenebenzenebutanal  (1, 
Figure 11), which mimics both the phenylalanine substrate and a portion of MIO. 
Treatment of this compound with AlCl3 followed by the addition of water led to the 
elimination of dimethylamine and generation of compound 4 (Figure 11).62 When the 
methoxy group of this molecule was replaced with a proton or a nitro group, elimination 
of dimethylamine was not 
observed. Even though these 
experiments do not prove that 
such a reaction occurs in an 
enzymatic environment, they 
do establish that an 
electrophilc aromatic 
substitution reaction with a 
molecule similar to MIO could 
occur.  
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 Although the Rétey mechanism provides a satisfying explanation as to how an 
enzyme could acidify the β-hydrogens of non activated substrates, it appears to be at 
odds with several experiments performed on MIO containing enzymes. First, a Friedel-
Crafts mechanism is completely inconsistent with the observations of Hermes and 
Furuta that carbanion intermediates are present in the reaction pathways catalyzed by 
PAL and HAL, respectively.44,63 Likewise, if a Friedel-Crafts mechanism were operative, 
it is unlikely that MIO containing enzymes would be able to utilize strongly deactivated or 
non aromatic compounds as substrates. However, Hermes noted that PAL catalyzes the 
conversion of 2,5 dihydrophenylalanine to the corresponding cinnamate derivative,44 
while Rétey and Poppe found that PAL could convert 2,3,4,5,6 pentafluoro cinnamic acid 
to the corresponding amino acid under conditions favoring the reverse reaction.43  
 Additionally, all MIO containing enzymes display maximum activity within a pH 
range of ~8.5 to 9.0. The formation of a carbocation is unlikely under such conditions. 
The reaction pathway for MIO-containing aminomutases requires that these enzymes 
maintain ammonia in their active sites after it is eliminated from the substrate. In the 
Hanson and Havir mechanism, ammonia could remain bound to the active site as an 
amino-MIO adduct; however, it is unclear how ammonia could be retained in the active 
site of these enzymes if Rétey’s mechanism is used. Moreover, if a Friedel-Crafts 
mechanism were utilized by MIO containing enzymes, it is unclear how these catalysts 
could prevent the removal of the hydrogen atoms adjacent to the carbocation in the 
substrate’s ring. Removal of this hydrogen would lead to a covalently linked MIO-adduct 
which could not be converted to product in a straightforward manner. Finally, the 
reactions catalyzed by MIO-containing ammonia lyases and aminomutases are known to 
be reversible.64,65 A chemically reasonable mechanism for the reverse reaction cannot 
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be drawn using a Friedel-Crafts reaction based on rearomatization of proposed 
intermediates. Thus, biochemical experiments failed to conclusively distinguish the 
mechanism of action of MIO-containing ammonia lyases. 
 
2.4 Structures of MIO-containing Enzymes 
 When we began our studies on the tyrosine aminomutase, SgTAM, the 
structures of several MIO-containing ammonia lyases had been solved. Although the 
crystallization of HAL was first reported in 1975,66 its structure was not solved until 
1999.67 In the resulting 2.1 Å resolution structure of HAL from P. putida, the enzyme 
crystallized as a homotetramer with D2 symmetry. Previous biochemical studies had 
suggested that a tetramer was the biologically active form of the enzyme.68 The structure 
was composed primarily of alpha helices, and the overall fold displayed some similarity 
to that of aspartase,69 which catalyzes the non-oxidative elimination of ammonia from 
aspartate. Inspection of electron density maps in the active site of HAL revealed that the 
electrophilic prosthetic group was not dehydroalanine, but was 4-methylidene-imidazole-
5-one (MIO). This novel prosthetic group is formed by autocatalytic cyclization of a 
conserved Ala-Ser-Gly motif in all HAL family members (Figure 12). Interestingly, the N 
atom of the glycine residue in the MIO moiety is sp3 hybridized in this structure. This 
conformation serves to increase the electrophilicity of MIO by preventing delocalization 
of the nitrogen lone pairs into the α,β unsaturated carbonyl system.70  
 Closer inspection of the area surrounding MIO revealed that residues from three 
of the four HAL subunits defined the active site of the enzyme. With the structure in 
hand, Rétey and colleagues modeled urocanate bound to MIO as a Friedel-Crafts 
adduct. This model did not show substantial interactions between the active site 
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residues and the bound intermediate; however, the authors believed that it was a valid 
model and the binding mode could change via an induced-fit mechanism.  
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Figure 12. (A) Tetrameric structure of HAL [pdb code: 1B8F] from P. putida. Alpha helices are shown in blue, beta sheets
are yellow, and the MIO prosthetic groups are shown as red spheres. (B) Close up view of MIO in the HAL monomer. Coloring
is as follows carbon (white), nitrogen (blue), oxygen (red).(C) Formation of MIO by autocatalytic cyclization of conserved
Ala-Ser-Gly motif.  
 In 2004, Calabrese and co-workers determined the X-ray crystal structure of 
phenylalanine ammonia lyase (PAL) from Rhodosporidium torulides.71 The resulting 2.1 
Å resolution structure showed that PAL displayed significant structural homology to HAL 
(Figure 13). Extra electron density was observed contiguous with the exo-methylene 
carbon of MIO in all PAL active sites. The prosthetic group was modeled as an NH2-MIO 
adduct, which appears to be stabilized by an NH to π* interaction with the aromatic ring 
of Phe413 in the PAL structure (Figure 13). Although the enzyme was crystallized in the 
presence of cinnamate, electron density corresponding to this molecule was evident in 
only one active site. Additionally, the electron density was not contiguous, and 
cinnamate was modeled into the observed density at partial occupancy (Figure 13). 
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Using this extra electron density as a guide, Calabrese and co-workers modeled the 
substrate phenylalanine into the active site as both amino-MIO and Friedel-Crafts 
adducts. Of these two models, the active site of PAL was able to accommodate the 
amino-MIO intermediate well, while several steric conflicts between active site residues 
and the Friedel-Crafts adduct were observed. Additionally, side chains of conserved 
residues in the active site of PAL provided more electrostatic interactions with 
phenylalanine when this substrate was modeled as an amino-MIO intermediate.  
 
 In addition to these models supporting the Hanson and Havir mechanism, 
Calabrese noted that MIO in the PAL active site sits at the apex of three alpha helices 
which point their positive helix dipoles directly at MIO (Figure 13). An additional three 
alpha helices also point positive dipoles at the active site.  These positive dipoles could 
serve several functions, such as increasing the electrophilicity of MIO and polarizing the 
aromatic ring of the substrate resulting in acidification of its β-hydrogens. However, the 
buildup of such a large positive charge near the active site would strongly disfavor the 
development of a carbocation intermediate during the reaction mechanism. Due to these 
observations, Calabrese and co-workers strongly favored the Hanson and Havir 
mechanism and they noted that if the Rétey mechanism were operative, “it would appear 
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to constitute the sole example of protein architecture working against an enzyme 
catalyzing its own physiological reaction”.71  
 The 1.7 Å structure of another PAL, from Petroselinum crispum, was also 
reported in 1999 by Ritter and Schulz.59 The structure of this lyase was very similar to 
that of PAL from R. torulides.71 In the resulting structure, the MIO cofactor in each active 
site was covalently modified with dithiothreitol (DTT), which was present in buffers during 
enzyme purification. Subsequent biochemical experiments showed that DTT acted as an 
inhibitor of PAL. Schulz and Ritter modeled L-phenylalanine in the active site of the 
enzyme as a Friedel-Crafts adduct and suggested that this mechanism was utilized by 
PAL. In the resulting model, the researchers note that the phenyl group of the substrate 
fits very tightly into the active site, with several close contacts between hydrophobic 
sidechains. However, they suggest that substrate binding could be relaxed via an 
induced fit mechanism upon binding. Thus, two schools of thought concerning the 
mechanism of MIO-based activity still existed at the beginning of our study as 
biochemical and structural studies of these enzymes had failed to provide a definitive 
answer as to which mechanism was operative.  
 During our ongoing studies of SgTAM, the structure of the tyrosine ammonia 
lyase from Rhodobacter sphaeroides was solved by Noel, Moore and co-workers.72 Like 
the other MIO-containing ammonia lyases, RsTAL crystallized as a homotetramer with 
222-point symmetry (Figure 14A). The structure of RsTAL is most similar to that of 
PpHAL, and the MIO prosthetic group is clearly formed in all monomers of RsTAL. Noel, 
Moore and colleagues crystallized the enzyme in the presence of its product, p-
coumarate and the product analog caffeate. These structures give significant insight into 
how TAL achieves substrate recognition. For instance, the carboxylate of coumarate 
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interacts electrostatically with the side chains of Arg and Asn residues in the active site. 
Moreover, the phenol of coumarate shares a strong hydrogen bond with His89 (Figure 
14B). 
 
 Mutation of this residue to a Phe resulted in the production of a TAL mutant that 
displayed increased PAL activity. This mutant was crystallized in the presence of the 
PAL specific inhibitor 2-aminoindan-2-phosphonate (AIP).73 In the resulting structure, a 
covalent bond between the exomethylene carbon of MIO and the amino group of AIP 
was observed (Figure 14C). Together, the structures of RsTAL solved by Noel and co-
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workers showed that earlier models of substrates bound to the active site of MIO-
containing lyases were inaccurate. Although AIP is not a substrate mimic, the structure 
of this molecule bound to the RsTAL mutant provided support for the formation of an 
amino-MIO adduct during lyase activity.  
 
2.5 The Structure of the L-tyrosine 2,3 Aminomutase SgTAM 
 As a first step towards understanding the mechanism of SgTAM, we crystallized 
the enzyme and solved its structure. Diffractable crystals of SgTAM were obtained as 
detailed below.74 Carl Christianson was responsible for the crystallization and initial 
structure determination of the native enzyme. 
  SgTAM, from the C-1027 biosynthetic pathway, was expressed as a His6 tagged 
construct in E. coli.24 For crystallization experiments, the protein was purified via Ni-NTA 
chromatography and the affinity tag was removed via proteolysis. The resulting enzyme 
was further purified in two chromatographic steps. After purification, approximately 10-20 
mg of SgTAM was obtained from a one liter culture.  
 High-throughput crystal screening revealed that small, needle-like crystals of 
SgTAM could be obtained when sodium formate was used as the precipitant. To obtain 
larger crystals, additive screening was performed. From these experiments, 
trimethylamine-N-oxide was found to promote larger crystal growth. Using these new 
conditions, diffractable quality crystals were obtained. SgTAM crystallized in the space 
group P21212, and the asymmetric unit contained two 58 kDa monomers. Molecular 
replacement techniques were utilized to obtain the initial phase information used to solve 
the structure. Histidine ammonia lyase from P. putida, which displays 36% sequence 
identity to SgTAM, was selected as a search model.67 The initial phase information used 
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to solve the structure of SgTAM was generated using a polyalanine model of HAL, and 
the correct solution had a preliminary R-value of 0.51 (For crystal statistics, see the 
Materials and Methods section). 
 The model of SgTAM was built into the resulting electron density maps and was 
refined to 2.5 Å. The two monomers in the asymmetric unit are very similar with a root-
mean-squared-deviation of 1.17 Å between equivalent backbone atoms. The final model 
of SgTAM contains residues 12-539 in the first monomer and 11-539 in the second 
monomer.  
 
2.6 The Overall Structure of SgTAM   
 SgTAM displays significant structural and sequence homology to MIO-containing 
ammonia lyases (Figure 15). Symmetry operations in the unit cell generate a head-to-tail 
dimer of dimers. The biologically active unit of SgTAM is assigned as a tetramer based 
on its homology to members of the HAL superfamily. The total buried surface area is 
calculated to be 8,400 Å2 per monomer. 
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Figure 15. Sequence alignment of representative MIO-based aminomutases and ammonia
lyases. The secondary structural elements of SgTAM are shown above the sequences. The
conserved Ala-Ser-Gly motif is boxed in green, and the inner and outer loop regions are shown
below the sequence. Sequences were aligned using the Clustal W pairwise alignment protocol.
Abbreviations used: SgTAM, S. globisporus L-tyrosine aminomutase; PaPAM, P. agglomerans
L-phenylalanine aminomutase; PpHAL, P. putida L-histidine ammonia lyase; RsTAL,
R. sphaeroides, L-tyrosine ammonia lyase.  
  SgTAM is composed primarily of alpha helices. Each monomer contains 21 
helices, and most of these run along the long axis of the monomer. There is a single β-
sheet, composed of two short strands, in each monomer. In the tetramer, a second β-
sheet is formed by two β-strands. These two short strands precede helix α-3 in one 
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monomer and helix α-15 in the adjacent monomer. The active sites of the tetramer are 
defined by the area surrounding the MIO prosthetic groups (Figure 16). In each 
monomer the prosthetic group sits at the termini of helices α-6, α-9, α-15, and α-17, 
which direct their positive dipoles towards MIO. This structural feature is conserved 
throughout the HAL superfamily. 
s 
2.7 MIO-containing Active Site of SgTAM 
 In SgTAM, the MIO prosthetic group in each monomer is formed by the 
autocatalytic cyclization of the Ala152, Ser153, and Gly154 residues. Examination of 
electron density maps reveals that MIO is formed in both monomers present in the 
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asymmetric unit. The two active sites are similar to one another in both the orientation of 
MIO and the conformation of amino acid side chains. At higher sigma levels in a 
composite omit electron density map, density contiguous with the methylene group of 
MIO is observed (Figure 17). Additionally, the N2 atom of the MIO ring appears planar, 
suggesting that this atom is sp2 hybridized. Together, this data suggests that a small 
molecule has reacted with MIO. β-mercaptoethanol (β-ME) was present in our 
purification buffers, and a model of the thiol adduct of this molecule with MIO fits well 
into the observed electron density. This result is not surprising as thiol nucleophiles such 
as DTT and L-cysteine have been shown to react with MIO.59,57  
 The active site of SgTAM 
sits at the subunit junction of the 
tetramer and residues from three 
of the four monomers surround 
MIO. The area around each 
prosthetic group is composed 
primarily of aromatic side chains, 
including Tyr63 and His93 from 
the A monomer, Tyr308 from the 
B monomer, and Tyr415 from the 
C monomer (the A monomer is defined as the chain containing MIO). Several polar 
sidechains, including those of Asn205, Gln438, and Gln 442 from chain A and Arg311 
from chain B, are also located in the active site of SgTAM. 
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Figure 18. Stereoview of a superposition of the active sites of SgTAM and the L-tyrosine ammonia lyase RsTAL
[pdb code: 2O6Y]. Residues and labels for SgTAM are dark grey, while those for RsTAL are light grey.
 
 The elucidation of the structure of SgTAM enables a direct comparison between 
the active site of this enzyme and those of MIO-containing ammonia lyases. The tyrosine 
ammonia lyase RsTAL shares the same substrate as SgTAM and these two enzymes 
display 38% sequence identity, yet they catalyze different overall transformations.72,75 
Whereas SgTAM is able to form (S)-β-tyrosine from a coumarate intermediate, RsTAL 
forms coumarate as the final product. The overlay of the active site of these two 
enzymes is shown in Figure 18. Overall, the active site geometries are extremely similar. 
The MIO prosthetic groups in SgTAM and RsTAL are in approximately the same 
orientations, and 9 of the 10 amino acids composing the active sites are conserved. The 
single difference in the active sites of these two enzymes is the presence of Tyr415 in 
SgTAM in the position occupied by Val409 in RsTAL. It is unclear how, if at all, this 
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single amino acid substitution contributes to the different reactions catalyzed by the 
aminomutase and the ammonia lyase. 
 
2.8 Inner and Outer Lid Loops in SgTAM 
 The previous structures of MIO-containing lyases revealed disordered loops 
(“open” conformations) near the active site and tunnels leading from MIO to bulk solvent 
in these enzymes were observed. 59,67,71,72 Conversely, SgTAM crystallizes in a “closed” 
conformation and the MIO in each active site is covered by two loops, which contain 
residues thought to be important for catalysis in the HAL superfamily of enzymes.76 The 
inner lid loop of SgTAM is composed of residues 56-84 from the A monomer. This loop 
covers the entrance to the active site and contributes side chain functionality to the area 
surrounding MIO. The outer lid loop sits on top of this inner loop, and it further covers 
and protects the highly reactive active site. This loop is composed of residues 271-308 
from the adjacent B monomer.  
 The inner loop is located close to MIO, and the 4-OH group of Tyr63 is within 5.6 
Å of the exomethylene carbon of the prosthetic group (Figure 18). The phenol of this 
residue forms a hydrogen bond with Gly70, and both residues are strictly conserved 
across all members of the HAL superfamily. Compared to MIO-containing ammonia 
lyases, the active site loops of SgTAM are longer and contain more secondary structure 
elements. For instance an α-helix (α-13) is formed in the outer loop and a β-sheet forms 
between two short β-strands in the inner loop of one monomer and the outer loop of 
another (Figure 19). These structural elements contribute to the closed and ordered 
active site as discussed below. 
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 Translating the mechanism of ammonia lyase activity to aminomutases suggests 
that the latter enzymes produce ammonia and α,β-unsaturated carboxylate 
intermediates and subsequently catalyze a 1,4-addition of ammonia to the intermediate. 
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Thus, an aminomutase would be expected to retain free ammonia in the active site and 
maintain it as a neutral, nucleophilic molecule. Although the active sites of SgTAM and 
RsTAL are very similar, the lid loops in SgTAM tightly restrict access to the MIO 
prosthetic group. Conversely, the structures of RsTAL and other ammonia lyases display 
open tunnels leading from the protein surface to the active sites of these enzymes. In 
SgTAM, two residues are particularly important for blocking access to the active site. 
Tyr303 and Glu71 form a hydrogen-bonding interaction which closes off the tunnel 
leading to MIO. This interaction is not present in any of the structures of MIO-containing 
ammonia lyases. The lack of this interaction in ammonia lyases could allow the diffusion 
of ammonia and reaction products to the bulk solvent. However, SgTAM is likely able to 
retain coumarate and ammonia in the active site due to the presence of the hydrogen 
bonding interaction between Tyr303 and Glu71 and the presence of additional 
secondary structural elements in its inner and outer lid loops. Thus, these elements likely 
contribute significantly to the different reaction pathways catalyzed by MIO-containing 
aminomutases and ammonia lyases.   
 
2.9 Substrate Recognition in SgTAM 
 The residues involved in substrate recognition by SgTAM can be predicted based 
on the significant structural homology of this enzyme with RsTAL. The structure of an 
RsTAL mutant bound to AIP was used as a guide to build a model of L-Tyr in the active 
site of SgTAM.72 In the resulting model, the amino group of the substrate is bound to the 
exomethylene carbon of MIO (Figure 20). This binding mode is consistent with the 
intermediate predicted by the Hanson-Havir mechanism for MIO-based lyase activity 
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(see Figure 6), and is in agreement with 
recent structural and modeling work 
involving phenylalanine ammonia lyase.77  
 In our model, L-tyrosine fits well into 
the active site of SgTAM and a significant 
number of interactions between the 
substrate and amino acids known to be 
important for catalysis are observed. In 
RsTAL, His89 has been shown to be 
important for substrate recognition.77 In the SgTAM model, the analogous His residue 
shares a hydrogen bonding interaction with the 4-OH of the tyrosine substrate. 
Additionally, the substrate’s phenol is within hydrogen bonding distance to Tyr415. 
Residues corresponding to Tyr415 are not present in RsTAL or other MIO-containing 
ammonia lyases. This interaction could serve to lower the Kd of the enzyme with the 
intermediate coumarate. Additional residues which interact with L-tyrosine in our model 
include Arg311 and Asn205. The side chains of these residues likely interact with the 
carboxylate of the substrate. Similar interactions were observed between a bound 
coumarate in RsTAL.72 
 
2.10 Mechanism of MIO-based Aminomutase Activity 
 As discussed above, during the course of our studies on SgTAM, the mechanism 
of MIO-based aminomutase and ammonia lyase chemistry was actively debated. The 
strong sequence homology among SgTAM and MIO-containing ammonia lyases 
suggests that these enzymes share a common catalytic pathway. Following this 
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assumption, SgTAM must first perform the reaction catalyzed by lyases followed by 
readdition of ammonia to a coumarate intermediate. The latter half of this reaction is 
chemically challenging as coumarate is a poor electrophile.  
 To address the structural basis of MIO-based aminomutase activity, we solved 
the X-ray crystal structure of SgTAM and compared it to the structure of the L-tyrosine 
ammonia lyase RsTAL. Overall, the active sites of the two enzymes are very similar. 
Substrate recognition in SgTAM is primarily achieved by four residues in the active site 
of this enzyme. Our model of substrate binding, which was based on the structure of an 
AIP/RsTAL mutant structure, suggests that the carboxylate of the substrate interacts 
with the side chains of Arg311 and Asn205 residues in the active site. Additionally, the 4-
OH of the substrate could share a hydrogen bond with both His93 and Tyr415. In the 
electron density maps of SgTAM, there appears to be significant shared density between 
the side chain of Tyr308 and both the exomethylene carbon and “imine” nitrogen of MIO 
generated from Ser153 and Ala152, respectively. This residue is strictly conserved in all 
known MIO-containing enzymes. The interaction between Tyr308 and MIO could serve 
several purposes. First, this Tyr residue could shield MIO from other nucleophiles such 
as water in an “unliganded” state. Additionally, electrostatic interactions between the Tyr 
sidechain and the MIO could prevent electron flow into the imine moiety of the prosthetic 
group, which would lead to an inactive form of the enzyme. 
 The two previous mechanisms put forth for MIO-based ammonia lyase activity 
attempt to account for the ability of the enzymes to acidify and remove the β-hydrogens 
of substrates. In SgTAM, Tyr63 appears well positioned to act as an enzymatic base. 
The pKa of the hydroxyl group of this residue is modulated by a hydrogen bonding 
interaction with the backbone amide of Gly70, thus the sidechain of Tyr63 is a 
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phenolate. Early kinetic experiments with PAL and HAL suggest that the MIO prosthetic 
group of these enzymes lowers the pKa of the substrate’s β-hydrogens by approximately 
four units.71 Thus, other structural features of the enzyme must modulate the acidity of 
these protons. In SgTAM, as well as all other structurally characterized MIO-containing 
enzymes, several alpha helices direct their positive dipoles directly at the active site. 
This structural feature could be used to increases the strength of an enzymatic base as 
well as modulate the electron withdrawing capabilities of the substrate’s aromatic ring. 
Additionally, the presence of positive helix dipoles would seem to disfavor the formation 
of a carbocation intermediate in the enzyme’s active site. With these results in mind, we 
favored the mechanism for MIO-based aminomutase and ammonia lyase activity put 
forth by Hanson and Havir. However, our structure of native SgTAM did not provide 
direct support for this mechanism over that put forth by Rétey and coworkers.   
 
2.11 Significance of SgTAM Structure 
 The conversion of α-amino acids to β-amino acids via a 2,3-amino-shift is a 
chemically challenging transformation. Previously characterized aminomutase enzymes 
utilize multiple cofactors and accomplish this transformation using radical-based 
mechanisms. Analysis of the gene sgcC4 from the C-1027 biosynthetic pathway 
revealed that this gene encodes for a novel type of enzyme, the MIO containing L-
tyrosine aminomutase SgTAM.13 Our work represents the first structure of an MIO-
containing aminomutase. Additionally, SgTAM is the first enzyme from an enediyne 
biosynthetic pathway to be structurally characterized. 
 The elucidation of the X-ray crystal structure of SgTAM allowed for a direct 
comparison between the structures of MIO-containing aminomutases and ammonia 
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lyases. This work suggests that MIO-containing aminomutases utilize a “closed” active 
site to sequester intermediates near the MIO prosthetic group.  Moreover, this structure 
revealed residues that are likely important for substrate recognition and catalysis. 
Although our model of L-Tyr bound to the active site of SgTAM supports the mechanism 
of MIO-based activity originally proposed by Hanson and Havir, it does not conclusively 
prove that amino-MIO adducts are formed in the reaction pathway of enzymes from the 
HAL superfamily. Thus, the mechanism of MIO-containing aminomutases and ammonia 
lyases remained a topic of debate. 
 To address these issues and provide support for our model, we planned to obtain 
crystal structures of SgTAM bound to various substrate analogs. Such structures could 
conclusively show which residues interact with the substrate. This information would be 
extremely useful for efforts aimed at developing novel SgTAM mutants with altered 
physical properties, broader substrate scope, or even improved lyase activity. These 
mutants could be used for the synthesis of novel β-amino acid building blocks and to 
decipher how MIO-based mutases evolved from lyases. As a first step to address these 
goals, we set about developing a kinetic assay that could be used to monitor SgTAM 
activity in vitro.  
  
2.12 Kinetic Analysis of SgTAM activity 
 For kinetic assays, SgTAM was overexpressed as a His6-tagged protein using E. 
coli as the host. The protein was purified by Ni-NTA affinity chromatography as detailed 
below in the Materials and Methods section. Elutions from the affinity binding column 
were dialyzed overnight into buffer containing 50 mM CAPS pH 9.0 and 50 mM KCl and 
the enzyme was subsequently concentrated to ~5.0 mg/mL. Initial experiments revealed 
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that the addition of β-ME to reaction mixtures inhibited SgTAM activity. Additionally, 
SgTAM lost activity upon prolonged storage at -20 °C. Thus, for kinetic assays, SgTAM 
was always used directly after purification and reductants such as β-ME were excluded 
from purification steps. 
 Reaction mixtures consisted of 50 mM CAPS pH 9.0, 0.5 mg/mL SgTAM, 50 mM 
KCl, and 0.01 to 1.0 mM L-tyrosine. Reactions were terminated by addition of HCl until 
pH 3.0 was reached. The resulting mixtures of L-tyrosine and (S)-β-tyrosine were 
derivatized with o-phthaldialdehyde and were separated by reverse phase HPLC (RP-
HPLC). To insure that initial rates of (S)-β-tyrosine formation were measured, all 
reactions were quenched before 15% conversion was observed and all experiments 
were repeated in triplicate.  
 As seen in Figure 21, SgTAM displays Michaelis-Menten kinetics. The KM for the 
substrate L-tyrosine is 29 μM while the kcat for the reaction is 0.01 s-1. These values are 
consistent with those obtained for SgTAM by researchers in the Shen lab.75 The KM of 
SgTAM is comparable to that of other MIO-containing aminomutases and ammonia 
lyases. For instance, the KM’s of the phenylalanine aminomutase (PAM) utilized in taxol 
biosynthesis and the tyrosine ammonia lyase RsTAL are 29 μM and 74 μM, respectively.  
 In general, the catalytic efficiencies of MIO-containing aminomutases are much 
lower than those of lyases from the HAL superfamily (Figure 22). For example, the 
kcat/KM  for SgTAM and PAM from Taxus brevifolia are 345 and 333 M-1s-1, respectively. 
As seen in figure 21, the same values for MIO-containing ammonia lyases are much 
greater and range from 1.77x106 for TAL from R. capsulatus to 2500 for PAL from P. 
luminescens. The efficiency of SgTAM could be low for several reasons. First, the β-
hydrogens of L-tyrosine are less acidic than those of phenylalanine and histidine and the 
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electron rich coumarate intermediate in the TAM pathway is a relatively poor 
electrophile. These arguments suggest that PAM from Taxus should be more efficient 
than SgTAM. However, these two enzymes have similar kinetic values. Another possible 
explanation for the low efficiency of these two enzymes is that PAM and SgTAM are 
used for the biosynthesis of secondary metabolites, while PAL and HAL enzymes are 
used in primary metabolic pathways. 
 
 Experiments performed on SgTAM in the Shen laboratory established the time 
course of the reaction catalyzed by this enzyme. At early time points, (S)-β-tyrosine is 
formed as the major product, and ~60% of L-tyrosine is converted to this compound. 
However, upon extended incubation coumarate is formed at the expense of both L-
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tyrosine and (S)-β-tyrosine.75 This activity is likely a direct result of the evolutionary 
lineage of SgTAM, which presumably evolved from MIO-containing ammonia lyases.  
 Shen and co-workers also noted that SgTAM displays β-tyrosine racemase 
activity. Although (S)-β-tyrosine is the major initial product of SgTAM, this enzyme 
generates an approximately 1:1 ratio of enantiomeric β-tyrosines upon extended reaction 
times. Moreover, in the reverse reaction SgTAM can convert both (R) and (S)-β-tyrosine 
to L-tyrosine and their respective enantiomers. However, the enzyme shows no activity 
when D-tyrosine is provided as a potential substrate. 
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Figure 22. (A) Kinetic values for MIO-containing enzymes. Abbreviateions used:
SgTAM, S. globisporus L-tyrosine aminomutase; taxPAM, taxus L-phenylalanine
ammonia lyase; RcTAL, R. capsulatus L-tyrosine ammonia lyase; PlPAL,
P. luminescens L-phenylalanine ammonia lyase;PpHAL, P. putida L-histidine
ammonia lyase. (B) Kinetic values for alternate substrates for SgTAM.
A.
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 In addition to establishing the stereochemical course of the reverse reaction, 
Shen and colleagues showed that SgTAM displays rather strict substrate specificity. In 
separate experiments L-alanine, L-histidine, L-phenylalanine, L-DOPA, L-3-
chlorotyrosine, and L-3-chloro-5-hydroxytyrosine were incubated with SgTAM under 
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standard reaction conditions. Of these compounds, only L-DOPA and L-3-chlorotyrosine 
were converted to their respective β-amino acid analogs. However, the kcat/KM for 
tyrosine is approximately 100 times greater than that of these two alternate substrates.75 
In contrast to these results, we found the SgTAM could convert L-phenylalanine to β-
phenylalanine in an overnight reaction. Analysis of this reaction by RP-HPLC confirmed 
~25% conversion to β-phenylalanine over a 16 hour time period. Thus, SgTAM is able to 
utilize L-phenylalanine and phenylalanine derivatives with substitution in the 3 and 4 
positions as substrates. 
 The solution of the structure of SgTAM coupled with the development of a kinetic 
assay to monitor the enzyme’s activity opened the door for us to further probe the 
mechanism of MIO-based aminomutase activity. With this data in hand, we set about 
designing substrate analogs which could be used to inhibit SgTAM activity. The efficacy 
of these compounds could be measured using the HPLC-based assay described above. 
We then hoped to obtain co-crystal structures of SgTAM bound to useful inhibitors. 
These structures would allow us to confirm or refine our model of substrate binding in 
the active site of SgTAM. Results obtained from such studies could be used to create 
SgTAM mutants with altered substrate specificity. We hoped to use these mutants to 
produce novel β-amino acids. These compounds could then be used as building blocks 
for other molecules, such as C-1027 analogs that find use as biological probes or as 
therapeutics with modulated reactivity. Efforts aimed at meeting these goals are 
described in Chapter 3. 
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Materials and Methods 
 
General Methods 
 E. coli BL21(DE3) cells from Novagen were used for protein expression. 
Chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO). SgTAM 
was purified on an FPLC system from Amersham Biosciences. The system consisted of 
the following components: system controller unit UPC-900, dual P-920 pumps, solvent 
mixer M-925, inlet valve INV-907, two PV-908 flow valves, and fraction collector Frac-
950. Protein peaks were measured at 280 nm. SgTAM purity was monitored by SDS-
PAGE. Gels were visualized in a Kodak Gel Logic 200 imaging system. 
 Protein and substrate stock solution concentrations were checked by UV 
absorbance using an Agilent 8453E UV-Vis spectroscopy system. HPLC assays were 
performed on a Shimadzu system consisting of the following: system control unit SCL-
10Avp, autoinjector SIL-10ADvp, dual LC-6AD pumps, a SPD-10Avp UV-Vis detector, 
and a Vydac C-18 protein and peptide column (5 μm, 250 mm x 4.6 mm). 
 
Cloning of SgTAM 
 The sgcC4 gene encoding for the tyrosine aminomutase SgTAM was amplified 
by PCR from the previously described vector pBS1005.24 The forward primer had the 
sequence 5′-tga att cca tat ggc att gac tca agt cga gac-3′. The EcoRI site of this primer 
is underlined, while the NdeI site is bolded. The reverse primer was 5′-att aag ctt tca gcg 
cag ctg gat gtc cgt ctc-3′. The HindIII site of this primer is bolded. The resulting PCR 
product was cloned into the EcoRI-HindIII sites of pGEM-3zf(+) giving pBS1023, which 
was sequenced to confirm PCR fidelity. The 1.7 kb sgcC4 gene in this vector was 
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removed and ligated into the NdeI-HindIII sites of pET28a affording pBS1022. This 
vector was inserted into E. coli BL21(DE3) cells and was used for the expression of 
SgTAM as an N-terminal His6-tagged fusion protein.  
 
Expression and Purification of SgTAM 
 BL21(DE3) E. coli cells harboring the SgTAM expression construct (graciously 
provided by B. Shen, U. Wisconsin, Madison) were grown in LB media at 37 °C until a 
cell density of O.D.600 nm = 0.6 was reached. At this time, cultures were cooled to 18 °C 
and overexpression was induced by addition of IPTG to a final concentration of 50 mM. 
Expression was allowed to progress overnight. Cells were pelleted by centrifugation, and 
the resulting pellet was stored at -80 °C in lysis buffer containing 20 mM Tris, pH 7.5 and 
500 mM NaCl. Cell pellets were thawed on ice, and were lysed by two passes through a 
French Press cell disruption system at 1000 psi. Lysate was clarified by centrifugation, 
and was incubated with 1 mL of Ni-NTA resin (Qiagen) at 4 °C for 1 hour. The enzyme 
was purified according to the manufacturer’s protocol and the hexa-histidine tag was 
removed by proteolytic cleavage using thrombin (48 hours, 4 °C). Further purification 
was performed with a HiTrap-Q ion exchange column followed by a Superdex 200 gel 
filtration column (GE Biosciences) 
 
Crystallization of Native SgTAM 
 As stated above, the crystallization of native SgTAM and the subsequent solution 
of the enzyme’s structure was performed by Carl Christianson. After purification, SgTAM 
was concentrated to 10 mg/mL by centrifugation using Amicon Ultra centrifugal filter 
devices with a molecular weight cutoff of 10,000 Da. Initial crystal hits were obtained 
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using Hampton Crystal Screens HR2-110 and HR2-112. Needlike crystals of SgTAM 
were produced in conditions containing 4.0 M sodium formate. Larger crystals were 
observed upon additive screening using Hampton Additive Screen HR2-428. Diffractable 
crystals of SgTAM were obtained by the hanging drop vapor diffusion method at 4 °C. 
SgTAM (1.5 μL of 10 mg/mL enzyme in 20 mM Tris-HCl containing 1mM β-ME and 100 
mM NaCl, pH 7.5) was mixed with an equal volume of reservoir solution (4.4 M sodium 
formate, 100 mM NaCl, pH 7.5). Crystals appeared within two days and were allowed to 
grow for approximately one week. Crystals were picked, transferred to cryprotectant 
consisting of the reservoir solution containing 20% glycerol, briefly soaked, and were 
flash frozen in liquid nitrogen. X-ray diffraction data was collected at the National 
Synchrotron Light Source at Brookhaven National Laboratory at beamline X26C. An 
ADSC Quantum 4 CCD detector was used for data collection, while crystals were shot at 
100 °K. The software package HKL200078 was used to index, integrate, and scale 
diffraction intensities as summarized in Table 1. The SgTAM crystal used for model 
building belongs to the space group P21212 and has unit cell dimensions: a=92.6 Å, 
b=146.2 Å, c=75.4 Å and α=β=γ= 90°. 
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Structure Determination 
 The initial structure solution was obtained using molecular replacement 
techniques. Due to its high sequence homology with SgTAM, histidine ammonia lyase 
from P. putida (pdb code: 1B8F) was used as an initial search model. A polyalanine 
model of the HAL monomer was used to generate initial solutions using the programs 
AMORE79 and MOLREP80 Several solutions were screened and evaluated for their 
ability to form symmetry-related tetramers consistent with the biologically active unit of 
SgTAM. 
 
Model Building and Refinement 
 The program COOT81 was used for model building with the initial polyalanine 
HAL model as a guide. Refinement cycles and generation of electron density maps were 
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performed using the CNS suite of programs.82 Parameter and topology files were 
modified to incorporate the MIO prosthetic group into the backbone of the protein. 
Cycles of rigid body refinement and simulated annealing guided by σ-weighted 
composite omit maps were performed until R-values were no longer improved. Graphic 
images were generated using the program Pymol from Delano Scientific (San Carlos, 
CA). 
 
SgTAM Kinetic Assays 
 L-Tyrosine stock solutions (10x) were made in 500 mM CAPS, pH 9.0. 
Concentrations were confirmed by UV absorbance. SgTAM was overexpressed as 
described above. The protein was purified by Ni-NTA chromatography. Elutions were 
pooled and dialyzed into buffer containing 50 mM CAPS and 50 mM KCl, pH 9.0. The 
protein was concentrated to 5 mg/mL as described above, and protein concentration 
was checked using the Bradford assay. Reactions were initiated by addition of SgTAM to 
a final concentration of 0.5 mg/mL. Reactions were typically performed on a 500 μL 
scale and consisted of 0.5 mg/mL enzyme, 0.1-1.0 mM L-tyrosine, and 50 mM KCl in 50 
mM CAPS, pH 9.0. Before 15% conversion was reached, reactions were quenched by 
addition of 0.2 M HCl to a final pH of 3.0. Protein was removed by centrifugation, and the 
resulting supernatant was brought to pH 9.0 by addition of 0.25 M NaOH. 
 Reaction mixtures were then derivatized by mixing with an equal volume of 
freshly degassed OPA reagent solution (16 mg of o-phthaldialdehyde in 200 μL of 
ethanol, 44 μL of β-mercaptoethanol, and 17 mL of 100 mM sodium borate pH 10.4). 
After 1 minute, the derivatization reaction was quenched by addition of an equal volume 
of 1% v/v acetic acid. The resulting isoindoles were separated by RP-HPLC on a Vydac-
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C18 protein and peptide column and peaks were measured at 330 nm. Eluents were 
extensively degassed prior to use. The derivatives were separated using the following 
program: 10% eluent B to 50% eluent B from 0 to 40 minutes, 90% B to 10% B from 40 
to 52 minutes, and 10% B for and additional 5 minutes. (eluent A: 5 mM sodium acetate, 
pH=5.7 in 95:5 H2O-THF / eluent B: 5 mM sodium acetate, pH=5.7 in 45:45:10 CH3CN-
CH3OH-H2O). The retention times for the isoindoles derived from L and (S)-β-tyrosine 
were 11.4 and 14.8 minutes, respectively. 
 Initial rates were calculated by dividing the mM of β-Tyr formed by the reaction 
time. All reactions were performed at 25 °C and were repeated in triplicate. The 
averages of these experimental rates were used for curve fitting. Curve fitting and the 
determination of kinetic parameters were performed using the program KaleidaGraph 
3.5.    
 
Assay of SgTAM Activity with L-phenylalanine 
 A 100 μL reaction containing 5.0 mM L-phenylalanine and 0.5 mg/mL of SgTAM 
was run in the standard reaction buffer described above. The reaction was performed at 
25 °C and was quenched after 16 hours. The resulting mixture was derivatized using the 
standard conditions described above. The isoindoles of L and β-phenylalanine were 
separated by RP-HPLC using gradients of eluent A and B. The following program was 
used: 5% eluent B to 40% eluent B from 0 to 38 minutes, 40% for an additional 2 
minutes, 40% B to 10% B from 40 minutes to 52 minutes. Peaks were measured at 335 
nM. In a 16 hour reaction, 25% conversion to β-phenylalanine was observed. Peaks co-
eluted with standards of the isoindoles derived from L and β-phenylalanine, which 
showed retention times of 36.0 and 39.1 min, respectively. 
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Chapter 3 
 
 
 
Mechanism of L-Tyrosine 2,3-Aminomutase and 
Other MIO-dependent Enzymes. 
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 3.1 Natural β-Amino Acids 
 Although β-amino acids are found in all kingdoms of life, their occurrence in 
nature is rare. These compounds are not found in proteins, but are used as building 
blocks for primary metabolites.1,2 For instance, β-alanine is used in coenzyme A (CoA) 
biosynthesis.3  
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Figure 1. (A) Structures of enediynes containing aromatic -amino acid moieties. (B) Other natural products
containing -amino acids. The producing organism and biological activity are indicated. -amino acids are
highlighted in blue  
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 Several natural products including the enediynes C-1027,4 kedarcidin,5 and 
maduropeptin6 contain aromatic β-amino acid moieties (Figure 1A). These specialized 
building blocks are often important for the biological activity of natural products. For 
example, the (S)-3-chloro-β-tyrosine moiety of C-1027 is thought to modulate the 
reactivity of the enediyne warhead in this molecule.7  Other biologically active natural 
products containing β-amino acids include taxol,8 andrimid,9 chondramide (Figure 1B).10   
 
3.2 β-Amino Acids as Building Blocks for Synthetic Molecules 
 Synthetic peptides composed of β-amino acids are useful biological probes and 
show potential as therapeutic agents. Such molecules, termed β-peptides, are known to 
form well-defined secondary structural motifs.11,12 The structures adopted by these 
peptides are predictable based on primary sequence and differ from those of normal α-
helices, β-strands, and turns composed of proteinogenic amino acids. Additionally, β-
peptides show resistance to proteolytic degradation.13 For these reasons, several 
research groups have studied β-peptides as potential drug candidates. For instance, 
Seebach and co-workers designed and synthesized a cyclic β-peptide that acts as a 
somatostatin analog (Figure 2A).14 Somatostatin is a human hormone which regulates 
the release of insulin and growth hormone, and sandostatin, a synthetic analog of 
somatostatin, is used clinically to treat acromegaly and intestinal cancers.15 Using a 
radiolabel assay, Seebach and colleagues showed that the designed β-peptide binds to 
somatostatin receptors with micromolar affinity. 
 Many organisms use medium-sized peptides (~ 15-30 amino acids) as antibiotics 
that are active against a wide range of pathogens.16 Gellman and colleagues have used 
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β-peptides to mimic the biological activity of such compounds. These researchers 
synthesized oligomers of the cyclic β-amino acids (R,R)-trans-2-
aminocyclopentanecarboxylic acid (ACPC) and (3R,4S)-trans-4-aminopyrrolidine-3-
carboxylic acid (APC) and tested their ability to inhibit bacterial growth.17 One promising 
antibiotic candidate identified in these studies is the compound shown in Figure 2B, 
which displays activity against pathogenic bacteria including vancomycin resistant 
Enteroccocus faecium. The biological activity of this helical, amphiphilic molecule arises 
from its ability to form pores in negatively charged bacterial cell membranes. 
Interestingly, this molecule specifically targets bacterial cells and does not show 
hemolytic activity towards human red-blood cells. The Seebach group has also designed 
β-peptides that inhibit cholesterol uptake in the small intestine of mammals. The 
compound shown in Figure 3C adopts a left-handed helical arrangement, and interacts 
specifically with the membrane-bound scavenger receptor protein SR-B1 which 
mediates sterol uptake (Figure 2).18 Peptides such as this show promise as therapeutics 
for the treatment of obesity and hypercholesterolemia. 
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 Although β-peptides show therapeutic potential, their use in a clinical setting is 
hampered by the difficulty in synthesizing β-amino acid building blocks. A number of 
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methods have been developed for the synthesis of β-amino acids; however, they require 
several synthetic steps, are generally low yielding, and often do not provide 
enantiomerically pure products. Additionally, methodologies for directly converting 
readily available proteinogenic amino acids to their corresponding β-amino acid analogs 
do not yet exist.  
 
3.3 Methods for β-Amino Acid Synthesis 
 Numerous methods for the synthesis of enantioenriched aromatic β-amino acids 
have been developed. Common strategies for the synthesis of these compounds include 
homologation of α-amino acids, 1,4-addition of amine equivalents to α,β-unsaturated 
compounds, and enolate addition to imines.  Examples of commonly utilized procedures 
are shown in Figure 3 and are discussed in detail below. 
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  One frequently used technique for the synthesis of β-amino acids involves Ardnt-
Eistert homologation of α-amino acids to diazoketones. Subsequent Wolff 
rearrangement of these compounds yields chiral β-amino acids (Figure 3A).14 Although 
this strategy utilizes readily available starting materials, yields of the overall sequence 
are generally low. The use of chiral auxiliaries for β-amino acid synthesis has been well 
documented. For example, Maryanoff and co-workers have reported a three step-
sequence, which utilizes the auxiliary (S)-3-chloro-3-amino-(3-pyridyl)propionate, for the 
construction of various aromatic β-amino esters (Figure 3B).19 In this method, β-keto 
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esters are first converted to Z-enamines by condensation with the auxiliary. 
Diastereoselective reduction of the enamine using Pearlman’s catalyst and BF3·OEt2 
followed by removal of the auxiliary yields chiral, aryl β-amino esters. The 
diastereoselectivity of this reduction ranges from 7:3 to 9:1 with various substrates. The 
BF3·OEt2 additive catalyzes the formation of E-enamines in the reaction mixture, and is 
required for diastereoselectivity as reduction of the corresponding Z-enamines leads to 
racemic products. One drawback of this method is that the overall yields are relatively 
low.  
 Additionally, Davis and coworkers have reported a method for the synthesis of 
enantioenriched β-amino acids that involves the addition of metal enolates to chiral 
sulfinimines (Figure 3C).20 The resulting sulfinamides are converted to amino acids in 
one step upon treatment with aqueous HCl. Although enolate addition occurs with high 
diastereoselectivity, the auxiliary is relatively expensive and the formation of chiral 
sulfinimines from aryl aldehydes is generally low yielding. 
 Several variations of asymmetric Mannich reactions have been applied to 
synthesize β-amino acid derivatives. Deng and co-workers have developed bifunctional 
thiourea-cinchona alkaloids capable of catalyzing a Mannich reaction between N-Boc 
protected imines and malonates (Figure 3D).21 Deng’s catalyst tolerates a wide range of 
substituted imine substrates and provides products in high yields. The resulting chiral 
malonates can be converted to Boc-protected β-amino acids in a two-step sequence 
involving reduction of the benzyl ester protecting group and decarboxylation.  
 Jacobsen and colleagues have used peptide-based thiourea catalysts for the 
synthesis of N-Boc protected β-amino esters.22 The Jacobsen thiourea catalyst shown in 
Figure 3E is capable of promoting a Mannich reaction between silyl ketene acetals and 
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N-Boc aldimines, which provides products in high yields and with good 
enantioselectivities. At elevated temperatures, racemic product is obtained due to high 
rates of the uncatalyzed background reaction. To minimize this unwanted activity low 
temperatures and extended reaction times are required.  
 Recently, Córdova and co-workers reported that the pyrrolidine catalyst shown in 
Figure 3F can be used for the formation of 5-hydroxyisoxazolidines in tandem reactions 
involving N-protected hydroxylamines and α,β-unsaturated aldehydes.23 The mechanism 
of this transformation likely involves 1,4-addition of the hydroxylamine to an intermediate 
α,β-unsaturated imine followed by intramolecular cyclization. β-amino acids can be 
obtained from the resulting products in a two-step sequence involving conversion to 5-
isoxazolidinones upon treatment with NaOCl followed by reduction of the N-O bond with 
Pd/C (Figure 3F). 
 
3.4 MIO-containing Enzymes as Chemoenzymatic Tools 
 Although numerous methods for β-amino acid synthesis exist, they often have 
disadvantages including limiting substrate scope, poor atom-economy, and low cost-
efficiency. These processes may also require the use of starting materials that are not 
readily available and provide products in low overall yields.  It may be possible to 
engineer promiscuous MIO-containing enzymes that could be used as chemoenzymatic 
tools for the synthesis of novel, chiral β-amino acids. By varying reaction conditions, 
these enzymes could yield α-amino acids or cinnamate/urocanate derivatives as 
products (Figure 4A). The use of MIO-containing enzymes as chemoenzymatic tools 
offers several advantages to the methods described above. Ideally, enantiopure 
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products could be obtained upon incubation of readily available starting materials with an 
engineered enzyme using only water as a solvent. 
 Several researchers have explored the substrate scope of native MIO-containing 
lyases and mutases. Retey and co-workers have found that phenylalanine ammonia 
lyase from P. crispum is capable of converting various halogenated cinnamic acids to 
(S)-α-amino acids under conditions which favor the reverse reaction.24 In all cases the 
enantiopurity of the products was > 99%, and some of the substrates were turned over 
more efficiently than the natural substrate, L-phenylalanine. Kinetic values for select 
substrates are shown in Figure 4B. 
 
 Recently, Walker and colleagues used the phenylalanine aminomutase (PAM) 
enzyme from Taxus brevifolia for the chemoenzymatic synthesis of (R)-β-amino acids.25 
In these experiments, various (S)-α-amino acids were incubated with the enzyme for two 
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hours, and product distribution was analyzed by GC/EI-MS. This study revealed that 
PAM can utilize (S)-α-aryl alanines with electron-donating or electron-withdrawing 
substituents as substrates. Interestingly, thien-2-yl-(S)-α-alanine (entry 3, Figure 4C) 
could be converted to the corresponding β-amino acid. Several of these substrates 
reacted faster than L-phenylalanine, and in all cases the enantiopurity of the products 
was greater than 99% (Figure 4C). 
 Additional research efforts have focused on engineering lyases with altered 
substrate specificity. Schmidt-Dannert and co-workers compared the primary sequences 
of various phenylalanine 
ammonia lyases (PALs) and 
tyrosine ammonia lyases 
(TALs) and noted that 
enzymes which utilized L-
phenylalanine as a substrate 
contain a Phe residue in the active site at position 89 (numbering corresponds to RsTAL 
from Rba. sphaeroides).26 However, the analogous residue in all lyases displaying 
significant activity with L-tyrosine is His. Biochemical experiments with the histidine 
ammonia lyase PpHAL, from P. putida, established that this His residue was important 
for activity as the H83L mutant of this enzyme could not convert L-histidine to urocanate. 
Schmidt-Dannert surmised that this residue could be acting as a substrate selectivity 
switch in ammonia lyases. To test this hypothesis, an His89Phe mutant of TAL from 
Rba. sphaeroides was created by site-directed mutagenesis. The resulting mutant 
enzyme lost nearly all activity with L-tyroisne, but could utilized L-phenylalanine as a 
substrate (Figure 5).  In fact, the kcat/KM for this mutant enzyme is 220 fold greater for L-
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phenylalanine versus the wild-type enzyme. To confirm that this residue was important 
for substrate selectivity in other MIO-containing lyases, the analogous mutant of PAL 
from Arabidopsis thaliana was made. The resulting Phe144His mutant of this enzyme 
lost PAL activity, and simultaneously gained TAL activity. This work represents a rare 
example of a single amino acid controlling the substrate specificity of an enzyme.  
 Mutants of the tyrosine aminomutase CmdF, which is responsible for the 
biosynthesis of (R)-β-tyrosine in C. crocatus, have also been biochemically 
characterized.27 Upon extended reaction times, this enzyme generates significant 
amounts of (S)-β-tyrosine. Müller and coworkers designed mutants that were engineered 
to display greater lyase activity or substrate specificity based on sequence alignment 
with other MIO-containing enzymes. The selectivity switch region of CmdF was replaced 
with the corresponding motif from PlPAL; however, the resulting mutant displayed no 
activity towards any substrate. In general, CmdF activity was greatly diminished when 
conserved lyase sequences were incorporated into the backbone of this aminomutase.  
Müller noted that Glu399 (numbering corresponds to CmdF) is conserved in the three 
known myxobacterial TAMs, while the corresponding residue in SgTAM is an Ala, and a 
Lys residue is found in this position in PALs. Interestingly, the CmdF mutant Glu399Lys 
produced (R)-β-tyrosine with increased enantioselectivity compared to the wild-type 
(WT) enzyme even though the activity of this mutant was greatly reduced. Together with 
the results described above for RsTAL, these experiments suggest that engineered 
mutases with broader substrate specificity and enhanced stereoselectivity can be 
generated via point mutations.  
 One difficulty in engineering TAMs with desirable characteristics is that the WT 
enzymes are generally not promiscuous. For instance, SgTAM is known to react only 
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with L-tyrosine, L-Dopa, L-3-chlorotyrosine, and sparingly with L-phenylalanine.28,29 
Similarly, CmdF displays no activity when D-tyrosine, L-phenylalanine, or L-histidine are 
provided as substrates.27 In addition, engineering TAMs that could be used as efficient 
catalysts for the synthesis of β-amino acids will require suppression of lyase activity. 
Unfortunately, the exact determinants of lyase versus aminomutase activity for these 
enzymes are not known. We planned to design and synthesize several substrate 
analogs for SgTAM and obtain co-crystal structures of the enzyme bound to these 
molecules. The resulting structures would allow us to confirm our model of substrate 
binding and provide insight into the mechanism of the reaction catalyzed by SgTAM. 
These studies would also be crucial in identifying active site residues that could be 
mutated to provide MIO-based aminomutases with altered substrate specificity and 
interesting physical properties. 
 
3.5 SgTAM Inhibitor Design   
 Early attempts to crystallize MIO-containing enzymes bound to substrates and 
products were unsuccessful, likely due to the high dissociation constants of these 
molecules.30,31  To circumvent this problem, we sought to design substrate mimics that 
could covalently modify the MIO prosthetic group and irreversibly bind to SgTAM. 
Additionally, we wanted to use several classes of inhibitors to test the various 
mechanisms proposed for MIO-based lyase and mutase activity (Figure 6).32,33  
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 We first turned our attention 
to developing probes that mimic L-
tyrosine, the substrate of SgTAM, 
and decided to synthesize (S)-2-
methyl-3-phenylpropanoic acid 
analogs, 1. This class of probes is 
isosteric to L-phenylalanine and 
could inhibit the forward reaction 
catalyzed by SgTAM as they lack a 
leaving group in the α-position. If the 
enzyme uses a Friedel-Crafts type of 
mechanism, these substrate analogs 
should form covalently-linked aryl-
MIO adducts that cannot be converted to product. 
 We also hoped to synthesize various β,β-difluoro tyrosine analogs, 2, which 
could be used as substrate mimics. These molecules should act as efficient inhibitors of 
the forward reaction for SgTAM and cannot be converted to products as they lack 
benzylic hydrogens. We were initially worried about the stability of these inhibitors as the 
synthesis of similar analogs with electron-donating substituents in the para-position had 
not been reported at the time of our studies.34,35 The α-hydrogens of these compounds 
should be relatively acidic, and several decomposition pathways are possible under the 
basic conditions required for SgTAM activity.  
 Additionally, a series of coumarate epoxides, 3, were targeted for synthesis. 
These compounds serve as useful mimics of the coumarate intermediate found in the 
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reaction pathway of SgTAM and contain a reactive functional group that could modify 
MIO. We were also concerned about the stability of this class of compounds and 
decided to avoid analogs with strong electron donating substituents in the para-position. 
Moreover, we wanted to obtain a series of α,α-difluoro-β-tyrosine analogs, 4, which 
mimic the product of SgTAM. These molecules should inhibit the reverse reaction of the 
enzyme [(S)-β-tyrosine to L-tyrosine] and lack hydrogens in the α-position. The 
coumarate epoxides and α,α-difluoro-β-tyrosine analogs could be used to test both 
mechanistic possibilities as these molecules contain reactive aromatic rings and 
heteroatoms which could add to MIO in a 1,4-fashion. The four classes of inhibitors 
mentioned above should be extremely useful in probing the substrate specificity and 
mechanism of SgTAM as they represent molecules which mimic the substrate, 
intermediate, and product throughout the reaction pathway. It was expected that each of 
these inhibitor classes could potentially bind to MIO in an irreversible manner. This 
chapter discusses the synthesis and kinetic characterization of SgTAM mechanistic 
probes. Additionally, the use of these probes in co-crystallographic studies to discern the 
mechanism of SgTAM activity is detailed. 
 
3.6 Synthesis of SgTAM Mechanistic Probes 
 We hoped to develop short, high-yielding synthetic routes to the mechanistic 
probes mentioned above.  It was deemed important that the synthetic methods 
employed gave access to enantiomers which mimicked the stereochemistry of L-tyrosine 
and (S)-β-tyrosine as D-amino acids were known to be unreactive towards MIO-
containing enzymes. We first turned our attention to the synthesis of (S)-2-methyl-3-
phenylpropanoic acid 1a (Scheme 1) and planned to install the methyl group of this 
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probe in a diastereoselective manner using chiral auxiliary based chemistry. The 
synthesis of this compound began with conversion of TBS protected 3-(4-
hydroxyphenyl)propanoic acid to chiral imide 6  upon treatment with Evan’s auxiliary 
under standard conditions.36 Exposure of this imide to NaHMDS and MeI resulted in a 
highly diastereoselective α-alkylation yielding 7. The desired product was obtained from 
this intermediate in a two-step sequence involving hydrolysis of the chiral auxiliary and 
removal of the silyl-protecting group.37 
 
 Next, we attempted the synthesis of β,β-difluoro tyrosine analog 2a (Scheme 2). 
The synthetic route to this compound began with α-bromination of para-methoxy 
acetophenone.34 Deoxyfluorination of the resulting bromide upon treatment with DAST38 
yielded the desired difluoro bromide 9. This intermediate was converted to the 
corresponding primary alcohol in a two-step sequence involving treatment with 
potassium acetate, followed by hydrolysis of the resulting ester. Dess-Martin oxidation39 
gave the desired aldehyde, which proved to be unstable upon heating. Unfortunately, 
conversion of the aldehyde to amino-nitrile 11, via a zinc-catalyzed Strecker reaction,40 
resulted in the formation of a complex mixture of products. Although small amounts of 
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the desired product were detected by 1H NMR, this reaction proved to be inefficient and 
we turned our attention to the synthesis of α,α-difluoro-β-tyrosine analogs, 4.  
 
 The desired α,α-difluoro-β-tyrosine analogs, 4a-c, were produced using chiral 
sulfinimine41 chemistry with adaptations from published methods.42,43 The synthesis of 
these analogs commenced with condensation of various para-substituted bezaldehydes 
(12a-c) with (R)-tert-butylsulfonamide.44 The resulting chiral sulfinimines (13a-c) 
underwent a highly diastereoselective Reformatsky reaction upon treatment with the zinc 
enolate derived from ethylbromodifluoro acetate. Complete deprotection of the 
sulfinamine intermediates under acidic conditions gave the desired compounds (4a-c) in 
good yields and high enantiopurities.45 
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Scheme 3: Synthesis of , -difluoro-based probes, 4. Reagents: (a) CsCO3, CH2Cl2; (b) Zn0, ethyl bromodifluoro-
acetate, THF; (c) 6N HCl; (d) i-PrOH, propylene oxide. Yields and percent diastereomeric excess are indicated.  
 Para-substituted ethyl cinnamates were used as starting materials for the 
synthesis of coumarate epoxides 3a-c. Enantioselective epoxidation of these 
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compounds with Shi’s chiral dioxarane catalyst46 gave the desired epoxides 16a-c in 
good yields. Saponification of the resulting α,β-epoxy esters yielded the desired analogs 
3a-c.47 As opposed to the free acids, the potassium salts were found to be stable upon 
prolonged storage. With these inhibitors in hand, we set about developing an assay that 
could be used to determine the efficiency of these molecules as inhibitors of SgTAM. 
 
 
3.7 Assay of Mechanistic Probe Efficacy 
 Binding of the designed inhibitors (3a-c, 4a-c) to SgTAM was evaluated by 
determination of their inhibition concentration (IC50) values. Various concentrations of the 
probes were incubated with SgTAM for 10 minutes, and reactions were initiated by 
addition of L-tyrosine at a final concentration of 75 μM. Reactions were quenched after 
2.5 minutes, and the inhibitory efficiency was measured using the previously described 
HPLC-based assay employing OPA derivation of the substrate L-tyrosine and the 
product (S)-β-tyrosine.28 These studies revealed that the mechanistic probes 3a-c and 
4a-c all display concentration-dependent inhibition of SgTAM activity. The IC50’s of these 
compounds range from 3.0 mM for epoxide 3a to 11.6 mM for 3b (Figure 7A).47 To 
observe adequate turnover in this assay, high concentrations of both enzyme (0.5 
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mg/mL) and L-tyrosine (75 μM) were required. In fact, this substrate concentration is 
nearly three times the KM for SgTAM. As a result of these reaction parameters, the IC50’s 
for each of the probes are relatively high and are in the mM range. Although these 
molecules are not ideal inhibitors, it was possible to use them for co-crystallization 
studies.  
 
 The IC50 of (S)-2-methyl-3-phenylpropanoic acid ,1a, could not be determined 
due to the low solubility of this compound (compared to its ability to inhibit the reaction) 
in aqueous solution at pH 9.0. However, we showed that this compound acts as a 
competitive inhibitor of SgTAM activity. In these experiments, 1a (25 μM) was first 
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incubated with SgTAM and reactions were initiated by addition of various concentrations 
of L-tyrosine. Derivatization with ortho-phthaldialdehyde (OPA) followed by separation of 
the reaction mixture by RP-HPLC allowed for the determination of the rates for each 
reaction (Figure 7C). Lineweaver-Burk analysis of the resulting Michaelis-Menten curves 
in the presence and absence of 1a suggests that this probe affects the apparent KM for 
L-tyrosine, but not the Vmax of the reaction; thus, this compound acts as a competitive 
inhibitor. 
 
3.8 Co-crystallization of SgTAM and Mechanistic Probes 
 Co-crystals of 3a-c and 4a-c were prepared by incubating the analogs with 
SgTAM for one hour at room temperature prior to setting up crystal trays. Co-crystals 
appeared within 48 hours and formed under conditions similar to those reported for the 
native structure.48 In all crystallization experiments, β-mercaptoethanol and other 
nucleophiles were excluded from purification and crystallization buffers. Crystals were 
allowed to grow for approximately one week before being harvested, frozen in 
cryoprotectant and screened. The morphology of co-crystals differed from that of native 
crystals (needle-like) as the co-crystals appeared to form large rectangular prisms. 
Unfortunately, co-crystals of 1a bound to SgTAM could not be obtained as this 
mechanistic probe was insoluble under the conditions required for crystallization of the 
enzyme.     
 Co-complex structures were solved using molecular replacement with native 
SgTAM as the guide. Structural resolution ranged from 2.0 Å for co-crystals of 4a to 2.4 
Å for the SgTAM-4b structure, while native crystals were resolved to 2.5 Å. All structures 
were solved in the space group P21212. The x-ray structures of 3a, 4a, and 4b provide 
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significant insight into the mechanism of SgTAM activity. Overall, the co-crystal 
structures are similar to the unliganded enzyme and no significant structural variations 
are observed. For example, the R.M.S.D. over all atoms for native SgTAM and the co-
crystal structure of 4a is 0.71 Å. In each of the co-crystal structures, the active sites were 
similar to those of the native enzyme and all active site loops were well defined.  Carl 
Christianson was responsible for solving the structure of 3a bound to SgTAM and 
provided helpful discussions concerning crystallography. 
 
3.9 Co-crystal Structures of α,α-Difluoro-β-tyrosine Probes Bound to SgTAM 
 The first co-crystal structure solved contained the mechanistic probe 4a. 
Although the overall structure of the native enzyme and inhibitor bound SgTAM are very 
similar, electron density contiguous with the exo-methylene carbon of the MIO-prosthetic 
group was observed in all active sites of the enzyme crystallized with 4a. This extra 
electron density corresponds to a covalent adduct between the inhibitor and MIO. 
Multiple conformations and binding possibilities for the inhibitor were evaluated using 
adducts found in both the Friedel-Crafts and amino-MIO mechanisms as a guide (Figure 
8).49,50  
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  Only the amino-bound adduct, corresponding to Path A in Figure 8, fits the 
observed density and the resulting covalently-bound amino-MIO complex was fully 
refined using simulated annealing and energy minimization (Figure 9A). This binding 
mode is consistent with the structure of the amino/phosphate inhibitor AIP bound to TAL 
from R. sphaeroides.51 Conversely, an MIO/phenyl ring adduct with inhibitor 4a, 
predicted by the mechanism in Path B (Figure 8), does not fit the observed electron 
density. In fact, the final model places the meta-carbon of the inhibitor 3.4 Å away from 
the methylene carbon of MIO. 
 To confirm that this binding mode was correct, the co-crystal structure of SgTAM 
bound to 4b was also solved. The diffraction data from the co-complex with 4b was 
applied to the isomorphous structure of SgTAM bound to 4a. In the resulting Fo-Fc 
electron density map, density corresponding to the variant methoxy group is clearly 
observed (Figure 9C). This map unambiguously establishes the position of the methyl 
group in 4b. The site of this functional group is occupied by an ordered water molecule 
in the structures of native SgTAM and 4a bound to the enzyme. The crystal structure of 
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4b bound to SgTAM confirmed that our model of 4a in the active site of the enzyme was 
correct. 
 
 The co-crystal structure of 4a/SgTAM provides detailed insight concerning how 
the enzyme achieves substrate recognition and catalysis. The key substrate specificity 
determinants in SgTAM are His93 and Tyr415. These two residues form a tight, 
bifurcated hydrogen bond with the phenol of 4a. The residue corresponding to His93 is 
known to act as a substrate specificity switch in other MIO-containing ammonia 
lyases.26,51 The probe 4a is also held in place by hydrogen bonds between its 
carboxylate and the side chains of Arg311 and Asn205. Together, these four residues 
appear to lock the probe in the active site and bring its α-amine within bonding distance 
to MIO. The active site of SgTAM contains a high percentage of aromatic residues 
including Phe356 (not shown), which stacks with MIO, and Tyr308 which is adjacent to 
the methylene group of MIO.  
 The identity of the enzymatic base in MIO-containing enzymes has been a topic 
of great debate. Prior to our work, suggestions for the identity of the base in HAL from P. 
putida included His83 and Tyr280 (numbering corresponds to HAL).30,52 Additionally, the 
enzymatic bases in PALs from R. toruloides and P. crispum were thought to be His137 
and Tyr351,respectively (numbering corresponds to individual PALs).30, 53 It is very 
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unusual for closely related enzymes to use different residues as a base. Unfortunately, 
the structures of the MIO-containing lyases mentioned above each displayed disordered 
loops near the active site,30,54 and this structural feature led to different assumptions for 
the enzymatic base. 
  In the co-crystal structure of 4a/SgTAM, Tyr63 is in close proximity to both the 
α− and β-carbons of the probe and appears to be perfectly positioned to act as the 
enzymatic base required for SgTAM activity. The phenolic oxygen of this residue is 
located 3.2 Å away from the α-carbon and 3.4 Å from the β-carbon of 4a. The side chain 
of Tyr63 appears to be in the phenolate state and a hydrogen bond between the 
hydroxyl group of this residue and the backbone amide of Gly70 is clearly evident. Both 
of these residues are strictly conserved in all known MIO-containing enzymes and this 
hydrogen bond likely serves to lower the pKa of Tyr63. The identity of Tyr63 as the 
enzymatic base for SgTAM agrees with the observations of Noel and co-workers that the 
identical residue in RsTAL serves the same purpose.31 Thus, our work confirms the 
identity of the enzymatic base in MIO-based lyases and mutases. The pKa of Tyr63 in 
SgTAM is also modulated by the presence of a number of positive helical dipoles 
pointed at the active site. Thus, this residue appears to be a strong enzymatic base that 
is capable of shuttling a proton between the β− and α-positions of the substrate. To 
confirm the importance of Tyr63 in the reaction mechanism, site-directed mutagenesis 
was employed to remove the phenol by substitution of this residue with phenylalanine. 
The resulting His63Phe mutant, created by Heather Cooke, has no measurable 
aminomutase activity in the presence of a large excess of substrate over extended 
reaction times. 
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 The structures of 4a and 4b bound to SgTAM serve to clarify how product-like 
molecules are bound to the active site of the enzyme and implicate several residues 
including His93, Tyr415, Arg311, Asn205, Tyr63 and Gly70 in substrate recognition and 
catalysis. In order to ascertain how molecules resembling L-tyrosine and coumarate bind 
to SgTAM, we set about solving the co-crystal structure of the enzyme bound to 3b. 
 
3.10 Co-crystal Structures of Epoxide Probe 3b Bound to SgTAM 
 The structure of the epoxide 3b bound to SgTAM was solved at a resolution of 
2.10 Å. Examination of the electron density maps reveals that the MIO-prosthetic group 
is covalently modified. In the refined structure it is clear that epoxide probe 3b has been 
converted to a 2,3-diol by addition of water to the epoxide moiety. The α-oxygen atom of 
this probe is covalently bound to the methylene carbon of MIO; thus, the binding mode 
observed in the co-crystal structure of 3b/SgTAM is analogous to that predicted for 
substrate amino acids bound to MIO-containing enzymes (Figure 10A). Interactions 
between the enzyme and 3b are similar to those observed in the co-crystal structure of 
4a/SgTAM. However, the presence of the 4-fluoro group in 3b pushes the aromatic ring 
of this molecule slightly upwards due to electrostatic repulsion between the fluorine atom 
and the side-chains of His93 and Tyr415. Another difference between the structures of 
3b and 4a/b bound to SgTAM is that the carbon-heteroatom bonds between the 
prosthetic group and the probes are on opposite faces of MIO (Figure 10 A and C). 
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  The 2,3-diol observed in the structure of 3b/SgTAM appears to be a single 
diastereomer (2R, 3S) and results from attack and inversion at the 3-position of 3b. To 
provide evidence that the ring-opening is enzyme catalyzed, 3c was incubated under 
standard assay conditions with and without enzyme. The probe 3c was converted to the 
corresponding diol in overnight reactions with SgTAM, but was recovered intact after an 
24-hour incubation in buffer without enzyme. These experiments confirmed that epoxide-
opening is enzyme catalyzed.  
 The co-crystal structures of 3b and 4a/b bound to SgTAM reveal that the 
designed mechanistic probes form covalent adducts with the MIO prosthetic groups in 
SgTAM. Inhibition of SgTAM activity by α,α-difluoro-β-tyrosine probes 4a/b occurs by 
1,4-addition of the β-amine of these probes to the methylene carbon of MIO (Figure 
11A). The resulting adduct becomes mechanistically stalled, as no removable hydrogens 
are present at the α-carbon of 4a/b. The structures of 4a/b bound to SgTAM accurately 
represent the product-bound intermediate in the reaction catalyzed by SgTAM. 
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  Epoxide analog 3b inhibits SgTAM activity via a similar mechanism. This 
molecule first binds to the active site of the enzyme and is converted to a 2,3-diol upon 
addition of water to the β-carbon of the epoxide probe. This ring-opening reaction is 
enzyme-catalyzed and can occur either by an SN1 or SN2 mechanism. After binding to 
the active site occurs, the α-hydroxyl group of the modified probe adds to MIO in a 1,4- 
fashion creating a covalent adduct that is functionally stalled (Figure 11B). The diol 
adducts accurately represent the substrate-bound adduct in the aminomutase reaction. 
 
3.11 Mechanism of the Reaction Catalyzed by SgTAM  
 The co-crystal structures of 3b and 4a/b bound to SgTAM provide important 
information about both substrate and product complexes along the aminomutase 
reaction pathway, respectively. The above findings provide conclusive support that MIO-
based aminomutase and ammonia lyase activity relies upon formation of amino-MIO 
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adducts. Such complexes would not be formed if these enzymes utilized a Friedel-Crafts 
mechanism. Furthermore, evidence for covalent bond formation between the aromatic 
rings of probes 3b and 4a/b was not observed in any of our experiments. 
 
 The above structural studies allow for a complete view of MIO-based 
aminomutase and ammonia lyase activity (Figure 12). For the reaction catalyzed by 
SgTAM, L-tyrosine first binds at the active site of the enzyme and its amino group adds 
to the methylene carbon of MIO in a 1,4-fashion. Substrate recognition is achieved 
primarily by four residues surrounding the MIO prosthetic group. Arg311 and Asn205 
form hydrogen bonds with the carboxylate of the substrate, while Tyr415 and His93 form 
a bifurcated hydrogen bond with the substrate’s phenol. Our studies further confirm that 
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the residue corresponding to His93 acts as a substrate recognition element in MIO-
containing enzymes which use L-phenylalanine and L-tyrosine as substrates.26,51  
 The reaction catalyzed by the related phenylalanine aminomutase from Taxus 
has been shown to proceed through stereospecific exchange of the substrate’s proS 
hydrogen.55 For SgTAM, a model of L-tyrosine bound to MIO in a trans-configuration 
places the proS hydrogen of the substrate in close proximity to Tyr63 and anti-periplanar 
to the ammonia leaving group (Figure 12). Removal of this hydrogen by Tyr63 leads to 
the formation of a carbanion intermediate, which collapses to form coumarate and an 
amino-MIO adduct. In this way, ammonia is retained in the active site as a neutral, 
nucleophilic intermediate.  
 In SgTAM, the coumarate intermediate remains bound in the enzyme’s active 
site while this molecule is released as a product by ammonia lyases (see Chapter 2, 
Fiugre 2). One difference in the active site of SgTAM and the tyrosine ammonia lyase 
RsTAL is that the former enzyme contains the residue Tyr415, which forms a hydrogen 
bond with the substrate’s phenol. The analogous residue in RsTAL is a valine.51 The 
presence of this extra hydrogen bond in SgTAM could serve to lower the binding 
constant of the enzyme for coumarate making it easier to be retained in the active site. 
Additionally, the tunnel leading to the active site of SgTAM is closed off by a hydrogen 
bonding interaction between Tyr303 and Glu71. This interaction seems to prevent 
excess leakage of coumarate, which would shut down aminomutase activity. 
 After formation of coumarate has occurred (Figure 8), 1,4-addition of amino-MIO 
to this intermediate generates a β-linked covalent adduct. From the co-crystal structures 
of 3b and 4a/b bound to SgTAM, it appears that the coumarate intermediate remains 
relatively fixed while the ammonia-MIO adduct rotates to present the nucleophile to the 
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β-carbon of coumarate.  Regeneration of MIO leads to release of (S)-β-tyrosine which 
diffuses into the surrounding environment, completing the reaction cycle.  
 Over extended reaction times, SgTAM forms a nearly equal ratio of (R) and (S)-
β-tyrosine, and this enzyme also displays β-tyrosine racemase activity.28 Additionally, the 
highly homologous tyrosine aminomutase from chondramide biosynthesis produces (R)-
 β-tyrosine as the major product.10 The stereochemistry of ammonia addition to 
coumarate is determined by which face of the double-bond is presented to the amino-
MIO adduct. Modeling studies show that the active site of SgTAM can tolerate rotation of 
the coumarate intermediate while still maintaining binding interactions between Arg311, 
His93, and Tyr415. Thus, rotation of this intermediate lowers the enantioselectivity of the 
overall pathway. 
 The crystal structures of mechanistic probes bound to SgTAM serve to clarify the 
mechanism of MIO-based aminomutase and ammonia lyase activity, which had been a 
topic of debate for nearly 50 years. Additionally, this work identifies structural elements 
and specific residues that are important for enzymatic activity and substrate recognition, 
setting the stage for the development of rationally engineered MIO-containing enzymes. 
The use of aminomutases with altered reactivity and specificity provides a potential route 
to the production of novel β-amino acids and natural product derivatives. These 
engineered enzymes may find use as chemoenzymatic tools in vitro and could 
potentially be applied to engineered biosynthesis in vivo. 
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3.12 Creation of SgTAM His93Phe Mutant 
 Previous studies of RsTAL 
have implicated the residue 
corresponding to His93 in SgTAM as 
a selectivity switch.26,51 When this 
residue was mutated to a 
phenylalanine in RsTAL, the mutant 
gained PAL activity and showed little 
reactivity with L-tyrosine. In our labs, 
Heather Cooke made the corresponding His93Phe mutant of SgTAM. Unfortunately, the 
resulting mutant showed no activity with L-tyrosine or L-phenylalanine.56 To ascertain 
why this mutant displayed no activity, we attempted its crystallization. Although the 
mutant enzyme overexpressed well (Figure 13), it did not crystallize under the conditions 
used for native SgTAM crystal growth. Additionally, high-throughput crystal screening 
revealed no conditions leading to crystallization. Subsequent isothermal titration 
calorimetry experiments established that this mutant enzyme does not bind to L-
tyrosine.56 These experiments suggest that in SgTAM, substitution of His93 with other 
residues yields a protein which is not properly folded or that has an incompletely formed 
MIO-prosthetic group. Thus, SgTAM activity seems to be more sensitive to changes in 
the active site compared to other MIO-containing enzymes.  
 
3.13 Comparison of SgTAM Active Site with Green Fluorescent Protein (GFP) 
 When the structure of HAL was first determined,54 it became apparent that the 
MIO prosthetic group is structurally related to the chromophore of green fluorescent 
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protein (GFP). While MIO is formed from an Ala-Ser-Gly motif,54 the GFP chromophore 
is formed from a Ser-Tyr-Gly tripeptide.57 The biosynthetic pathways to these 
imidazolones both involve three main steps: backbone cyclization via covalent bond 
formation between a glycine nitrogen and a carbonyl carbon two residues upstream, 
dehydration of the oxygen atom derived from this carbonyl, and either oxidation of the 
tyrosine Cα-Cβ bond in GFP or dehydration of the serine sidechain in MIO formation. 
Although these two prosthetic groups share similar structures, they are found in vastly 
different protein environments. While members of the HAL family are primarily α-helical, 
GFP and homologs use an 11-stranded β-barrel architecture with a distorted α-helix in 
the center of the protein to drive fluorophore maturation (Figure 14).58  Moreover, MIO is 
typically found in solvent exposed channels while the GFP chromophore is buried deep 
within a β-barrel. 
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 Extensive mutational and structural studies have established that the order of 
transformations in GFP biosynthesis is likely cyclization-dehydration-oxidation with 
molecular oxygen acting as the oxidant.57 In such a conjugation-trapping mechanism, 
oxidation of the tyrosine residue makes the process irreversible, driving chromophore 
formation. Like MIO formation, no metals or cofactors are needed for GFP chromophore 
biosynthesis. Structural studies of various GFP mutants have revealed that unusual 
structural features imposed by the distorted helix exclude hydrogen bonds that would 
prevent chromophore cyclization and align molecular orbitals so covalent bond formation 
can occur.59 Less is known about the factors controlling MIO formation in the HAL family 
of enzymes. Density functional theory calculations performed by Zimmer led to the 
assumption that dehydration precedes cyclization in MIO formation.60 However, recent 
structural studies on HAL mutants suggested that cyclization occurs first in these 
proteins. Schulz and co-workers found that strict steric constraints imposed by residues 
surrounding the Ala-Ser-Gly peptide motif seem to drive MIO formation in the wild-type 
enzyme and these workers concluded that MIO-formation occurs after protein-folding 
has occurred.61  
 Determination of the factors controlling the post-translation modifications required 
for GFP chromophore and MIO-formation will enhance our ability to design proteins 
effectively expanding the genetic code. Engineered GFP and MIO-containing proteins 
could be used for novel applications in biology and biotechnology. For instance, GFP, its 
mutants, and homologs thereof have revolutionized the field of in vivo cell-imaging.62 
Engineering GFP-mutants which contain an Ala-Ser-Gly motif or HAL mutants which 
contain the GFP-chromophore can provide significant insight into how overall protein 
architecture controls post-translation modification chemistry. To address these issues, 
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Getzoff and co-workers substituted the Ser-Tyr-Gly residues in GFP with Ala-Ser-Gly. 
The structure of the resulting GFPhal mutant was solved using X-ray crystallography.57 It 
was found that the engineered MIO-moiety in this protein was fully formed. However, the 
N3 atom of this prosthetic group was sp2 hybridized and the MIO did not react with 
external nucleophiles. Thus, it 
appears that specific structural 
features of HAL enzymes modulate 
the reactivity of MIO, preventing 
this prosthetic group from being 
aromatic in an unliganded state. 
Rationally controlling the reactivity 
of this unusual prosthetic group in 
other protein environments remains 
a challenge. 
SgTAM Ser153Tyr,
58 kDa
FT W E1 E2
Figure 15. SDS-PAGE gel of SgTAM Ser153Tyr purified by
Ni-NTA chrmoatography.
 To ascertain whether the protein architecture of SgTAM can support the 
formation of other imidazolones, we created a Ser153Tyr mutant of SgTAM (Figure 15), 
hoping that cyclization and oxidation of the resulting Ala-Tyr-Gly motif would occur. If 
these events take place, the resulting enzyme could find use in molecular-tagging 
studies. Additionally, it will be interesting to learn if factors such as the local steric protein 
environment and positive helical dipoles allow such an engineered chromophore to react 
with external nucleophiles.  
 Successful mutation of this residue was confirmed by sequence analysis. The 
protein was expressed in E. coli and was purified by three-chromatographic steps. High-
throughput crystal screening revealed that small, plate-like crystals of the enzyme 
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formed in approximately one week in sodium formate. Unfortunately, repeated 
optimization attempts have not yielded better crystals.  Perhaps substitution of Ala152 
with Ser and/or truncation of side chains in the active site of this SgTAM mutant will yield 
better crystals. It will be extremely interesting to discover if such mutants are fluorescent 
or display reactivity with external nucleophiles.   
 
3.14 Conclusions and Future Directions 
 The presented structures of SgTAM bound to mechanistic probes allowed for the 
determination of residues important for substrate recognition and catalysis. These 
results provide strong support for a mechanism of MIO-based aminomutase and 
ammonia lyase activity involving covalent bond formation with the α-amine of substrates. 
For ammonia lyases, this covalent adduct orients both the enzymatic base and leaving 
group in the ideal position for an E1cb elimination. For aminomutases, 1,4-addition of 
ammonia to an α,β-unsaturated carboxylate intermediate is facilitated by proper 
alignment of the neutral, nucleophilic amino-MIO adduct with the antibonding orbitals of 
the coumarate/cinnamate intermediate. Differentiation of these two catalytic pathways 
arises from the ability of aminomutases to retain ammonia within a closed active site 
while maintaining binding interactions with the requisite coumarte/cinnamate 
intermediate. Our results resolved a mechanistic debate which had been ongoing for 
over 50 years. Additionally, these structures allow for the rational design of MIO-
containing enzymes with altered catalytic properties. 
 Future work will be focused on the generation of MIO-containing mutases with 
broader substrate scope. Additionally, it will be interesting to create SgTAM mutants 
which display only lyase or mutase activity. Early results suggest that mutation of 
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residues within the active site of this enzyme often lead to little or no activity of any kind 
with L-tyrosine or additional substrates. It may be necessary to engineer other MIO-
containing enzymes, with more proficient wild-type activity, for use as tools in the 
chemoenzymatic synthesis of aromatic-β-amino acids. Additional alterations of the MIO 
prosthetic group in these enzymes could lead to the generation of novel enzymes 
containing GFP-like chromophores. Such enzymes may find use in a variety of in vivo 
cell imaging studies.  
 
Materials and Methods  
 
General.  
 Infrared spectra (IR) were recorded on a Perkin Elmir 781 spectrophotometer, 
νmax in cm-1. Bands are characterized as broad (br), strong (s), medium (m), and weak 
(w). 1H NMR spectra were recorded using a Varian Unity INOVA 400 MHz (400 MHz) 
spectrometer. Chemical shifts are reported in ppm from trimethylsilane with the solvent 
as the internal standard (CDCl3: δ 7.26 ppm, DMSO-d6: δ 2.50 ppm, CD3OD: 
δ 4.87 ppm). Data are reported as follows: chemical shift, (multiplicity [singlet (s), doublet 
(d), triplet (t), quartet (q), doublet of doublets (dd), triplet of doublets (td), and multiplet 
(m)], coupling constants [Hz], and integration). 13C NMR spectra were recorded on a 
Varian Unity INOVA 400 MHz (100 MHz) spectrometer with complete proton decoupling. 
Chemical shifts are reported with the solvent as the internal standard (CDCl3: 
δ 77.23 ppm, DMSO-d6: δ 39.51 ppm, CD3OD: δ 49.15 ppm) 19F NMR spectra were 
recorded on a Varian Unity INOVA 400 MHz (376 MHz) using trifluoroacetic acid as an 
internal standard (δ -76.55 ppm). High resolution mass spectrometry (MS) was 
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performed at the Mass Spectrometry Facility at Boston College on an LCT ESI-MS. 
Diastereomeric/ enantiomeric ratios were determined using chiral HPLC analysis (Chiral 
Technologies Chiralpak AD column (0.46 cm x 25 cm). Optical rotations were measured 
on a Rudolph Research Analytical Autopol IV Polarimeter. Kinetic curves were 
generated using the program Kaleidagraph. 
 Chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO). 
Unless otherwise stated, all reactions were performed in flame-dried glassware under an 
atmosphere of N2 and were performed in solvents dried and purified using stills from 
Glass Contour (Santa Monica, CA). Deuterated NMR solvents were purchased from 
Cambridge Isotope (Andover, MA). Purification of intermediates was performed on silica 
gel 60 from VWR (West Chester, PA). All work-up and purification procedures were 
performed in air using solvents purchased from Fisher Scientific (Pittsburgh, PA). All 
previously synthesized compounds made in our lab match published spectra. Unless 
stated otherwise, chemicals were used as received from the manufacturer. 
 
Enzyme Production.   
 Wild-type and mutant SgTAM constructs were prepared in the pET28a vector 
with the sgcC4 gene inserted into the NdeI and HindIII sites. The vector was transformed 
into BL21(DE3) cells and grown in LB media at 37 ˚C until cell density reached O.D.600 = 
0.6. Overexpression was induced by addition of IPTG (50 μM), followed by overnight 
incubation at 18 ˚C. Cells were pelleted by centrifugation and lysed using a French 
Press cell disruption system.  The enzyme was then purified with Ni-NTA affinity resin 
(Qiagen), followed by cleavage of the hexa-histidine tag with the protease thrombin (2 
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days at 4 ˚C).  Further purification was performed on a HiTrap-Q ion exchange column 
followed by a HiLoad 16/60 SuperDex 200 gel filtration column (GE Biosciences). 
 
Crystallization and Data Collection.  
 SgTAM (58 kDa, 539 amino acids) from Streptomyces globisporus (Locus 
AY048670) was crystallized in the presence of inhibitors by the hanging drop vapor 
diffusion method at 20 ˚C.  SgTAM (1.5 μL of 20 mg/mL in 50 mM CHES and 50 mM 
KCl, pH 9.0) was mixed 1:1 with 2.5 mM stock solutions of inhibitors (50 mM CHES and 
50 mM KCl, pH 9.0). This solution was incubated at room temperature for 1 hr before 1.5 
μL of the solution was mixed with 1.5 μL of reservoir solution (4.2 M sodium formate, 
100 mM TMAO).  Needle-like crystals appeared within two days and were allowed to 
grow for several additional days.  Crystals were transferred to a cryoprotectant solution 
of the reservoir solution with 20% glycerol and briefly soaked before being flash frozen in 
liquid nitrogen.  X-ray diffraction data was collected on the X26C beamline at the 
National Synchrotron Light Source at Brookhaven National Labs on an ADSC Quantum 
4 CCD detector. The data sets were collected at 100 K. Diffraction intensities were 
indexed, integrated, and scaled with HKL2000 as summarized in Table 1. All crystals 
belong to the space group P21212. 
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Example electron density map of the ring-opened
epoxide analog 3b bound to SgTAM. The 2Fo-Fc
map is modeled a 1.4 .  
 
 
Model Building, Refinement, and Graphics.   
 The structures were obtained by simple molecular replacement with the native 
structure of SgTAM (PDB code: 2OHY). Refinement cycles and generation of 2Fo-Fc 
and Fo-Fc maps were done using the CNS suite of programs.63 Cycles of rigid body 
refinement, simulated annealing, composite omit maps, and the addition of waters into 
the structure were done until Rfree values were no longer improved to any extent. To 
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generate images of the structure, the program PyMOL (Delano Scientific, San Carlos, 
CA) was used. The structure containing the epoxide probe 3b was modeled with the 
inhibitor in one active site only. 
 
Generation of SgTAM Tyr63Phe Mutation.  
 The Tyr63Phe mutation was introduced into the active site by the Quikchange 
site-directed mutagenesis protocol (Stratagene). The Y63F mutation was introduced with 
the following primer pair: 5′-cag aac atc ccc atc ttc ggg gtg acc acc ggg-3′ and 3′-ccc ggt 
ggt cac ccc gaa gat ggg gat gtt ctg-5′ (with the Y63F mutant underlined). Several 
modifications to the Quikchange protocol were made to successfully generate mutations 
to SgTAM. Reaction mixtures consisted of the following: 100 ng of template DNA, 500 
ng of each primer, 200 μM dNTPs, 5% (v/v) DMSO, 1 x buffer, and 1 unit of Pfu 
polymerase in a final volume of 100 μL. The PCR program was the following: initial 
denaturing at 95 ˚C for 5 min, followed by 35 cycles at 95 ˚C for 30 s, 62 ˚C for 45 s, and 
72 ˚C for 10 min, and completed by an additional 10 min at 72 ˚C. Following PCR, 20 
units of DpnI was added directly into the reaction and incubated at 37 ˚C for 2 hr. The 
entire digested reaction mixture was purified using the Qiagen PCR purification kit and 
then cyclized overnight by the addition of 400 units of T4 DNA ligase at 16 ˚C. The 
reaction mixture was transformed into NovaBlue Singles (Novagen). The Y63F mutant 
was confirmed by sequencing the full SgTAM coding region. Following sequence 
confirmation, the Y63F construct was transformed into BL21 (DE3) cells. 
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HPLC Assay of Y63F Mutant of SgTAM.  
 Enzyme was obtained in the same manner as above. Upon Ni-NTA purification, 
the enzyme was dialyzed into 50 mM CHES and 50 mM KCl, pH 9.0. The Y63F mutant 
was then brought to a final concentration of 5 mg/mL. Reactions were run on a 100 μL 
scale with 0.5 mg/mL of Y63F enzyme and varying concentrations of L-Tyrosine. All 
solutions were kept constant at 50 mM CHES and 50 mM KCl, pH 9.0. The enzyme was 
mixed with buffer and allowed to sit at 25 ˚C for 5 min. The reaction was then initiated by 
the addition of L-tyrosine. The reactions were incubated at 25 ˚C before quenching by 
addition of 10 μL of 200 mM HCl. The reaction was then brought back to a pH of 9.0 by 
the addition of 10 μL of 250 mM NaOH. L-tyrosine and β-tyrosine were then derivatized 
with 10 μL of a freshly degassed ortho-phthaldialdehyde (OPA) solution (8 mg OPA, 100 
μL MeOH, 22 μL β-ME, and 8.5 mL of sodium borate buffer pH 10.4). The derivation was 
quenched after 1 min by the addition of 1.2 μL of glacial acetic acid. HPLC analysis was 
then performed on 100 μL of the resulting solution.28 
 
Generation of SgTAM H93F Mutant and Attempted Crystallization 
 This mutant was designed and cloned by Heather Cooke. The mutation was 
introduced as described above for the Y63F construct. The following primer pair was 
used: H93F 5’-cca atc tcg tcc gta gct tca gcg cgg gag tcg gtc c-3’ and 3’-ggt tag agc agg 
cat cga agt cgc gcc ctc agc cag g-5’ (the site of mutation is underline). The protein was 
expressed and purified as described above. High-throughput crystal screening was 
performed at 4 and 20 °C using Hampton screens HR2-110 and HR2-112. 
Unfortunately, no crystal hits were observed. Additional attempts to crystallize this 
mutant under conditions which yielded crystals for the native protein also failed. 
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 Generation of SgTAM Ser153Tyr Mutant and Attempted Crystallization 
 This mutant was designed and cloned by Carl Christianson. The mutation was 
introduced as described above. The following primer pairs were used: 5’-cac tcg ggg cgt 
acg gcg acc tgg c-3’ and 3’-gcc agg tcg ccg tac gcc ccg agt g-5’ (the site of mutation is 
underlined). Protein was expressed and purified as described above. High-throughput 
crystal screening was performed at 20 °C using the Hampton screens HR2-110 and 
HR2-112 and the Qiagen JCSG Core Suites I and II. After 1 week, crystals appeared in 
several conditions including 1) 0.05 M Magnesium chloride, 0.1 M Tris pH 8.5, 40% (v/v) 
ethanol 2) 0.2 M sodium formate 3) 0.2 M Lithium sulfate, 0.1 M Tris pH 8.5, 30% (w/v) 
PEG 4000. Attempts to optimize these conditions did not result in crystal formation. 
 
Determination of IC50’s:  
 All reactions were performed at 25 °C and were repeated in triplicate. Reactions 
were performed on a 100 μL scale and consisted of 0.5 mg/mL enzyme, 0 – 4.65 mM 
inhibitor, and 25 μM L-tyrosine in an aqueous solution buffered to pH 9.0 with 50 mM 
CHES and 50 mM KCl. The enzyme and inhibitor were incubated for 10 min prior to the 
addition of L-tyrosine and reactions were quenched after 2.5 minutes by addition of 10 
μL of 200 mM HCl until a pH of 2.0 was reached. The enzyme was precipitated by 
centrifugation at 10,000 RPM for 2 min and the supernatant was returned to pH 9.0 by 
addition of 10 μL of 250 mM NaOH. L-Tyrosine and (S)-β-tyrosine were then derivatized 
with 10 μL of OPA reagent (8 mg OPA, 100 μl MeOH, 22 μL β-ME, and 8.5 mL of 
sodium borate buffer pH 10.4). The derivation was quenched after 1 min by the addition 
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of 1.4 μL of glacial acetic acid and 100 μL of the resulting solution was analyzed by 
HPLC using a previously reported method.28  
 
Enzymatic Conversion of Epoxide 3c to Diol:  
 
 A 100 μL reaction containing 1.5 mM of (+)-potassium (2S,3R)-3-phenyloxirane-
2-carboxylate 3c and 0.5 mg/mL enzyme was rUn for 24 hours at 25 °C in an aqueous 
solution buffered to pH 9.0 with 50 mM CHES and 50 mM KCl. The reaction was 
quenched by addition of 10 μL of 200 mM HCl and the mixture was extracted with 500 
μL of ethyl acetate. The organic layer was collected, dried with MgSO4, and submitted 
for MS analysis. HRMS (ESI-) m/z calculated for (C9H9O4)-  182.05 found 182.05. A 
control was run as above in the absence of enzyme. No peak corresponding to the diol 
could be observed by MS. 
 
Inhibition of SgTAM activity by α-Methyl tyrosine analog 1a 
 All reactions were performed at 25 °C and were repeated in triplicate. Reactions 
were performed on a 250 μL scale and consisted of 0.5 mg/mL enzyme, 0.25–10 mM L-
tyrosine, and 0.25 mM of 1a in an aqueous solution buffered to pH 9.0 with 50 mM 
CHES and 50 mM KCl. The enzyme and inhibitor were incubated for 5 minutes before 
initiating the reaction by addition of substrate. Reactions were quenched, derivatized, 
and analyzed as described above. 
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 Chemical Synthesis.  
Synthesis of α-Methyl Tyrosine Inhibitor (1a) 
 The synthesis of 1a was realized using Evan’s auxiliary to control the 
diastereoselectivity of methyl group addition.36 
 
Synthesis of (S)-4-benzyl-3-(3-(4-(tert-butyldimethylsilyloxy)phenyl)propanoyl)- 
oxazolidin-2-one (6) 
 
 Compound 5 (1.005 g, 3.54 mmol) was dissolved in anhydrous diethyl ether (25 
mL) and the solution was cooled to -78 °C. Triethyl amine (0.52 mL, 3.71 mmol) and 
pivaloyl chloride (0.45 mL, 3.71 mmol) were added separately via syringe. The resulting 
mixture was warmed to 0 °C and allowed to stir for 1 hour. In a separate flask, (S)-4-
benzyl-2-oxazolidinone (0.657 g, 3.71 mmol) was dissolved in anhydrous THF (20 mL) 
and the solution was cooled to -78 °C. Freshly titrated n-butyl lithium in hexanes (3.71 
mmol) was added dropwise to this flask, via syringe, over 10 minutes. The resulting 
mixture was transferred via cannula to the first flask, which had been re-cooled to -78 °C 
and the reaction was stirred for 30 minutes before being warmed to 0 °C. The reaction 
progressed for an additional 2 hours and was then quenched by addition of saturated 
NH4Cl (50 mL). The organic layer was collected, and the aqueous layer was washed 
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with CH2Cl2 (3 x 25 mL). The combined organic fractions were dried with Na2SO4, 
filtered, and concentrated by rotary evaporation. The crude product was purified by flash 
chromatography using 75:25 hexanes-ethyl acetate as eluent. After purification, 6 (0.932 
g, 2.12 mmol) was obtained as a white solid in 60% yield.  1H NMR (400 MHz, CDCl3) δ: 
7.34-7.16 (m, 5H), 7.11 (d, J = 8.4 Hz, 2H), 6.75 (d, J = 8.4  Hz, 2H), 4.73-4.60 (m, 1H), 
4.21-4.10 (m, 2H), 3.33-3.13 (m, 3H), 3.02-2.86 (m, 2H), 2.75 (dd, J = 13.2, 9.6, 1H), 
0.97 (s, 9H), 0.18 (s, 6H). 13C NMR (100 MHz, CDCl3) δ: 172.50, 154.05, 153.42, 
135.28, 133.12, 129.53, 129.49, 129.02, 127.42, 120.08, 66.39, 55.37, 38.15, 37.65, 
29.88, 26.03, 18.54, -4.02 
 
(S)-4-benzyl-3-((S)-3-(4-(tert-butyldimethylsilyloxy)phenyl)-2-methylpropanoyl)- 
oxazolidin-2-one (7) 
OTBS
O N
OO
Ph
OTBS
O N
OO
PhMe
NaHMDS,
MeI, THF
6 7  
 A 1 mmol solution of NaHMDS in THF (2.60 mL) was added dropwise to a 
solution of 6 (0.913 g, 2.07 mmol) in THF (15 mL) at -78 °C. The resulting mixture was 
allowed to stir for 30 minutes, and then CH3I (0.98 mL, 15.6 mmol) was added dropwise. 
The reaction was allowed to proceed for 30 minutes, and was then warmed to -45 °C. 
The reaction was allowed to stir for an additional 3 hours at this temperature. After this 
time, the reaction was allowed to warm to room temperature and was then concentrated 
by rotary evaporation. The resulting residue was dissolved in ethyl acetate (100 mL), 
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and the organic layer was washed with water (2 x 50 mL) then with brine (1 x 50 mL). 
The organic layer was dried with MgSO4, filtered, and concentrated in vacuo. The 
product was purified by flash chromatography (70:30 to 50:50 hexanes-ethyl acetate). 
After purification, 7 was obtained as a colorless oil (0.715 g, 1.64 mmol) in a 79% yield. 
1H NMR (400 MHz, CDCl3) δ: 7.34-7.22 (m, 5H), 7.06 (d, J = 8.4 Hz, 2H), 6.73 (d, J = 
8.4  Hz, 2H), 4.56-4.46 (m, 1H), 4.07-4.02 (m, 2H), 3.96 (t, J = 8.4 Hz 1H), 3.22 (dd, J = 
13.5, 3.2 Hz 1H), 2.95 (dd, J = 13.6, 7.6, 1H), 2.75 (dd, J = 13.3, 9.5 Hz, 1H), 2.62 (dd, J 
= 13.4, 7.5, 1H), 1.22 (d, J = 6.7 Hz, 3H) 0.96 (s, 9H), 0.17 (s, 6H). 13C NMR (100 MHz, 
CDCl3) δ: 176.44, 154.04, 152.90, 135.30, 131.83, 130.04, 129.43, 128.88, 127.29, 
119.83, 66.09, 55.52, 39.80, 39.42, 38.08, 18.45, 17.22, 14.49, -4.02.  
 
(S)-3-(4-(tert-butyldimethylsilyloxy)phenyl)-2-methylpropanoic acid (17) 
OTBS
O N
OO
PhMe
OTBS
O OH
Me
LiOH, H2O2,
THF
7 17  
  A solution of 7 (0.742 g, 1.64 mmol) in THF (25 mL) was cooled to 0 °C. To this 
solution was added LiOH (0.137 g, 3.27 mmol) in H2O2 (7.50 mL of 30% w/v, 66.14 
mmol). The resulting mixture was allowed to warm to room temperature and stirring 
proceeded for an additional 12 hours. After this time, the reaction was quenched by 
dropwise addition into a 1 M solution of sodium bisulfite (40 mL). The mixture was 
extracted with ethyl acetate (5 x 30 mL). The combined organic layers were dried with 
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MgSO4, filtered, and concentrated via rotary evaporation. The crude product (17) was 
used without further purification. 
 
(S)-3-(4-hydroxyphenyl)-2-methylpropanoic acid (1a) 
 
 Crude 17 (0.247 g , 0.84 mmol) was dissolved in THF (20 mL) and several drops 
of water were added to this solution. A solution of 1.0 M TBAF in THF (4.79 mL) was 
added, and the reaction was allowed to stir at room temperature for 1.5 hours. The 
reaction was quenched by addition of a saturated solution of NH4Cl (25 mL), and the 
resulting mixture was extracted with ethyl acetate (3 x 25 mL). The organic layers were 
combined, dried with MgSO4, filtered, and concentrated via rotary evaporation. The 
crude product was purified by flash chromatography (50:49:1 hexanes-ethyl acetate-
acetic acid). The product 1a (0.212 g, 1.18 mmol) was obtained as a white solid in a 
72% yield over two steps. 1H NMR (400 MHz, CDCl3) δ: 7.03 (d, J = 8.5 Hz, 2H), 6.72 (d, 
J = 8.5 Hz, 2H), 2.94 (dd, J = 13.0, 7.0 Hz, 1H), 2.72 (q, J = 7.0 Hz, 1H), 2.67-2.61 (m, 
1H), 1.18 (d, J = 6.9 Hz, 3H) 13C NMR (100 MHz, CDCl3) δ: 153.96, 131.27, 130.20, 
115.40, 41.84, 38.92, 16.99. optical rotation [α]D25 = 35.19° (c = 1.00, CHCl3) for a > 97 
% ee sample. The enantiomeric excess of the product was determined by chiral HPLC 
analysis. Chiralpak AD column (0.46 cm x 25 cm) isocratic elution (80:20 hexanes-
 140
isopropyl alcohol, 1.0 mL/min, 254 nm). Further characterization of this compound 
matches published data.64 
 
 
Attempted Synthesis of 2-amino-3,3-difluoro-3-(4-methoxyphenyl)propanoate (2) 
 The synthesis of 2 was attempted using a route to this compound developed by 
Schlosser and co-workers with minor modifications.34 
 
Synthesis of 2-bromo-1-(4-methoxyphenyl)ethanone 
OMe
O
OMe
O
Br2, CHCl3,
Br8 18  
 A solution of para-methoxy acetophenone (8) (6.000g, 29.52 mmol) in CHCl3 
(100 mL) was added to a round-bottom flash sealed with a septum. The solution was 
warmed to 40 °C, the septum was punctured with a vent needle, and Br2 (2.05 mL, 39.95 
mmol) was added to the solution dropwise. After 15 minutes, the reaction was allowed to 
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cool to room temperature and was diluted with diethyl ether (100 mL). The organic layer 
was washed with a saturated solution of NaHCO3 (3 x 100 mL). The organic layer was 
then collected, dried with MgSO4, filtered and concentrated via rotary evaporation giving 
compound 18 (9.013 g 39.35 mmol) as a white solid in a crude yield of 99%. The crude 
product, contaminated with small amounts of dibrominated material (< 2%), was carried 
forward without further purification. NMR spectra for 18 match published data.34 
 
Synthesis of 1-(2-bromo-1,1-difluoroethyl)-4-methoxybenzene (9) 
 
 The fluorinating reagent DAST (5.00 mL, 38.60 mmol) was added dropwise to a 
refluxing solution of 18 (8.843 g, 38.60 mmol) in CH2Cl2 (50 mL). After the initial setup of 
the reaction, DAST was added portionwise to make the reaction proceed. Over a period 
of 5 days, DAST (2.50 mL, 14.30 mmol) was added every 12 hours until a total of 25.00 
mL of the reagent had been added to the reaction (193.00 mmol total). The reaction was 
allowed to proceed for an additional 12 hours. After this time, the reaction was allowed to 
cool to room temperature, and was quenched by slow addition to water (100 mL) at 0 °C. 
The organic layer was collected, and was washed with saturated NaHCO3 (3 x 125 mL), 
and then with brine (1 x 100 mL). The organic layer was dried with MgSO4, filtered, and 
concentrated via rotary evaporation. The crude product was purified by flash 
chromatography (95:5 hexanes-ethyl acetate) yielding 9 (7.449 g, 29.67 mmol) as a 
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yellow oil in a 74% yield over two steps. The characterization of this compound matches 
published data.34 
 
Synthesis of 2,2-difluoro-2-(4-methoxyphenyl)ethyl acetate (19) 
 
 A solution of 9 (5.274 g, 21.01 mmol), potassium acetate (8.246 g, 84.03 mmol), 
and 18-crown-6 (0.555 g, 2.10 mmol) in DMF (20 mL) was refluxed for 16 hours. The 
resulting solution was allowed to cool to room temperature, diluted with water (75 mL), 
and was extracted with CH2Cl2 (3 x 75 mL). The combined organic layers were dried with 
MgSO4, filtered, and concentrated via rotary evaporation. The crude product 19 (4.834 g, 
21.00 mmol) was obtained as a yellow oil in a 99% yield. The crude product was used 
without further purification, and spectra for this compound matches published data.34 
 
Synthesis of 2,2-difluoro-2-(4-methoxyphenyl)ethanol (10) 
 
 Crude ester 19 (4.834 g, 21.00 mmol) was dissolved in a solution of 80:20 water-
ethanol (20 mL) containing NaOH (1.778 g, 44.45 mmol). The resulting mixture was 
allowed to stir at room temperature for 2.5 hours and was then diluted with water (50 
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mL). This mixture was extracted with diethyl ether (3 x 50 mL). The organic layers were 
combined, dried with MgSO4, filtered, and concentrated. The crude product was purified 
by flash chromatography (95:5 to 80:20 hexanes-ethyl acetate). After purification, 10 
(1.806 g, 9.60 mmol) was obtained as a white solid in a 46% yield over two steps. 
Spectra for this compound matches published data.34   
 
Synthesis of 2,2-difluoro-2-(4-methoxyphenyl)acetaldehyde (20) 
 
 Dess-Martin reagent (3.179 g, 7.50 mmol) was added to a solution of 20 (1.410 g 
7.50 mmol) in CH2Cl2 (10 mL) and the resulting suspension was stirred at room 
temperature for 5 hours. The reaction was diluted with diethyl ether (50 mL), and the 
resulting mixture was slowly added to a solution of sodium thiosulfate pentahydrate (7.50 
mmol) in saturated NaHCO3 (50 mL). The resulting mixture was stirred for 15 minutes, 
the organic layer was collected, and the aqueous layer was extracted three times with 
diethyl ether (20 mL). The combined organic layers were dried with MgSO4, filtered, and 
concentrated by rotary evaporation yielding 20 (0.879 g, 4.70 mmol) as a clear oil in 63% 
crude yield. As the compound decomposed upon distillation, the crude product was used 
without further purification. Spectra for 20 match published data.34 
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Attempted Synthesis of 2-amino-3,3-difluoro-3-(4-methoxyphenyl)propanenitrile 
(11) 
OMe
O
F
F
OMe
CN
F
FH2N
20 11
H
TMSCN, ZnI2;
NH3, CH3OH
 
 ZnI2 (0.029 g, 0.090 mmol) and TMSCN (0.66 mL, 4.93 mmol) were added to a 
round bottom flask containing 20 (0.835 g, 4.49 mmol). The reaction was allowed to stir 
at room temperature for 30 minutes. After this time, 7M NH3 in methanol (6.4 mL) was 
added, and the mixture was heated to 40 °C. After 12 hours the reaction was cooled to 
room temperature and concentrated by rotary evaporation. The residue was dissolved in 
10 mL of CH2Cl2, dried over MgSO4, filtered, and concentrated. Analysis of the crude 
mixture revealed a complex mixture of products had been formed. Unfortunately, these 
products were difficult to purify and the route was abandoned.   
 
Synthesis of α,α-difluoro-β-tyrosine Analogs 
 The synthetic route to α,α-difluoro-β-tyrosine analogs was accomplished with 
modifications to published procedures.42,43 For the Reformatsky chemistry, zinc was 
activated prior to use as follows: The required amount of zinc was added to 6 N HCl and 
was slowly stirred until bubbling of the solvent ceased. The zinc was then collected by 
vacuum filtration, washed 3 times with distilled water, three times with acetone, and 
three times with diethyl ether. Clumps of zinc were broken up, and the activated zinc 
was dried overnight under vacuum. 
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Synthesis of Chiral Sulfinimines: 
 
(R)-N-(4-(tert-butyldimethylsilyloxy)benzylidene)-2-methylpropane-2-sulfinamide 
(13a)  
 
 To a mixture of cesium carbonate (1.516 g, 4.65 mmol) and (R)-(+)-2-Methyl-2-
propanesulfinamide (0.513 g, 4.23 mmol) in anhydrous dichloromethane (20 mL) was 
added 4-[(tert-butyldimethylsilyl)oxy]benzaldehyde (12a) (1.000 g, 4.23 mmol). The 
resulting mixture was refluxed for 12 hours. The reaction was cooled to room 
temperature, filtered through celite, and concentrated in vacuo. The crude product was 
purified by flash chromatography (99:1 to 95:5 hexanes-ethyl acetate) yielding 13a 
(0.947 g, 2.79 mmol) as a white solid in a 66% yield. m.p. 72-73 °C FTIR cm-1 3027 (s), 
2930 (m), 1593 (w), 1087 (w)  1H NMR (400 MHz, CDCl3) δ: 8.50 (s, 1H), 7.75 (d, J = 8.6 
Hz, 2H), 6.91 (d, J = 8.6  Hz, 2H), 1.25 (s, 9H), 0.98 (s, 9H), 0.24 (s, 6H) 13C NMR (100 
MHz, CDCl3) δ: 161.92, 159.81, 131.32, 127.94, 120.62, 57.72, 25.81, 22.79, 18.50, -
4.12 HRMS (ESI+) m/z calculated for (C17H29NO2NaSSi)+ 362.159, found 362.159 
Optical Rotation: [α]D25 = -33.5 (c = 1.00, CHCl3). 
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Synthesis of (R)-N-(p-Methoxybenzylidene)-t-butanesulfinamide (13b) 
 
 
 
 13b was synthesized from para-methoxybenzaldehyde (12b) and purified using 
the above procedure on a 4.23 mmol scale. 13b (0.947 g, 2.79 mmol) was obtained as a 
white solid in 66% yield. The spectra and characterization data for 13b matches 
published data.44  
 
Synthesis of (R)-N-benzylidene-t-butanesulfinamide (13c) 
 
 13c was synthesized from benzaldehyde and was purified by flash 
chromatography as described above. The procedure was performed on a 4.12 mmol 
scale. The compound 13c (0.771 g, 3.68 mmol) was obtained as a colorless oil in 90% 
yield. The spectra and characterization data for 13c matches published data.44  
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Synthesis of difluoro sulfinimine adducts: 
 
(R)-ethyl-3-(4-(tert-butyldimethylsilyloxy)phenyl)-3-((R)-1,1-dimethylethyl 
sulfinamido)-2,2-difluoropropanoate (14a) 
OTBS
HN
S
O
OTBS
HN
S
O
OEt
O
F F
Zn0,
THF
Br
OEt
O
F F
13a 14a  
 To a mixture of activated zinc (0.497 g, 7.60 mmol) in anhydrous, degassed THF 
(7 mL) was added ethyl bromodifluoroacetate (0.980 mL, 7.60 mmol). The resulting 
mixture was allowed to stir at 30 °C for 5 minutes and additional ethyl 
bromodifluoroacetate (0.10 mL, 0.31 mmol) was added. The resulting mixture was 
transferred via cannula to a solution of 13a (0.860 g, 2.53 mmol) in anhydrous, 
degassed THF (7 mL). The reaction was allowed to stir for 24 hours at room temperature 
and additional Reformatsky reagent (5.58 mmol) was added in the above manner. This 
reaction was stirred for an additional 24 hours, filtered through celite, and concentrated 
in vacuo. The crude product was purified by flash chromatography (95:5 to 85:15 
hexanes-ethyl acetate) yielding 14a (0.661 g, 1.42 mmol) as a colorless oil in 56% yield. 
FTIR cm-1 3045 (s), 2925 (m), 1773 (w), 1066 (w)  1H NMR (400 MHz, CDCl3) δ: 7.21 (d, 
J = 8.4 Hz, 2H), 6.82 (d, J = 8.4 Hz, 2H), 4.91 (td, J = 12.8, 4.4 Hz, 1H), 4.23 (q, J = 7.2 
Hz, 2H), 4.05 (d, J = 4.8 Hz, 1H), 1.59 (s, 1H), 1.23 (t, J = 7.2 Hz, 3H), 1.20 (s, 9H), 0.97 
(s, 9H), 0.19 (s, 6H) 13C NMR (100 MHz, CDCl3) δ: 162.89, 156.80, 130.70, 125.21, 
120.35, 116.93 (t, J = 256 Hz), 63.51, 60.92 (t, J = 24 Hz), 56.49, 25.89, 22.72, 18.47, 
14.08, -4.12  19F NMR (376 MHz, CDCl3) δ: -111.92 (dd, J = 258 , 12.4 Hz, 1F), -117.14 
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(dd J = 255, 14.5 Hz,  1F) HRMS (ESI+) m/z calculated for (C21H35F2NO4NaSSi)+ 
486.192, found 486.192 optical rotation [α]D25 = -54.62° (c = 1.00, CHCl3) for a >98% 
de sample.  The diastereoselectivity of the reaction was determined using chiral HPLC 
analysis according to a published procedure for similar compounds.42 Chiralpak AD 
column (0.46 cm x 25 cm) isocratic elution (98:2 hexanes-isopropyl alcohol, 1.0 mL/min, 
254). 
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(R)-ethyl-3-((R)-1,1-dimethylethylsulfinamido)-2,2-difluoro-3-(4-
methoxyphenyl)propanoate (14b) 
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 14b was synthesized and purified as above starting from 13b (0.593 g, 1.75 
mmol). After purification, 14b (0.501 g, 1.37 mmol) was obtained as a clear oil in 55% 
yield.  FTIR cm-1 2987 (m), 1778 (w), 1079 (w) 1H NMR (400 MHz, CDCl3) δ: 7.29 (d, J  
= 8.2 Hz, 2H), 6.89 (d, J  = 8.2 Hz, 2H), 4.94 (td, J = 12.6, 4.4 Hz, 1H), 4.25 (q, J = 7.2 
Hz, 2H), 4.10 (d, J = 3.2 Hz, 1H), 3.81 (s, 3H), 1.26 (m, 3H), 1.21 (s, 9H) 13C NMR (100 
MHz, CDCl3) δ: 162.81, 160.50, 130.71, 124.45, 114. 49 (t, J =256 Hz), 114.21, 63.49, 
60.75 (t, J = 23.2 Hz), 56.43, 55.43, 22.67, 14.03 19F NMR (376 MHz, CDCl3) δ: -112.73 
(dd, J = 255, 12.0 Hz, 1F) -116.24 (dd J = 255, 14.0 Hz, 1F) HRMS  (ESI+) m/z 
calculated for (C16H23F2NO4S)+ 364.139, found 364.139 optical rotation = -41.86 ° (c = 
1.00, CHCl3) for a 84 % de sample. The diastereomeric excess of this reaction was 
determined by chiral HPLC analysis. Chiralpak AD column (0.46 cm x 25 cm) isocratic 
elution (95:5 hexanes-isopropyl alcohol, 1.0 mL/min, 254 nm).  
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Synthesis of (R)-ethyl 3-((R)-1,1-dimethylethylsulfinamido)-2,2-difluoro-3-
phenylpropanoate (14c) 
 
 14c was synthesized from 13c (0.334 g, 1.60 mmol) and was purified as 
described above. After purification, 14c (0.239 g, 0.72 mmol, 90% de) was obtained as a 
colorless oil in 45% yield. Characterization of 14c matches published data.42 The 
diastereoselectivity of this reaction was determined by chiral HPLC analysis. Chiralpak 
AD column (0.46 cm x 25 cm) isocratic elution (95:5 hexanes-isopropyl alcohol, 1.0 
mL/min, 254 nm). 
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Synthesis of α,α difluoro-β amino acids: 
 
(R)-3-amino- 2,2-difluoro-3-(4-hydroxyphenyl)propanoic acid (4a) 
 
 A solution of 14a (0.614 g, 1.33 mmol) in 6N HCl (20 mL) was heated to reflux for 
2.5 hours. The solution was allowed to cool to room temperature and was concentrated 
by rotary evaporation. The resulting residue was dissolved in 15 mL of i-PrOH and 
propylene oxide (0.46 mL, 6.63 mmol) was added. The resulting mixture was stirred at 
room temperature for 12 hours and the precipitate was collected by vacuum filtration. 
The precipitate was washed with diethyl ether yielding 4a (0.158 g, 0.73 mmol) as a 
white solid in 55 % yield.  m.p. 247-248 °C  1H NMR (400 MHz, CD3OD) δ: 7.30 (d, J = 
8.8 Hz, 2H), 6.79 (d, J = 8.8 Hz, 2H)  4.76 (dd, J = 9.2, 5.2 Hz, 1H) 13C NMR (100 MHz , 
CD3OD)  δ: 165.79 (t, J = 26 Hz) 158.93, 130.04, 120.56, 115.52, 113.91 (t, J = 257 Hz), 
57.07 (t, J = 26 Hz) 19F NMR (376 MHz, CD3OD) δ: -106.98 (dd, J =  257, 7.52 Hz, 1F) -
119.41 (dd,  J  = 257, 18.42 Hz, 1F) HRMS (ESI-) m/z calculated for (C9H9F2NO3)- 
216.047, found 216.076 optical rotation [α]D25 = -9.11° (c = 1.00, H2O) for a > 98 % ee 
sample. This method of deprotection was previously shown not to affect the optical purity 
of products.43 
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(R)-3-amino-2,2-difluoro-3-(4-methoxyphenyl)propanoic acid (4b) 
 
 4b was synthesized as above from of 14b (0.100 g, 0.22 mmol). After purification 
as detailed above, 4c (0.034 g, 0.16 mmol) was obtained as a white solid in a 73 % 
yield. Spectra and characterization data for 4b matches published data.43 
 
(R)-3-amino-2,2-difluoro-3-phenylpropanoic acid (4c) 
 
 4c was synthesized as described above from 14c (0.559 g, 1.68 mmol). After 
purification as detailed above, 4c (0.286 g, 1.42 mmol) was obtained as a white solid in 
85% yield. Spectra for this compound matches published data.43 
 
Synthesis of Epoxides 3a-3c. 
 The synthesis of epoxide probes employed a chiral epoxidation developed by Shi 
and co-workers.46 
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(2S,3R)-ethyl-3-(4-methoxyphenyl)oxiranecarboxylate (16a) 
 
 The epoxidation of ethyl cinnamates was performed using a reported procedure 
with minor modifications.46 Briefly, an aqueous solution containing Na2(EDTA) (1 x 10-4 
M, 9.7 mL) and a catalytic amount of tetrabutylammonium hydrogen sulfate (0.0395 g, 
0.116 mmol) was added to a solution of 15a (0.400 g, 1.93 mmol) in CH3CN (9.7 mL) in 
a 100-mL round bottom flask equipped with a magnetic stirbar. The resulting solution 
was cooled to 0 °C. A portion of a finely ground mixture containing Oxone® and NaHCO3 
(5.962 g, 9.70 mmol; 2.525 g, 30.06 mmol) was added with vigorous stirring until a pH > 
7.0 was reached. A solution of Shi’s catalyst (0.205 g, 0.68 mmol) in CH3CN (6.8 mL) 
was then added to the mixture. The remaining mixture of Oxone® and NaHCO3 was 
added portionwise over a period of 6 h in order to maintain a pH range of 7.0-7.8. After 
this addition was complete, the mixture was stirred for an additional 18 h at 0 °C. The 
reaction was then warmed to 23 °C, diluted with H2O (40 mL), and extracted with ethyl 
acetate (3 x 50 mL). The combined organic layers were washed with brine (50 mL) and 
dried with Na2SO4 (s). The filtrate was concentrated in vacuo and purified by flash 
chromatography (99:1 to 95:5 hexanes-ethyl acetate) yielding the epoxide 16a as a 
colorless oil (0.117 g, 28% yield, 86% ee).  The % ee was determined by chiral HPLC: 
Chiracel ODA column, 98:2 hexanes-IPA, 0.6 mL/min, detection at 254 nm. Spectra and 
characterization data of this compound matches published data.46 
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(2S,3R)-ethyl 3-(4-fluorophenyl)oxiranecarboxylate (16b) 
 
 The synthesis and purification of 16b was performed as described above starting 
from 15b (0.200 g, 1.03 mmol). After purification, 16b (0.080 g, 0.38 mmol, 97% ee) was 
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obtained as a colorless oil in a 37% yield. The % ee was determined by chiral HPLC: 
Chiracel OD column, 98:2 hexanes-IPA, 0.6 mL/min, detection at 254 nm. Spectra and 
other characterization data for this compound match published data.46 
 
 
 
(2S,3R)-ethyl 3-phenyloxiranecarboxylate (16c) 
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The synthesis of 16c was performed as detailed above beginning from 15c (0.400 g, 
2.27 mmol). After purification, 16c (0.177 g , 0.93 mmol, 95%ee) was obtained as a 
colorless oil in 41% yield. The % ee for 16c was determined by chiral GC on a β-dex 
column with an oven temperature of 125 °C and a head pressure of 18 psi. Spectra for 
this compound match published data.46 
 
Peak#
1
2
Ret.
Time
129.8
130.5
Area
20361.7
841294
Area %
2.363
97.637  
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Synthesis of Potassium Carboxylates 
 
Potassium (2S,3R)-3-(4-methoxyphenyl)oxiranecarboxylate (3a) 
 
 A 3M solution of KOH in absolute ethanol (0.37 mL, 1.11 mmol) was added to a 
solution of 16a in absolute ethanol (0.50 mL) cooled to 0 °C. The resulting mixture was 
allowed to stir at 0 °C for 15 minutes. The resulting white precipitate was collected by 
vacuum filtration, washed with cold ethanol (10 mL), and dried under vacuum yielding of 
3a (0.072 g, 0.312 mmol) as a white solid in 61% yield. Spectra for this compound 
matches published data.65 
 
 
Potassium (2S,3R)-3-(4-fluorophenyl)oxiranecarboxylate (3b) 
 
 The synthesis of 3b was performed as described above beginning from 16b 
(0.123 g, 0.58 mmol). 3b (0.092 g, 0.42 mmol) was obtained as a white solid in 72% 
yield. m.p. > 300 °C, FTIR cm-1 1612 (s) 1H NMR (400 MHz, D2O) δ: 7.38-7.35 (m, 2H), 
7.17-7.13 (m, 2H), 3.98 (d, J = 3.6 Hz, 1H) 3.56 (d, J = 3.6 Hz, 1H)  13C NMR  (100 MHz, 
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D2O) δ: 175.4, 164.2, 131.7, 128.2, 115.8, 59.0, 57.2 HRMS (ESI-) m/z calculated for 
(C9H6FO3)- 165.04 found 165.03. optical rotation [α]D25 = 148.84° (c = 1.00, 1:1 H2O-
acetone) for a 97% ee sample. 
 
Potassium (2S,3R)-3-phenyloxiranecarboxylate (3c) 
 
 The synthesis of 3c was performed as described above beginning from 16c 
(0.165 g , 0.86 mmol) 3c (0.121g, 0.60 mmol) was obtained as a white solid in 70% 
yield. Spectra for 3c match published data.66  
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Chapter 4 
 
 
 
Structural Studies of Microviridin J Biosynthesis
4.1 Structure and Biological Activity of Microviridins 
 Cyanobacteria are prolific producers of natural products. Most of the secondary 
metabolites isolated from these organisms are biosynthesized via NRPS, PKS, or hybrid 
pathways.1,2 Recent genetic studies have established that cyanobacteria also produce 
ribosomal peptide natural products.3,4,5 Many of the ribosomal peptides characterized 
from these organisms are cyanobactins, which are cyclic oxazole/thiazole containing 
compounds, including the patellamides,3 lissoclinamides,6 patellin,5 and trunkamide 
(Figure 1).7 
 
 In 2008, the gene clusters responsible for the biosynthesis of microviridins in 
Microcystis aeruginosa NIES298 and Microcystis UOWOCC MRC were sequenced and 
annotated.8 This study revealed that the microviridins, previously thought to be derived 
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from an NRP pathway, were in fact ribosomal peptides. Microviridins are a family of N-
acetylated tricyclic depsipeptides that are 13 to 14 amino acids in length. Each of these 
natural products contains a lactam ring formed by condensation between the sidechains 
of an aspartate or glutamate residue at position 2 and an invariant lysine at position 9 
(numbering begins from the C-terminus). Additionally, lactone rings are formed between 
aspartate or glutamate residues at positions 3 and 5 and serine or threonine residues at 
positions 6 and 11, respectively (Figure 2A). Such crosslinks are unprecedented in other 
cyanobacterial natural products.  
 Microviridins are the largest peptidic natural products (based on MW) ever 
isolated from cyanobacteria, and they are potent inhibitors of various proteases (Figure 
2B).9 These compounds are produced as feeding deterrents and are toxic to Daphnia, 
which are small planktonic crustaceans that prey on cyanobacteria.9 Several 
microviridins show therapeutic potential as elastase inhibitors and may find use in a 
clinical setting for treatment of lung emphysema.10,11 To date, eleven microviridin-type 
natural products have been isolated (Figure 2).9-15 Of these compounds, seven have 
unique amino acid sequences. Each of these natural products contains a conserved 
KYPSD motif within their core. Several of these microviridin derivatives appear to be 
methanolysis products of a parent compound, suggesting that the lactam formed by the 
Glu3 sidechain is somewhat labile.  A recent genomic study suggests that these 
compounds may also be produced by organisms other than cyanobacteria, including the 
myxobacterium Sorangium cellulosum and the sphingobacterium Microscilla marina.15 
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IC50 = 0.019 g/mL
IC50 = 1.4 g/mL
Microviridin I Oscillator ia (Planktothr ix) agardhii
strains 2 and 18
Elastase IC50 = 0.34 g/mL
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Figure 2. (A) Structures of characterized microvirdins. (B) A list of the microvirdins, their producing organisms, known
molecular targets, and potencies (refs. 9-15).  
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4.2 Biosynthesis of Microviridins 
 The gene clusters encoding for microviridin biosynthesis in several 
cyanobacterial species have been sequenced and annotated (Figure 3A).8,15 These 
genetic studies revealed that five gene products are required for the biosynthesis of this 
class of compounds. One gene in each of the clusters encodes for a prepeptide, which is 
approximately 50 amino acids in length. Two proteins that share homology to members 
of the ATP-grasp family of enzymes are responsible for lactone and lactam formation. 
The tailoring reactions catalyzed by these enzymes are unprecedented in cyanobacterial 
natural product biosynthesis. After tricycle formation occurs, the N-terminal leader 
sequence of the prepeptide is cleaved by a protease. Only one sequenced microviridin 
biosynthetic cluster, from Nostoc sp. PCC 7120, contains a protease thought to be 
specific for the microviridin prepeptide. In this pathway, the protease is N-terminally 
fused to an ABC transporter protein. While the majority of microviridin gene clusters do 
not encode for a protease, most contain a gene for production of an ABC transporter 
protein. It is unknown if a specific protease in the producing organism is responsible for 
microviridin maturation. After proteolytic cleavage of the leader sequence, the N-terminal 
amino acid of the natural product is modified by an N-acetyl transferase enzyme. Genes 
encoding for this enzyme are present in most microviridin clusters.  
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  The biosynthesis of microviridins has been the focus of several recent studies. 
Dittimann and Hertweck successfully reconstituted the biosynthesis of microviridins B 
and J in E. coli.8 This work is only the second report of successful production of a 
cyanobacterial natural product in a heterologous host. Additionally, Hemscheidt and co-
workers have studied the enzymes involved in microviridin K biosynthesis, from 
Planktothrix agardhii CYA126, in vitro. The biosynthesis of this compound involves four 
proteins: the ATP-grasp proteins MvdC and MvdD, the N-acetyl transferase MvdB, and 
the ABC transporter MvdA (Figure 3B). The prepeptide, which is 48 amino acids in 
length, is encoded by the gene mvdE. MvdC and MvdD were successfully expressed in 
E. coli as His6-tagged constructs. Biochemical experiments involving incubation of a 
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synthetic 48-mer, corresponding to the microviridin K prepeptide, with these enzymes 
and ATP revealed that MvdD acts first, catalyzing the formation of the ester bonds 
present in the natural product. After lactone formation occurs, MvdC catalyzes lactam 
formation between the side chains of Glu2 and Lys9 (Figure 3B). Hemscheidt and co-
workers found that MvdD and MvdC do not react with truncated constructs of the 
prepeptide, MvdE, suggesting that the full length 48-mer is the natural substrate for 
these grasp ligases. Additional experiments revealed that these enzymes use ATP to 
activate the substrate as a carboxylate-phosphate mixed anhydride with the concomitant 
release of ADP.8 This mechanism is consistent with that utilized by other ATP-grasp 
ligases.  
 Recently, the microviridin K prepeptide MvdE was expressed in E. coli as a His6-
tagged fusion. Alteration of the amino acid sequence of MvdE by site-directed 
mutagenesis has allowed for the determination of the substrate tolerance of the grasp 
ligases MvdC and D. The two sidechains involved in lactone formation were removed 
individually by substitution with Ala. Replacement of Thr38 with an Ala residue yielded a 
peptide which was unreactive with MvdC, while the Ser43Ala mutant was converted to a 
monolactone. The resulting cyclic product was unreactive with MvdD. These results 
suggest that the large lactone ring (between Thr38 and Asp44) is formed first and the 
presence of a second lactone is required for MvdD activity. Additional experiments 
revealed that MvdC was not capable of forming lactone rings which differed in size from 
those present in the natural product. Interestingly, this enzyme could convert an 
engineered prepeptide containing an Ala residue in every position of the natural product 
not involved in ring formation to a monolactone which was hydrolytically unstable.16 
Overall, these results suggests that the ATP-grasp ligases used in microviridin 
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biosynthesis could be utilized as chemoenzymatic tools for the cyclization of various 
peptide substrates. Although the structures of several ATP-grasp ligase proteins have 
been solved, none of these proteins are highly homologous to those from microviridin 
biosynthesis. The structural characterization of these novel grasp ligases will yield a 
wealth of information concerning the structural determinants of microviridin biosynthesis. 
Additionally, this structural information will aid in efforts to engineer these proteins for 
use as peptide cyclization catalysts.  
 
4.3 Structure and Chemistry of ATP-Grasp Ligases 
 Soon after the structure of D-alanine-D-alanine ligase (DDlig)17 was solved, it was 
realized that the tertiary structure of this enzyme is similar to that of glutathione 
synthetase (GST).18,19 The sequence homology of these two E. coli proteins is only 12%, 
yet they share a common ATP binding fold which differed from that of all previously 
characterized proteins.18 Subsequent genomic and structural studies have revealed that 
over 100 different proteins contain a similar ATP-binding motif.20 These enzymes 
constitute a superfamily of proteins called the ATP-grasp ligases.19   
 The grasp ligases catalyze an ATP-dependent coupling of a carboxyl group 
carbon to a nucleophile and are capable of forming amides, esters, and thioesters. In 
some enzymes, including succinyl-CoA synthetase, GTP can be utilized for substrate 
activation.21 The substrate specificity of individual enzymes of this superfamily varies 
greatly; for instance, the carboxylate-containing substrate can be as simple as formic 
acid or carbonate, which are utilized by phosphoribosylglycinamide formyltransferase22 
and N5-carboxyaminoimidazole ribonucleotide synthetase (PurK),23 respectively. 
Conversely, the carboxylate containing substrate of the ribosomal S6 modification 
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protein RimK is an entire protein.24 Nucleophiles used by the grasp ligases include 
ammonia, primary and secondary amines, thiols, and hydroxyl groups. For example, 
carbamoyl-phosphate synthetase utilizes ammonia as a substrate,25 while the 
nucleophile in the reaction catalyzed by biotin carboxylase is the N' atom of an enzyme-
bound biotin molecule.26 Additionally, enzymes such as succinyl-CoA synthetase use 
CoA as a nucleophile.27 
 
 The mechanism of substrate activation in grasp ligases differs significantly from 
that utilized by NRPS adenylation domains and tRNA synthetases (Figure 4A). These 
latter enzyme classes use ATP to activate amino acids as aminoacyl adenylates 
releasing pyrophosphate (PPi) as a byproduct. Conversely, ATP-grasp ligases activate 
carbonyl-containing substrates as aminoacyl phosphates with concomitant release of 
ADP. The resulting mixed anhydride is then coupled to a nucleophile (Figure 4B). While 
most ATP-grasp ligases bind ATP and substrates in the same region, several enzymes 
in this superfamily have separate binding sites for ATP and substrates. For instance, the 
nucleotide and CoA binding sites in succinyl CoA synthetase from E. coli are separated 
by approximately 35 Å. In this enzyme, the phosphate group from ATP is first transferred 
to a histidine residue, which relays the phosphate to the carboxyl group of the substrate. 
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This mechanism requires that the loop containing the catalytic His residue must swing 
between the two active sites.28 
 
 Structural features common to all characterized ATP-grasp proteins are 
discussed below and are illustrated for DDlig and GST in Figure 5. In general, the ATP-
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grasp domain contains approximately 200 residues and consists of two α + β subunits 
which ‘grasp’ the nucleotide between them (Figure 5A-B). Each subunit is organized 
around an antiparallel β-sheet containing four to six β-strands and contains a loop which 
defines part of the active site. The N-terminus of the ATP-grasp domain begins with a 
conserved helix-residue-helix motif, with the two helices oriented approximately 90° with 
respect to one another (Figure 5C-D). In DDlig, this motif consists of residues from 
Gly87-Gly106. The N-terminal subdomain of the ATP-grasp fold contains a Gly and/or 
Ser rich loop, termed the B loop. In unliganded structures, this loop is often disordered. 
Upon nucleotide binding, the B loop undergoes a rearrangement, and the amide 
hydrogens of two residues near the C-terminus of this loop form hydrogen bonds with 
the β and γ-phosphates of the nucleotide. In DDlig, these two residues are Ser150 and 
Ser151, while the corresponding residues in GST are Gly166 and Gly167. The 
structures of unliganded and ADP-bound GST have been solved allowing for 
visualization of the structural rearrangement of this loop.29,30  
 Most characterized grasp ligases contain a second loop known as the Ω loop. 
Residues from this loop interact with the B loop and serve to further protect the β and γ 
phosphates of the nucleotide and/or sequester the putative acyl phosphate intermediate 
from exposure to external nucleophiles. The size of this loop varies greatly among 
members of the superfamily. For instance, the Ω loop of GST consists of residues 
Pro227-Gly240,30 while the corresponding loop in PurK is much shorter and runs from 
Gln185-Gly187.23   
 The C-terminal domain of the grasp ligase fold ends in a conserved strand-loop 
sequence termed the J loop (Figure 5E-F). This motif contains a conserved Glu-X-Asn 
sequence involved in Mg2+ binding. The residues in the J loop are conserved among 
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enzymes with the same function but display low similarity among members of the 
superfamily.23 Secondary structural elements located after the C-terminal end of the J 
loop differ greatly among ATP-grasp proteins. For instance, the J loop appears at the C-
terminus of DDlig,17 while PurK contains additional globular features after this motif.23 
Thus, the J loop is generally considered to be end of the ATP-grasp fold. 
 In every nucleotide-bound ATP-grasp protein which has been structurally 
characterized, the ribose ring of the substrate is bound in a 2′-endo, 3′-exo 
conformation.31 Residues involved in both Mg2+ and ATP binding are generally 
conserved among superfamily members (Figure 6). In most grasp ligases, the charged 
phosphates interact with the sidechains of three positively charged Lys or Arg residues. 
In DDlig, these residues correspond to Lys97, Lys144, and Lys215 (Figure 6A). These 
residues are located within the helix-residue-helix motif, on a β-strand directly N-terminal 
to the B loop, and on the Ω loop, respectively. The backbone amides of the two C-
terminal residues of the B loop in grasp ligases also participate in hydrogen bonding 
interactions with the β and γ-phosphates of the nucleotide. The residues are usually Gly-
Gly or Ser-Ser; however, this is not always the case.23 
 In grasp ligases which utilize ATP, the adenine ring of the nucleotide is located in 
a hydrophobic binding pocket and the N1 atom of this substrate shares a hydrogen bond 
with the backbone amide of a conserved Leu or Ile residue. In DDlig, the backbone 
amide of Leu183 is within 3.6 Å of the N1 atom of ATP. In addition to this interaction, a 
conserved Glu or Gln residue accepts a hydrogen bond from the 6-amino group of ATP 
(Glu180 in DDlig).17 In most grasp ligases, the 2′ and 3′ hydroxyl groups of the ribose 
moiety of the nucleotide share hydrogen bonds with a conserved Glu or Asp residue 
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(Glu187 in DDlig) This residue is generally found in a sequence between the B and Ω 
loops of the protein. 
 
 A role for metal ions in catalysis by ATP-grasp enzymes is not completely 
understood. However, the sidechains of three conserved residues in these proteins are 
involved in Mg2+ binding. The first of these residues can be either a Glu or Asp residue. 
In DDlig, this residue corresponds to Asp257, which is located on a β-strand preceding 
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the J loop.  Additionally, the J loop of ATP-grasp ligases contains the conserved Glu-X-
Asn sequence involved in metal binding (Glu270-Ala271-Asn272 in DDlig). Interestingly, 
the ATP-grasp ligase PurK contains an Ala in place of this Asn residue, suggesting that 
this enzyme uses a different strategy for metal binding.23 The importance of this 
structural feature is not yet known. A list of conserved residues involved in cofactor 
binding in the ATP grasp ligases is provided in Figure 6B. 
 The above ATP-grasp enzymes are involved in either primary metabolism or 
protein modification chemistry (e.g. RimK). The recent sequence analysis of several 
microviridin biosynthetic gene clusters revealed that this class of enzymes can also be 
used for the biosynthesis of secondary metabolites. Side-chain cyclizations, like those 
found in the microviridins, are rare in ribosomal peptide (RP) natural products. 
Characterized RPs containing similar macrocylces include the lasso peptide microcin 
J25 and capistruin.32,33 In microcin biosynthesis, the enzyme McjC is thought to be 
responsible for lasso formation. This enzyme is not homologous to the grasp ligases 
from microviridin pathways, and appears to be closely related to asparagine synthase. 
Few mechanistic details concerning side-chain cyclizations in RP biosynthesis are 
known. Any information concerning this process will further our knowledge of enzyme 
mechanisms and could lead to the development of novel, chemoselective 
macrocyclization catalysts. 
 
4.4 Studies Concerning the Biosynthesis of Microviridin J 
 Microviridin J is a tricyclic depsipeptide produced by Microcystis UOWOCC MRC. 
It consists of thirteen amino acids, and has been shown to affect molting in Daphnia.9 
The gene cluster for the biosynthesis of microviridin J consists of only three genes, 
 187
mdnABC. The products of these genes include the prepeptide MdnJA, which is 49 amino 
acids in length, and the ATP-grasp ligases MdnJ-B and MdnJ-C.8 Based on sequence 
homology to the biochemically characterized grasp ligases from microviridin K 
biosynthesis,15 it is evident that MdnJ-B and MdnJ-C catalyze lactam and lactone 
formation, respectively (Figure 7). Thus, the biosynthesis of microviridin J likely involves 
synthesis of the prepeptide, lactonization of the 49-mer by MdnJ-C, followed by 
macrocyclization with MdnJ-B. The identity of the peptidase responsible for the cleavage 
of the leader sequence of MdnJ-A and the N-acetyl transferase which modifies the N-
terminal Leu residue of the natural product are not known. 
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 We have recently started a research program focusing on the biosynthesis of 
microviridin J using a combination of biochemical techniques and X-ray crystallography. 
We plan to optimize the activity of the ATP-grasp ligases MdnJ-B and C and develop an 
efficient assay which can be used to monitor the activity of these enzymes. In addition, 
we will study the structure and function of these unique enzymes using X-ray 
crystallography. Ideally, we would like to observe multiple steps along the catalytic 
pathway and hope to obtain structures of both enzymes bound to ATP, substrate, and 
product. Structural information gained from these studies will greatly increase our 
mechanistic understanding of macrocycle formation in RP biosynthesis. Additionally, this 
information could be used to design novel enzymes that may find use as peptide 
cyclization catalysts. 
 
4.5 Attempted Expression of the Prepeptide MdnJ-A 
 Recently, Hemscheidt and co-workers have reported the heterologous 
expression of the microviridin K prepetide in E. coli.16 This N-terminal His6-tagged 
construct was expressed as a soluble peptide and was obtained in quantities which 
allowed for the biochemical characterization of the enzymes involved in the biosynthesis 
of microvridin K. We have attempted to repeat these experiments for the expression of 
the microviridin J prepeptide.  
 A pMA vector containing the mdnJ-A gene was synthesized using primer-based 
PCR methods, and the gene was subcloned into a pET28a vector. The resulting 
construct was transformed into E. coli BL21(DE3) cells. Attempts to express His6-MdnJ-
A as a soluble peptide from 1 L cultures of E. coli grown in Luria-Bertani (LB) media 
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failed.  Screening of expression temperatures between 18 and 25 °C did not improve 
results. 
 To circumvent this problem, we attempted to express His6-MdnJ-A in inclusion 
bodies. This strategy has been used successfully for the expression of a number of 
natural product prepeptides.32,34 Expression at 37 °C followed by purification under 
denaturing conditions following standard protocols did not yield His6-MdnJA at a 
detectable concentration. Two explanations for these failures are possible. First, 
translation of the gene may be inefficient. Alternatively, the prepetide may be cleaved by 
endogenous proteases. These problems are often observed for the expression of short 
peptides in E. coli. 
 
4.6 Crystallization of the Grasp Ligases MdnJ-B and MdnJ-C 
 MdnJ-B and MdnJ-C are highly homologous, displaying 40% identity and 60% 
similarity in their primary sequences. Sequence alignment of the ATP-grasp domains of 
MdnJ-B and MdnJ-C with those of DDligase and other characterized enzymes from 
microviridin biosynthesis allows for the prediction of amino acids important for ATP and 
Mg2+ binding. As seen in Figure 8, all characterized grasp ligases involved in microviridin 
biosynthesis contain two lysines and an arginine residue predicted to interact with the 
phosphate moiety of ATP. Additionally, each of these enzymes contain an Asp residue 
and a conserved Gln-X-Asn motif likely important for Mg2+ binding. Furthermore, it 
appears that the grasp ligases from microviridin pathways contain Gln and Glu residues 
which may form hydrogen bonding interactions with the adenine ring and ribose moiety 
of ATP, respectively.  
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  Structural characterization of both MdnJ-B and MdnJ-C is of interest for several 
reasons. First, it is important to discover how these enzymes achieve substrate 
recognition and are able to bind such large peptides (~50 amino acids). Additionally, it is 
intriguing that enzymes which are so similar catalyze different reactions (lactam vs. 
lactone formation). Characterization of these two enzymes by X-ray crystallography will 
provide a basis for the understanding of substrate recognition and catalysis by this class 
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of enzymes and will further our mechanistic understanding of peptide cyclizations in 
natural product biosynthesis. 
 To address these issues, we are attempting to crystallize both MdnJ-B and 
MdnJ-C. The genes for these enzymes were synthesized using primer based PCR 
methods and were subcloned into a pET28a vector. The resulting vectors were 
separately transformed into E. coli. BL21(DE3) cells, which are used as hosts for protein 
expression. MdnJ-C expresses well at 18 °C, and typical yields of this protein are ~7-8 
mg/L culture after purification by three-chromatographic steps.  
 High throughput-crystal screening at both 4 and 20 °C revealed several 
conditions which consistently led to the formation of microcrystals. Optimization of each 
of these separate 
conditions showed that 
both PEG 8K and PEG 
5K monomethyl ether 
are suitable 
precipitants for 
crystallization. Additive 
screening has revealed 
several compounds 
which may improve 
crystal quality and size 
for MdnJ-C. Optimization of crystallization conditions for this enzyme is currently 
underway.  
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 MdnJ-B expresses well at 20 °C, and typical yields of this protein after 
purification range from 0.4-0.6 mg/L culture. High-throughput crystal screening at both 4 
and 20 °C led to the discovery of 
multiple conditions that produce 
crystals. Optimization of each of 
these conditions revealed that 
use of the precipitants PEG 6K 
and PEG 8K leads to the 
consistent formation of crystals 
that appear as rectangular 
prisms. Additive screening 
showed that spermine and EDTA 
improve crystal quality. Currently, 
we have several native crystals 
which diffract to ~ 4 Å.  
Unfortunately, micro and 
macroseeding experiments have 
not improved crystal size. It is 
possible that diffraction quality crystals of MdnJ-B can be grown in the presence of the 
substrates ATP and MdnJ-A. Attempts to crystallize the enzyme in the presence of Mg2+, 
ATP, ADP, and the non-hydrolyzable ATP analog adenyl-imidodiphosphate have not 
yielded better quality crystals. Since we have not yet expressed MdnJ-A, we obtained a 
synthetic 30-mer corresponding to the C-terminal portion of this substrate. Addition of 
this compound to a solution of MdnJ-B leads to the immediate precipitation of the 
MdnJ-B, 39 kDA
A.
B. C.
D. E.
Figure 10.(A) SDS-PAGE gel of MdnJ-B purified by Ni-NTA chromatography.
(B) Crystals of MdnJ-B grown using PEG 8K as the precipitant. (C) Crystals
grown with Na2EDTA as an additive. (C) Crystals grown with spermine as an
additive. (D) Crystals of SeMet protein with Na2EDTA as an additive.
 193
protein. Attempts to optimize conditions leading to better quality crystals are currently 
underway. 
 No proteins with significant sequence homology to MdnJ-B have been 
structurally characterized. Thus, it is unlikely that molecular replacement techniques can 
be used to solve the structure of this grasp ligase. To address this issue, we have 
developed a protocol which yields Se-Met labeled MdnJ-B. This labeled protein 
expresses well in minimal media and can be purified to homogeneity. Unfortunately, 
crystals of the Se-Met labeled protein grow as small 2-dimensional needles. 
Optimization of crystallization conditions may yield better, diffractable quality crystals of 
this construct. Moreover, we have attempted to crystallize MdnJ-B in the presence of the 
additive Fe3+Na+ EDTA. Crystals grown in the presence of this additive appear similar in 
size and morphology to native crystals. The anomalous signal from the iron atom in this 
additive could be used to solve the phases needed to obtain a solution for the structure 
of MdnJ-B. Optimized crystallization conditions for  Fe3+ labeled and native protein are 
the focus of current research efforts in our laboratory.  
 
4.7 Conclusions and Future Directions 
 We have developed protocols for the heterologous expression of the two grasp 
ligases, MdnJ-B and MdnJ-C, from the microviridin J biosynthetic pathway. Several 
conditions which lead to the crystallization of both of these proteins have been identified 
and are currently being optimized. We hope to obtain structures of each of these 
proteins in the apo-form and in substrate and/or product bound states. These structures 
would allow us to visualize intermediates along the catalytic pathway of these enzymes 
and should provide an understanding of how these proteins achieve substrate 
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discrimination and catalysis. This structural information could allow for the engineering of 
grasp ligases which may be used as general, chemoselective peptide cyclization 
catalysts.  
 In the near future, we hope to develop a protocol for the expression of the 
microviridin J prepetide, MdnJ-A. We plan to screen several different E. coli strains for 
use as expression hosts. If MdnJ-A cannot be obtained in this manner, we will try to 
express it in a cell-free system. It is expected that co-crystallization experiments 
involving the prepeptide and MdnJ-C will yield better quality crystals for this enzyme. 
With the prepeptide in hand, we also plan to optimize and biochemically characterize the 
activity of MdnJ-B and MdnJ-C. Additionally, we hope to obtain the di-lactone product 
upon incubation of the prepeptide with MdnJ-C and use this molecule for co-
crystallization studies with MdnJ-B. 
 After obtaining crystal structures of MdnJ-B and MdnJ-C, we will compare how 
these two-enzymes achieve substrate recognition and catalyze different reactions. Using 
information gained from these studies, we plan to create mutants with altered reactivity. 
For instance, it may be possible to convert a macrolactonization enzyme to a mutant 
which forms lactams and vice-versa. Additionally, we plan to develop mutants of MdnJ-B 
and MdnJ-C which display relaxed substrate specificity. Such enzymes may find use as 
catalysts for the generation of libraries of macrocyclic compounds.  
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Materials and Methods 
 
Cloning of MdnJ-A 
A pMA vector containing the mdnJ-A gene between 5' NdeI and 3' HindIII restriction 
sites was synthesized by Mr. Gene ® (Regensburg, Germany). The vector was 
transformed into NovaBlue cells, which were cultured overnight on LB agar containing 
kanamycin. Cultures of the single colonies were grown overnight in 5 mL of LB broth 
supplemented with kanamycin. Cells were pelleted by centrifugation, and the plasmid 
was isolated using the QIAprep Spin Miniprep Kit (Qiagen). The plasmid was digested 
with NdeI and HindIII for 3 hours at 37 °C, and the reaction was purified by agarose gel 
electrophoresis. The desired insert was removed from the gel and was purified using the 
QIAquick Gel Extraction kit (Qiagen). The insert containing the mdnJ-A gene was cloned 
into the NdeI and HindIII sites of pET28a using T4 DNA ligase. The resulting plasmid 
was transformed into BL21(DE3) E. coli cells, which were cultured overnight on LB Agar 
containing kanamycin.  
 
Attempted Expression of MdnJ-A 
A single colony containing pET28a-mdnJ-A was grown for 16 hours at 37 °C in 5 mL of 
LB broth supplemented with kanamycin. The overnight culture was used to inoculate 1 L 
of LB broth containing 30 mg of kanamycin. The resulting culture was grown at 37 °C 
until a cell density of O.D.600 = 0.6 was reached. At this time, the culture was cooled to 
the desired temperature (18-25 °C) and expression was induced by addition of IPTG to a 
final concentration of 100 mM. Expression was allowed to progress overnight. Cells were 
pelleted by centrifugation (20 min, 2000 g) and the resulting pellet was stored at -80 °C 
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in lysis buffer containing 20 mM Tris-HCl, pH = 7.5, and 500 mM NaCl. Cell pellets were 
thawed on ice, and were lysed by two passages through a French Press cell disruption 
system at 1000 psi. The protease inhibitor PMSF (100 μL of a 100 mM solution) was 
added to the lyaste, which was clarified by centrifugation (20 min, 10,000 g). The 
supernatant was incubated for 1 hour at 4 °C with freshly washed Ni-NTA resin. The 
flow-through was collected and the remaining Ni-NTA resin was washed with lysis buffer 
(3 x 10 mL). Protein was eluted by addition of elution buffer (3 x 10 mL) containing 20 
mM Tris-HCl, pH 7.5, 500 mM NaCl, 250 mM imidazole. The first two elutions were 
dialyzed overnight against H2O and were analyzed by HPLC-ESI-MS. The desired 
peptide was not observed.  
 The above procedure was repeated with the modifications detailed below. 
Protein expression in a 1 L culture maintained at 37 °C was induced by addition of IPTG 
to a final concentration of 100 mM. Expression was allowed to progress for 2 hours, and 
cells were pelleted by centrifugation. The cell pellet was frozen and stored at -80 °C. Cell 
pellets were thawed on ice. Lysis was achieved by stirring the pellet for 1 hour at room 
temperature in lysis buffer containing 100 mM NaH2PO4, 10 mM Tris-HCl, pH = 8.0, and 
6 M guanidinium hydrochloride. The lyaste was incubated with Ni-NTA resin as 
described above. The flow-through was collected and the remaining Ni-NTA resin was 
washed with buffer containing 100 mM NaH2PO4, 10 mM Tris-HCl, pH = 6.3, and 6 M 
guanidinium hydrochloride. Protein was eluted by addition of buffer containing 100 mM 
NaH2PO4, 10 mM Tris-HCl, pH = 5.9, and 6 M guanidinium hydrochloride (3 x 5 mL). An 
additional elution was collected using buffer containing 20 mM Tris, pH 7.5, 500 mM 
NaCl, 250 mM imidazole (1 x 5 mL). Elutions were dialyzed as described above. 
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Analysis of the elutions by HPLC-ESI-MS revealed that the desired peptide was not 
obtained. 
 
Cloning of MdnJ-C 
A pMA vector containing the mdnJ-C gene between 5' NcoI and 3' SacI restriction sites 
was synthesized by Mr. Gene ®. The vector was transformed into NovaBlue cells, which 
were cultured as described above. A 5 mL culture of one colony was grown overnight in 
5 mL of LB broth supplemented with kanamycin. Cells were pelleted by centrifugation, 
and the plasmid was isolated using the QIAprep Spin Miniprep Kit (Qiagen). The plasmid 
was digested with NcoI and SacI for 4 hours at 37 °C, and the reaction was purified by 
agarose gel electrophoresis. The desired insert was removed from the gel and was 
purified using the QIAquick Gel Extraction kit (Qiagen). The insert containing the mdnJ-C 
gene was cloned into the NcoI and SacI sites of pET28a using T4 DNA ligase. The 
resulting plasmid, encoding for His6-MdnJ-C production, was transformed into 
BL21(DE3) E. coli cells, which were cultured overnight on LB Agar containing 
kanamycin. 
 
Expression and Purification of MdnJ-C 
A single colony harboring the pET28a-mdnJ-C plasmid was grown overnight at 37 °C in 
5 mL of LB broth supplemented with kanamycin. This culture was used to inoculate 1 L 
of LB broth, which was grown at 37 °C until an O.D.600 = 0.6 was reached. The culture 
was cooled to 18 °C, and expression was induced by addition of IPTG to a final 
concentration of 100 mM. Expression was allowed to occur for 16 hours. Cells were 
pelleted by centrifugation, and the resulting pellets were stored at -80 °C in 20 mL of 
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lysis buffer containing 20 mM Tris-HCl, pH = 7.5, and 500 mM NaCl. Cell pellets were 
thawed on ice and were lysed by two passages through a French Press cell disruption 
system at 1000 psi. The lyaste was clarified by centrifugation, and IPTG (100 μL, 100 
mM) was added to this mixture. The lysate was incubated with Ni-NTA resin (0.75 mL) 
for 45 minutes at 4 °C. The flow-through was collected, and the Ni-NTA resin was 
washed with lysis buffer containing 10 mM imidazole (3 x 10 mL). Protein was eluted by 
addition of buffer containing 20 mM Tris-HCl, pH = 7.5, and 500 mM NaCl, 250 mM 
imidazole (3 x 10 mL). The first two elutions were dialyzed for 2 hours against 20 mM 
HEPES, pH 7.5, 10 mM NaCl. Further purification was performed using a HiTrap-Q ion 
exchange column followed by a Superdex 200 gel filtration column (GE Biosciences). 
Buffers used for purification included: 20 mM HEPES, pH = 7.5 (Mono Q buffer A), 20 
mM HEPES, pH 7.5, 1M NaCl (Mono Q buffer B), and 20 mM HEPES, 100 mM NaCl 
(Gel filtration buffer). 
 
Crystallization of MdnJ-C 
Purified His6-MdnJ-C (343 amino acid, 38.9 kDa) was concentrated to 10 mg/mL using 
Amicon Ultra centrifugal filter devices with a molecular weight cutoff of 10,000 Da. High-
throughput crystal screening was performed at 4 and 20 °C using Hampton screens 
HR2-110 and HR2-112 as well as JCSG Core Suites I and II. The crystal hits identified 
are listed below in Table 1. 
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  Each of the above hits was screened for reproducibility. These experiments 
revealed that conditions 10 and 12 from table 1 yielded microcrystals reproducibly. 
These two conditions were subjected to additive screening using the Hampton Research 
Additive ScreenTM HR2-428. It was found that 3-(1-pyridinio)-1-propanesulfanote (NDSB-
201) improved crystal quality when both PEG 8K or PEG 5K monomethyl ether were 
used as precipitants. 
 
Cloning of MdnJ-B 
A pMA vector containing the mdnJ-B gene between 5' NcoI and 3' SacI restriction sites 
was synthesized by Mr. Gene ®. The vector was transformed into NovaBlue cells, which 
were cultured as described above. Cultures of single colonies were grown overnight in 5 
mL of LB broth supplemented with kanamycin. Cells were pelleted by centrifugation, and 
the plasmid was isolated using the QIAprep Spin Miniprep Kit (Qiagen). The plasmid 
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was digested with NcoI and SacI for 4 hours at 37 °C, and the reaction was purified by 
agarose gel electrophoresis. The desired insert was removed from the gel and was 
purified using the QIAquick Gel Extraction kit (Qiagen). The insert containing the mdnJ-B 
gene was cloned into the NcoI and SacI sites of pET28a using T4 DNA ligase. The 
resulting plasmid, encoding for His6-MdnJ-B production, was transformed into 
BL21(DE3) E. coli cells, which were cultured overnight on LB Agar containing 
kanamycin. 
 
Expression, Purification, and Crystallization of MdnJ-B 
Expression of His6-MdnJ-B (345 amino acids, 38.9 kDa) was performed as describe 
above for MdnJ-C. For MdnJ-B, expression was induced at 20 °C. After purification, 
MdnJ-B was concentrated to 10 mg/mL using Amicon Ultra centrifugal filter devices with 
a molecular weight cutoff of 10,000 Da. High-throughput crystal screening was 
performed at 4 and 20 °C using Hampton screens HR2-110 and HR2-112 and JCSG 
Core Suites I and II. The conditions which led to crystallization are listed below in Table 
2. 
 Each of these conditions was screened to see if crystals could be obtained in a 
reproducible fashion. Of these conditions, 17-19 yielded reproducible, needle-like 
crystals. These three conditions were subjected to additive screening using the Hampton 
Research Additive ScreenTM HR2-428. It was found that the additives spermine and 
Na2EDTA in condition 18 yielded single crystals as rectangular prisms. Repeated 
experiments have shown that crystals are obtained in PEG 8K concentrations ranging 
from 4-18 % (w/v) with 0.01-0.1 M additive.  
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Buffer Salt/Additive Precipitant Temperature
1) 1.5 M NaCl 10% EtOH 4 °C
2) 0.1 M HEPES, pH = 7.5 0.2 M MgCl2 15% EtOH 4 °C
3) 0.09 M HEPES, pH = 7.5 27% PEG 400 4 °C
4) 0.1 M HEPES, pH = 7.5
5) 0.1 M HEPES, pH = 7.5 10% PEG 8K
6) 0.1 M HEPES, pH = 7.5
7) 0.2M Magnesium Formate
8 ) 0.1 M HEPES, pH = 7.5 2.0M Ammonium Formate
9) 0.1 M MES, pH 5.0 10% MPD
10) 0.1 M Na/K phosphate, pH = 6.2 0.2 M NaCl 40% PEG 400
11) 0.095 M HEPES, pH = 7.5 0.19 M CaCl2
5% glycerol
26.6% PEG 400
12) 0.1 M HEPES, pH = 7.5 0.2 M MgCl2 30% PEG 400
4 °C
4 °C
4 °C
20 °C
20 °C
20 °C
20 °C
20 °C
20 °C
Table 2. Hits from high-throughput crystal screening of MdnJ-B
0.18 M MgCl2
10% glycerol
10% PEG 6K
5% MPD
8% ethylene glycol
10% PEG 8K
13) 0.1 M Na/K phosphate, pH = 6.2 0.2 M NaCl 20% PEG 1K 20 °C
14) 0.095 M HEPES, pH = 7.5 15% glycerol 17% PEG4K
8.5% IPA
15) 0.1 M citric acid, pH = 5.0 1.0 M LiCl 20% PEG 8K
16) 0.1 M bicine, pH = 9.0 1.0 M LiCl 10% PEG 6K
17) 0.1 M HEPES, pH = 6.5 10% PEG 6K
18) 0.1 M HEPES, pH = 7.5 10% PEG 6K
5% MPD
19) 0.1 M HEPES, pH = 7.5 10% PEG 8K
20 °C
20 °C
20 °C
20 °C
20 °C
20 °C
 
 
Expression and Purification of Se-Met Labeled MdnJ-B 
Single colonies harboring the pET28a-mdnJ-B plasmid were grown overnight at 37 °C in 
5 mL of LB broth supplemented with kanamycin. A 1 L solution of M9 media 
supplemented with glucose (3 g), MgSO4 (2 mL of a 1M solution), CaCl2 (50 μL of a 2 M 
solution), thiamin (1 mg), biotin (2mg), FeSO4 (1 mL of a 15 mM solution), kanamycin (3 
mg), and all amino acids excluding Gly, Ala, Pro, Gln, Asn, Cys, and Met (40 mg each)  
was inoculated with 25 μL of an overnight culture. The 1 L culture was grown at 35 °C 
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until an O.D.600 = 0.7 was reached and the culture was cooled to 25 °C. At this time, Thr, 
Lys, and Phe (100 mg each) and Leu, Ile, and Val (50 mg each) were added to the 
culture. After 15 minutes, D/L-SeMet (120 mg) was added, and after an additional 15 
minutes expression was induced by addition of IPTG to a final concentration of 100 mM. 
Overexpression was allowed to occur overnight, and cells were harvested as described 
above. Se-Met labeled MdnJ-B was purified as above using freshly degassed buffers 
containing 5 mM DTT. 
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